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i Summary 
To  plan  a  public  health  response  to  the  hepatitis  C  virus  (HCV)  epidemic  in  Scotland, 
in  terms  of  treatment  needs  and  preventive  measures,  quantitative  estimates  of  the 
current  and  future  burden  of  HCV  disease  are  required.  The  overwhelming  majority  of 
HCV  infections  in  Scotland  have  been  associated  with  injecting  drug  users  (IDUs); 
therefore,  the  work  described  in  this  thesis  focussed  on  this  risk  group.  A  forward 
projection  model  was  used  to  estimate  the  numbers  of,  both  current  and  former,  IDUs 
who  acquired  HCV  infection  and  progressed  to  mild,  moderate  and  severe  HCV 
disease  in  Glasgow  and  Scotland  between  1960  and  2030.  The  model  was  developed 
initially  for  Glasgow  because  more  epidemiological  information  exists  for  this  region, 
than  elsewhere  in  Scotland,  to  calibrate  model  outcomes  with  local  data  relating  to 
HCV  and  its  consequences.  Insights  gained  from  the  model  fitting  process  in  Glasgow 
were  then  used  to  extend  the  model  to  the  rest  of  Scotland. 
First,  the  incidence  and  cessation  of  injecting  drug  use  in  Glasgow  during 
1960-2000  were  derived  through  the  use  of  a  modified  Delphi  approach.  Instead  of 
the  usual  iterative  process  to  refine  experts'  estimates,  the  elicitation  of  IDU  incidence 
and cessation  provided  an  opportunity  to  combine  these  data  and examine  coherence 
with  capture-recapture  IDU  prevalence  estimates.  Coherent  estimates  indicated  that 
incidence  (median:  28  to  49)  and  cessation  (1  to  2%)  remained  low  and stable  during 
1960-1975,  rose  steeply  between  1975-1985  (incidence  from  49  to  1,335;  cessation 
from  2%  to  6%),  and  by  2000  there  had  been  a  decline  in  incidence  (1,195)  but  a 
further  rise  in  cessation  (15%). 
Secondly,  stochastic  simulation  was  used  to  model  the  transmission  of  HCV 
among  current  IDUs  in  Glasgow,  according  to  their  injecting  risk  behaviours,  and 
111 estimate  the  past  incidence  of  HCV  infection.  The  model  that  considered  higher 
infectivity  during  acute  viraemia  following  infection  produced  seroprevalences 
(median:  62-72%)  and  incidences  (18-30  per  100  susceptible  injector-years) 
consistent  with  observed  data  during  the  1990s.  The  annual  number  of  new  HCV 
infections  among  current  IDUs  in  Glasgow  was  estimated  to  be  low  during  1960-1976 
(median:  10-60),  rise  steeply  during  the  early  1980s  to  peak  in  1985  (1,120),  stabilise 
during  1991-1997  (510-610)  and  rise  again  during  1998-2000  (710-780).  Scenario 
analyses  indicated  that  potentially  as  many  as  4,500  HCV  infections  (10th  and  90th 
percentiles:  2,400-7,700)  had  been  prevented  in  Glasgow  during  1988-2000  as  a  result 
of  harm-reduction  measures. 
Scenario  analyses  also  permitted  the  gauging  of  changes  in  risk  behaviours 
required  to  effect  appreciable  reductions  in  the  incidence  of  HCV  infection.  Incidence 
can  be  successfully  reduced  if  IDUs  who,  unavoidably,  share  needles/syringes  confine 
their  borrowing  to  one  person;  with  this  strategy  alone,  an  estimated  5,300  HCV 
infections  (10th  and  90th  percentiles:  4,100-6,700)  could  have  been  averted  in  Glasgow 
during  1988-2000.  Such  insights  will  inform  those  responsible  for  developing  new 
ways  to  prevent  HCV  transmission  among  IDU  populations. 
Thirdly,  linkage  of  laboratory  data  on  diagnosed  HCV  antibody  positive 
persons  in  Scotland  to  clinical  data  from  hospital  and  death  records  provided  a  unique 
national  epidemiological  dataset  to  estimate  the  number  who  had  progressed  to  severe 
HCV  disease.  The  number  of  persons  with  newly  developed  HCV-related 
decompensated  cirrhosis  in  Scotland  was  estimated  to  have  increased  from  230  (95% 
CI  220-250)  in  1996-1998  to  300  (280-320)  in  1999-2001,  highlighting  HCV  as  a 
growing  burden  on  healthcare  resources.  Alcohol  was  a  prominent  factor  among 
persons  who  had  died  (78%  of  134)  or  were  hospitalised  (72%  of  442)  with  HCV- 
lv related  decompensated  cirrhosis  during  1996-2001  in  Scotland.  The  younger  age  of 
decompensated  patients  presenting  to  hospital  with  both  HCV  and  alcohol  (78%  of 
320  were  aged  <50  years  old)  suggests  that  the  combined  effect  of  these  two  factors 
accelerates  liver  disease  progression  more  than  if  only  one  of  these  factors  were 
present  (HCV:  48%  of  122;  alcohol:  33%  of  8,465). 
Fourthly,  a  meta-analysis  was  carried  out  to  explore  the  relationship  between 
HCV  chronic  liver  disease  and  the  consumption  of  alcohol.  The  pooled  relative  risk  of 
cirrhosis  associated  with  heavy  alcohol  intake  (defined  in  the  range  of  at  least  210  to 
560g  per  week)  was  2.33  (95%  CI  1.67-3.26)  by  the  random  effects  model.  Studies 
investigating  the  risk  of  HCV-related  cirrhosis  include  patients  undergoing  liver 
biopsy  and  therefore  could  under-represent  heavy  alcohol  users;  such  selectivity  may 
have  under-estimated  the  regression  effect  of  alcohol. 
Finally,  the  HCV  projection  model  was  designed  to  synthesize  information  on 
the  incidence  and  cessation  of  injecting  drug  use,  the  incidence  of  HCV  infection 
among  current  IDUs,  the  rate  of  HCV  disease  progression  (including  the  influence  of 
alcohol  and  other  host  factors),  and  the  annual  number  of  IDUs  developing  HCV- 
related  decompensated  cirrhosis.  A  total  of  17,400  (95%  CI  14,300-22,200)  and 
42,900  (32,400-60,600)  persons,  who  had  ever  injected  drugs,  were  estimated  to  be 
living  with  HCV  antibodies  by  the  end  of  2003  in  Glasgow  and  Scotland, 
respectively.  This  compares  with  approximately  5,000  (29%)  and  13,900  (32%) 
diagnosed,  respectively.  Of  these  HCV-infected  IDUs  in  Glasgow  and  Scotland, 
13,200  (10,800-16,900)  and  32,200  (24,300-45,500)  were  estimated  to  be  living  with 
chronic  HCV  and  therefore  at  risk  of  developing  cirrhosis.  The  number  of  IDUs 
developing  HCV-related  decompensated  cirrhosis  in  Scotland  is  estimated  to  double 
between  2000  and  2020.  As  high  as  16%  and  27%  of  Glasgow  former  IDUs  in  2005 
V aged  30-39  and  40-49  years,  respectively,  were  estimated  to  have  moderate  disease 
(32%  and  47%  of  those  chronically  infected,  respectively),  which  highlights  the 
potential  benefit  of  targeting  HCV  testing  at  former  IDUs  who  belong  to  these  age 
groups. 
The  treatment  with  antiviral  therapy  of  15,000  former  IDUs  in  Glasgow  with 
moderate  HCV  disease  over  the  next  26  years  (62%  of  those  HCV  infected)  could 
potentially  prevent  between  24%  and  86%  of  severe  HCV-related  events  during  2005- 
2030  (based  on  45%  to  100%  response  and  compliance  to  therapy,  respectively).  The 
identification  and  treatment  of  a  larger  proportion  of  former  IDUs  with  HCV  disease, 
education  about  the  importance  of  minimal  alcohol  consumption,  and  the 
development  of  more  effective  therapies  are  needed  now  to  help  achieve  a  greater 
impact  on  the  future  morbidity  and  mortality  of  this  disease. 
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xxvi Chapter  1:  Introduction 
1.1  Background  to  the  hepatitis  C  virus 
The  hepatitis  C  virus  (HCV)  was  first  discovered  in  19891  and  diagnostic  tests  to 
reliably  detect  infection  were  subsequently  developed2.  Of  those  infected  with  HCV, 
60-85%  fail  to  clear  the  virus3'4  and  consequently  are  at  risk  of  developing  severe  liver 
disease  -  decompensated  cirrhosis  and  hepatocellular  carcinoma  (HCC)  -  over  a  long 
and  variable  incubation  period  depending  on  age  at  infection,  gender,  alcohol  intake 
and  co-infection  with  HIVS'6.  There  is  no  vaccine  available  at  present  to  prevent 
infection  with  HCV;  however,  treatment  with  pegylated  interferon  alpha  and  ribavirin 
given  in  combination  leads  to  sustained  viral  clearance  in  50-60%  of  patients  with 
moderate  disease7'8.  Liver  transplantation  is  the  only  option  to  prolong  life  for  patients 
who  have  reached  severe  HCV  disease. 
HCV  is  a  blood-borne  virus  that  is  transmitted  primarily  through  direct 
percutaneous  exposure.  Since  1991,  screening  of  blood  donors  and  products  for  HCV 
has  virtually  eradicated  transfusion-associated  HCV  in  developed  countries9.  While 
this  infection  has  been  shown  to  be  transmitted  vertically  from  mother  to  child  and 
through  unprotected  sexual  intercourse  10,  HCV  in  western  countries  is  most 
commonly  transmitted  among  injecting  drug  users  (IDUs)  who  share  injecting 
equipment  II.  HCV  seroprevalence  rates  exceeding  50%  have  been  detected  among 
populations  of  IDUs  throughout  the  world12 
The  World  Health  Organisation  estimated,  on  the  basis  of  limited  country- 
specific  data,  that  around  170  million  people  worldwide  were  chronically  infected 
with  HCV  in  199713;  thus,  HCV  is  more  than  four  times  as  prevalent  as  the  human 
immunodeficiency  virus  (HIV)14.  In  the  United  States,  HCV  has  become  the  leading cause  of  cirrhosis  and  liver  transplantation15,16,17  Scotland  is  likely  to  have  one  of  the 
highest  prevalences  of  HCV  in  Western  Europe  because  of  its  high  prevalences  of  (i) 
IDUs18"9  and  (ii)  HCV  amongst  its  IDU  population  (described  below,  Table  1.1). 
Furthermore,  HCV  has  been  circulating  among  IDUs  in  Scotland  since  at  least  the 
early  1980s20;  therefore,  it  is  expected  that  increasing  numbers  of  individuals  will 
begin  to  present  with  HCV-related  complications  over  the  next  10  to  20  years. 
Accordingly,  it  is  important  that  methods  to  forecast  the  extent  and  type  of  HCV- 
related  disease  in  Scotland  -  which  the  National  Health  Service,  local  authorities  and 
non-governmental  organisations  will  need  to  respond  to  in  future  years  -  are 
developed. 
1.2  Prevalence  of  HCV  infection  in  Scotland 
The  prevalence  of  HCV  in  Scotland  varies  considerably  depending  on  the  population 
studied;  as  in  other  western  countries10,  the  highest  rates  were  reported  among  IDUs 
and  recipients  of  blood  and  blood  products  (described  below,  Tables  1.1  and  1.2).  Of 
14,390  persons  diagnosed  with  HCV  antibodies  in  Scotland  by  the  end  of  June  2002, 
almost  90%  (8,719/9,728)  of  those  for  whom  at  least  one  risk  factor  was  known  had 
injected  drugs,  6%  (584/9,728)  had  received  blood  or  blood  products  and  4%  reported 
occupational  needlestick  injuries,  tattoos,  body  piercings  or  sexual  contact21.  These 
data,  and  those  described  below,  clearly  illustrate  that  the  current,  principal  risk  factor 
for  HCV  infection  in  Scotland  is  injecting  drug  use. 
1.2.1  Pregnant  women 
The  unlinked  anonymous  testing  of  residual  dried  blood  spots  on  neonatal  metabolic 
screening  cards  is  regarded  as  the  most  cost-effective  means  of  providing  minimally 
2 biased  estimates  of  HCV  prevalence  in  a  large  general  population22.  The  overall 
prevalence  of  maternal  HCV  antibodies  in  Scotland  during  2000  was  low  (0.4%);  this 
rate  was  higher  than  that  modelled  for  England/Wales  (0.15%)23  though  lower  than 
regional  estimates  for  the  rest  of  Western  Europe  (1-2%)24,  the  United  States  (2- 
4%)25'26'27  and  Australia  (1.1%)  28.  HCV  seroprevalence  among  Scottish  childbearing 
women  is  consistent  with  that  expected  from  injecting  drug  use  as  primary  route  of 
exposure:  highest  (i)  among  25-29  year  olds  (0.4-0.57%),  (ii)  in  high  deprivation  areas 
(0.92-1.07%),  and  (iii)  in  Greater  Glasgow  (0.83-0.96%)  and  Grampian  (0.38-0.62%) 
health-board  areas.  A  study  of  pregnant  women  in  Dundee  during  1997  found  a 
significantly  higher  HCV  seroprevalence  among  those  who  reported  injecting  drug 
use  (41%  of  only  17)  than  those  who  had  not  (0.45%  of  3,531)  (p<0.0001),  and  also 
highlighted  the  increased  risk  of  HCV  acquisition  among  the  sexual  partners  of  IDUs 
(15%  of  33)29 
1.2.2  Children 
During  June  2002,  a  pilot  study  to  investigate  the  feasibility  of  surveying, 
anonymously,  HCV  infection  among  healthy  children  by  means  of  an  oral  fluid 
specimen  was  undertaken  in  the  Child  Dental  Health  Department  of  Glasgow  Dental 
Hospital  and  School.  This  study  found  a  HCV  seroprevalence  of  3%  (95%  CI  0.4- 
10.3%)  among  a  small  sample  of  70  children3o 
1.2.3  Blood  donors 
The  prevalence  of  HCV  antibodies  among  Scottish  blood  donors  in  1991-1992  was 
0.09%31,  a  rate  which  was  similar  to  that  detected  in  parts  of  England  (e.  g.  London 
3 (0.07%)32,  North  West  (0.04%)33)  but  lower  than  that  found  in  the  United  States 
0.36%)34. 
1.2.4  Recipients  of  blood  and  blood  products 
Prior  to  1985,  most  patients  with  clotting  disorders  were  exposed  to  HCV  through  the 
receipt  of  contaminated  blood  products.  Evidence  of  HCV  infection  was  found  in  all 
but  one  of  78  haemophiliacs  treated  with  non-virus  inactivated  clotting  factor 
concentrates  in  Edinburgh35.  In  1985,  heat  treatment  of  clotting  factor  concentrates  for 
haemophiliacs  was  introduced  in  Scotland36 
In  1991,  the  estimated  seroprevalence  of  HCV  in  three  Glasgow  Renal 
Dialysis  Units  was  3.9%  (19/483)37.  The  number  of  blood  transfusions  received  and 
the  length  of  time  on  dialysis  were  positively  associated  with  HCV  antibody  status. 
HCV  antibody  testing  of  all  new  entrants  to  dialysis  units,  and  thereafter  at  six 
monthly  intervals,  has  since  been  implemented. 
1.2.5  Other  patient  groups 
The  HCV  antibody  prevalence  for  16-49  year  old  males  undergoing,  or  eligible  to 
undergo,  surgery  was  3.8%  (103/2,702)38.  While  the  risk  of  HCV  transmission  from 
patient  to  surgeon  is  low,  the  prevalences  observed  among  surgical  patients  indicate 
that  surgeons  working  in  areas  of  high  injecting  drug  use  prevalence  and  high  HCV 
prevalence  among  IDUs  will  frequently  operate  on  HCV  infected  patients. 
Of  80  patients  with  histologically  confirmed  liver  cancer  presenting  to  the 
Royal  Infirmary  of  Edinburgh  between  1985  and  1994,30%  were  found  to  be  positive 
for  HCV  antibodies39.  This  study  highlighted  that  chronic  HCV  infection  could  be  a 
major  risk  factor  for  the  development  of  HCC  in  Scotland. 
4 1.2.6  Healthcare  workers 
The  overall  prevalence  of  HCV  antibodies  among  healthcare  workers  in  Glasgow  was 
low  (0.28%  of  8,412)  40  and  comparable  with  that  reported  in  England  (0.21- 
0.28%)41'42.  The  Glasgow  study  indicated  that  the  performance  of  exposure  prone 
procedures  does  not  necessarily  result  in  an  increased  risk  of  HCV  acquisition  by 
healthcare  workers  (0.23%  of  2,205  currently  performing  compared  to  0.3%  of  6,207 
not  currently  performing  exposure  prone  procedures,  p=0.6;  no  significant  differences 
in  HCV  prevalence  were  found  between  these  groups  stratifying  by  age).  A  study  of 
880  dental  healthcare  workers  in  the  West  of  Scotland  reported  a  seroprevalence  of 
0.1  %,  from  which  the  authors  suggested  that  HCV  was  not  a  significant  occupational 
hazard  in  the  dental  setting  either43 
1.2.7  Genitourinary  Medicine  Clinic  Attenders 
The  HCV  seroprevalence  among  non-injecting  heterosexual  men  and  women  was  0.8 
(32/4,135)  and  0.3%  (10/3,035),  respectively,  and  0.6%  (4/668)  among  non-injecting 
homosexual/bisexual  men  attending  genitourinary  medicine  clinics  in  Scotland  during 
1996-199744.  These  findings  are  in  keeping  with  the  prevailing  view  that  HCV  is  not 
easily  transmitted  through  unprotected  sexual  intercourse. 
1.2.8  Prisoners 
HCV  antibody  prevalence  was  estimated  at  58%  and  3.5%  among  536  injector  and 
899  non-injector  inmates,  respectively,  surveyed  in  five  Scottish  prisons  during  1994- 
199645.  Similarly,  53%  and  4.0%  of  173  injector  and  406  non-injector  inmates, 
respectively,  surveyed  at  Shotts  prison  during  1999-2000  were  estimated  to  be  HCV 
5 antibody  positive  (personal  communication:  Dr  Jennifer  Champion,  SCIEH).  The 
prevalence  and  potential  transmissibility  of  HCV  in  injector-inmates  are  therefore 
both  high.  For  inmates  surveyed  in  1999-2000  who  reported  ever  having  injected 
drugs,  the  HCV  incidence  was  12  (95%  Cl  5-32)  per  100  person-years  of 
incarcerationa6 
1.2.9  Injecting  drug  users 
HCV  has  been  circulating  among  IDUs  in  Scotland  since  at  least  the  mid  1970s:  73% 
of  275  IDUs  who  had  tested  hepatitis  B  surface  antibody  positive  in  Glasgow  during 
1973-1984  were  HCV  antibody  positive  (personal  communication:  Dr.  Sheila 
Cameron,  Glasgow  Regional  Virus  Laboratory);  similarly,  87%  of  126  IDUs  who  had 
a  hepatitis  B  surface  antibody  test  in  Edinburgh  during  1984  were  HCV  antibody 
positive20.  Of  almost  2,000  current  IDUs  recruited  during  community-wide,  multi-site 
surveys  in  Glasgow  during  1990-1996,  the  overall  estimated  HCV  seroprevalence  was 
72%47.  Seroprevalence  rates  per  survey  year  ranged  from  the  highest  of  79%  from  365 
IDUs  in  1990  to  the  lowest  of  66%  from  195  IDUs  in  1996.  These  data  suggest  that 
the  incidence  of  HCV  among  IDUs  in  Glasgow  had  decreased  during  this  period. 
In  the  late  1980s  and  throughout  the  1990s,  Scotland  implemented,  and 
continued  to  develop,  interventions  -  including  the  provision  of  sterile  injecting 
equipment  -  to  reduce  needle/syringe  sharing  and  thus  the  transmission  of  blood- 
borne  viruses  among  IDUsas'49  To  determine  if  the  prevalence  of  HCV  antibodies 
among  IDUs  in  Scotland  had  changed  in  this  era  of  harm  reduction,  residual  sera  from 
IDUs  who  had  undergone  a  named  HIV  antibody  test  during  1989-2000  were  tested 
for  HCV  antibodies  (Table  1.2)50;  this  survey  approach  revealed  significant  reductions 
in  HCV  seroprevalence  among  IDUs  aged  under  25  years  from  Glasgow  and  Lothian 
6 between  1990  (Glasgow  91%;  Lothian  69%)  and  1995  (59%;  31%)  and  1997  (43%; 
13%),  suggesting  that  there  had been  a  steady,  continual  decrease  in  the  incidence  of 
HCV.  However,  no  further  significant  reductions  in  HCV  seroprevalence  were  found 
among  this  group  during  the  late  1990s  (Glasgow  1997  and  1999-2000:  43%  and 
41%,  respectively;  Lothian  1997  and  1999:  13%  and  17%,  respectively;  Table  1.2). 
The  most  recent  findings  highlight  that  existing  harm  reduction  measures, 
acknowledged  as  having  helped  to  reduce  the  spread  of  HCV,  are  not  sufficient  to 
bring  this  epidemic  under  control.  The  high  seroprevalence  of  HCV  (58%  of  466) 
detected  among  recently  initiated  IDUs  (i.  e.  average  of  2-3  years'  injecting  career) 
surveyed  in  Glasgow  during  2001-2002  suggests  that  the  incidence  of  HCV  might  be 
on  the  increase  (personal  communication:  Dr.  Sarah  Wadd,  SCIEH);  such  a  trend 
would  be  consistent  with  the  observed  increase  in  injecting  risk  behaviours  in  1999 
compared  to  previous  years  1991-19945  1 
1.3  Public  health  relevance  of  projecting  the  future  HCV-related  disease  burden 
Most  of  those  infected  with  HCV  in  Scotland,  as  in  many  other  developed  countries, 
acquired  their  infection  at  a  young  adult  age  and  during  the  past  thirty  years  through 
the  sharing  of  contaminated  injecting  equipment.  Given  that  HCV  progresses  slowly, 
particularly  among  young  adults,  and  does  not  result  in  major  morbidity  and  mortality 
for  many  years,  then  Scotland  has  not  yet  experienced  the  full  consequences  of  this 
epidemic.  As  the  large  pool  of  currently  infected  patients  ages  and  their  disease  has 
time  to  progress,  more  patients  will  develop  complications  of  liver  disease  and  the 
burden  on  the  healthcare  system  will  increase  as  a  result. 
As  at  the  end  of  June  2002,  a  total  of  14,390  persons  had  been  diagnosed  with 
HCV  in  Scotland21,  of  whom  only  1,500-3,000  were  likely  to  have  been  in  active 
7 follow-up  with  specialist  care  services  and  even  fewer  (1,000-1,500)  had  received 
antiviral  treatment52.  Plausibly,  a  major  factor  contributing  to  the  low  uptake  of 
antiviral  therapy  was  the  ineligibility  of  many  cases  due  to  their  current  injecting 
status at  the  time  of  diagnosis.  Based  on  a  study  among  pregnant  women53,  it  was 
estimated  that  70-80%  of  HCV  infected  women  (of  childbearing  age)  in  Scotland 
during  2000  were  undiagnosed;  accordingly  such  individuals  were  making  few 
demands  on  HCV-related  healthcare  services.  Overall,  the  current  burden  placed  on 
the  healthcare  system  in  Scotland  by  HCV  is  relatively  small  when  placed  in  the 
context  of  the  large  reservoir  of  infected  persons.  That  said,  waiting  times  for  new 
patient  appointments  to  see  a  specialist  for  evaluation  of  HCV  disease  in  Scotland 
range,  depending  on  region,  between  several  months  and  several  years.  Strategies  to 
diagnose,  monitor  and  successfully  treat  chronic  HCV  infection  need  to  be  designed, 
evaluated,  funded  and  implemented  before  large  numbers  of  individuals  start  to 
develop  severe  liver  disease,  which  is  unresponsive  to  antiviral  therapy.  Treatment  of 
severe  liver  disease  is  limited  by  the  shortage  of  cadaveric  donor  livers  for 
transplantations4 
Patients  with  chronic  hepatitis  use  healthcare  resources  in  obvious  and  direct 
ways,  such  as  clinic  visits,  diagnostic  tests,  counselling,  drug  therapy,  hospitalisation 
for  the  management  of  liver  failure  and  HCC,  and  liver  transplantation.  Care  of 
patients  with  HCV  is  provided  by  a  wide  range  of  professionals  from  many  different 
disciplines  including  health  promotion,  primary  care,  drug  addiction  services, 
voluntary  sector,  social  work  services,  prisons,  blood  transfusion  service,  genito- 
urinary  medicine,  obstetrics,  neonatology,  virology,  gastroenterology,  hepatology, 
infectious  diseases,  haematology,  public  health  and  occupational  health.  The  high  cost 
8 of  managing  patients  with  HCV  enforces  the  need  for  a  systematic  approach  to  this 
condition  so  that  resources  are  used  most  effectively. 
Services  provided  for  prevention,  detection  and  management  of  chronic  HCV 
in  Scotland  have  so  far  been  guided  by  a  national  needs  assessment52  and  regional 
strategies55.  Projections  (with  uncertainty  limits)  of  moderate  and  severe  HCV-related 
disease  will  further  inform  the  planning,  and  subsequent  costing,  of  healthcare 
provision  for  HCV-infected  patients.  By  producing  projections  with,  and  without, 
implementation  of  a  range  of  treatment  and  prevention  interventions,  the  effectiveness 
(and  cost)  of  these  strategies  for  reducing,  or  delaying,  the  incidence  of  severe  HCV- 
related  disease  can  be  assessed  and  compared  with  similar  data  on  competing 
treatment  and  prevention  regimes  associated  with  other  conditions.  These  data  will 
thus  ultimately  inform  the  Scottish  Executive  Health  Department  as  to  the  level  of 
priority  to  give  HCV  infection  in  the  nation's  healthcare  budget. 
1.4  The  role  of  modelling  in  the  study  of  infectious  diseases 
Mathematical  and  statistical  models  have  played  a  significant  role  in  shaping  our 
understanding  of  the  epidemiology  of  infectious  diseases.  Primarily,  infectious  disease 
models  have  been  used  to  (i)  quantify  the  relationships  between  characteristics  of  a 
specific  disease,  the  contact  patterns  in  the  population  which  cause  transmission  and 
the  resulting  incidence  and  prevalence  of  the  disease,  (ii)  estimate  the  potential  impact 
of  proposed  interventions  on  the  incidence  and  prevalence  of  the  disease,  and  (iii) 
forecast  future  trends  in  disease  burden. 
Transmission  models  have  helped  to  determine  the  key  factors  influencing  the 
spread  of  HIV  and  other  sexually  transmitted  diseases56,  such  as  the  role  of  specific 
groups  of  individuals  with  high-risk  injecting  and  sexual  behaviours57.  The  natural 
9 history  of  HIV  infection  has  largely  been  informed  from  cohort  studies,  but  the  effect 
of  possibly  important  biological  parameters,  which  could  not  be  easily  studied 
empirically,  has  been  postulated  from  modelling.  For  example,  Longini  et  al.  58  argued 
based  on  modelling  results  that  infectiousness  is  very  high  in  the  first  acute  phase  of 
HIV  infection,  very  low  during  the  long  asymptomatic  phase  and  high  again  when  the 
first  symptoms  of  AIDS  become  manifest.  The  effect  of  this  phenomenon  was 
similarly  explored  in  modelling  work,  presented  in  Chapter  3,  undertaken  to  assess  the 
transmission  of  HCV  among  IDUs  in  Glasgow. 
Transmission  models  have  also  been  used  to  evaluate  the  effectiveness  of 
behavioural  and  medical  interventions  on  the  spread  of  infectious  diseases59.  Kaplan60 
modelled  the  spread  of  HIV  among  IDUs  via  shared  needles/syringes  in  shooting 
galleries  and  illustrated  that  the  provision  of  sterile  injecting  equipment  to  this 
population  by  needle  exchange  programmes  could  significantly  reduce  the  risk  of  new 
infections.  Mathematical  models  of  the  transmission  dynamics  of  the  hepatitis  B  virus 
have  provided  the  framework  to  assess  the  costs  and  benefits  of  different  vaccination 
strategies61.  In  recent  years,  models  have  been  developed  to  help  explore  the  impact  of 
control  measures  on  the  spread  of  hospital-acquired  infections62,  smallpox  from  a 
bioterrorism  attack63,  and  the  foot  and  mouth  epidemic64.  Chapter  3  presents  the 
findings  of  a  HCV  transmission  model  among  IDUs  in  Glasgow,  which  investigated 
the  changes  in  injecting  risk  behaviours  required  to  effect  appreciable  reductions  in 
the  incidence  and  prevalence  of  HCV  infection  in  this  population.  Furthermore, 
Chapter  6  outlines  the  impact  of  different  antiviral  treatment  strategies  on  the  future 
incidence  of  severe  HCV-related  disease  from  modelling  work  undertaken  among 
IDUs  in  Glasgow. 
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course  of  infectious  disease  epidemics.  The  back-calculation  method  has  been  most 
widely  used  in  projections  of  acquired  immune  deficiency  syndrome  (AIDS)65'66  and, 
more  recently,  variant  Creutzfeldt-Jakob  disease67.  This  approach  combines  available 
data  on  the  number  of  reported  cases  of  disease  (e.  g.  AIDS),  after  adjustment  for 
reporting  delays,  with  a  mathematical  representation  of  the  time  course  between 
infection  and  disease  diagnosis  to  back-calculate  the  number  of  persons  infected  in  the 
past  and  then  project  forward  to  obtain  predictions  of  the  future  incidence  of  disease. 
The  application  of  the  back-calculation  technique,  and  other  modelling  approaches,  to 
generate  projections  of  HCV-related  severe  sequelae  is  discussed  in  Section  1.5 
below. 
1.5  Previous  modelling  approaches  to  projecting  the  future  HCV-related  disease 
burden 
Markov  models  have  been  developed  to  determine  the  cost-effectiveness  of  treating 
chronic  HCV  infection  with  antiviral  therapy6s'69''0'71''2''3,  the  cost-effectiveness  of 
pre-treatment  management  strategies  74  ' 75,  and  the  future  healthcare  costs  of  not 
treating  HCV  infection  among  IDUs76'77.  The  prospect  of  an  alarming  rise  in  HCV- 
related  sequelae  over  the  next  10  to  20  years  is  generally  recognized,  and  thus  recently 
an  increasing  number  of  countries  -  namely  France78'79,  Australia  80'81,  the  United 
States  82'83'84,  Canada  85,  Switzerland86  and  Greece87 
- 
have  focussed  attention  on 
generating  projections  of  their  HCV  epidemics.  Few  of  these  have  however  attempted 
to  validate  their  projections  by  comparing  model  outcomes  to  past  epidemiological 
trends  relating  to  HCV  and  its  consequences83 Precise  quantification  of  the  future  HCV-associated  morbidity  and  mortality 
burden  requires  knowledge  of  both  the  past  incidence  of  HCV  infection  and  the 
natural  history  of  the  disease.  Reliable  data  on  the  progression  of  HCV  infection  are 
beginning  to  accumulate  as  the  length  of  follow-up  in  cohorts  of  chronically  infected 
cases  increases.  However,  determining  the  time  of  HCV  acquisition  for  all  currently 
infected  subjects  is  problematic  because  most  acute  infections  are  asymptomatic, 
clinical  disease  is  greatly  under-reported,  and  a  diagnostic  test  for  HCV  has  been 
available  only  since  1991  yet  epidemics  have  been  established  for  many  decades. 
Table  1.3  outlines  the  approaches  used  previously  to  model  the  future  HCV- 
related  disease  burden  in  other  countries,  with  emphasis  on:  (i)  estimation  of  the  past 
incidence  of  HCV  infection,  (ii)  account  for  mortality  from  causes  unrelated  to  HCV, 
(iii)  assumptions  used  to  model  the  progression  of  HCV  disease,  and  (iv)  data  used  to 
validate  model  results. 
1.5.1  Estimation  of  the  past  incidence  of  HCV  infection 
In  previous  HCV  projection  models,  the  past  incidence  of  HCV  infection  has  been 
generated  through  different  approaches:  (1)  back-calculation  of  HCV-related  HCC 
deaths,  (2)  estimation  of  the  past  pattern  of  injecting  drug  use  and  HCV  incidence 
among  IDUs,  (3)  adjustment  of  surveillance  data  on  acute  HCV,  and  (4)  calibration  of 
HCV  seroprevalence  and  HCC  mortality  data.  Rather  than  gauge  the  past  incidence  of 
HCV  infection,  a  fifth  approach  estimated  the  number  of  persons  currently  infected 
with  HCV  by  stage  of  disease.  These  five  approaches  are  described  below. 
12 1.5.1.1  Back-calculation  from  HCV-related  HCC  deaths 
Deuffic  et  al.  78  employed  the  back-calculation  technique  with  French  statistics  on 
HCV-related  HCC  deaths  during  1979-1995  (and  1979-1998  in  an  updated 
analysis79),  in  combination  with  data  on  the  age  distribution  at  infection  and  a  general 
model  of  the  natural  history  of  HCV  disease,  to  estimate  the  annual  incidence  of  HCV 
through  an  optimisation  process  which  essentially  minimized  the  difference  between 
modelled  and  observed  HCC  deaths  data. 
Implementation  of  the  back-calculation  model  relies  on  the  proportion  of  HCC 
deaths  attributed  to  HCV  being  known  and  also  on  the  consistency  and  completeness 
of  death  statistics  over  the  entire  time-period.  Even  if  this  information,  and  other  key 
data  described  above,  were  available,  the  slow  progression  of  the  virus  is  likely  to 
hinder  the  wider  application  of  this  approach  to  other  countries.  Many  decades  can 
elapse  before  decompensated  cirrhosis  or  HCC  develops  after  primary  HCV  infection. 
France's  HCV  epidemic  dated  back  to  the  1940s,  with  12,000  new  infections 
estimated  during  its  mid-epidemic  year  in  1955.  As  a  result,  France  witnessed 
between  1,000  and  1,700  HCV-related  HCC  deaths  per  annum  during  the  1990s78 
Therefore,  a  country's  HCV  epidemic  would  need  to  have  been  established  well 
before  1970  to  culminate  in  substantial  numbers  of  HCC  deaths  during  the  1990s. 
1.5.1.2  Estimation  of  the  past  pattern  of  injecting  drug  use  and  HCV  incidence 
among  IDUs 
The  approach  adopted  by  Law  et  al.  in  199980  and  200381  on  behalf  of  the  Hepatitis  C 
Virus  Projections  Working  Group  in  Australia  focussed  on  the  IDU  population  and 
applied  the  following  strategy:  (i)  first,  the  number  of  people  injecting  drugs  in 
Australia  over  the  last  three  decades  was  estimated;  (ii)  based  on  this  pattern  of 
13 injecting  drug  use  and  estimates  of  HCV  incidence  among  IDUs  derived  from  cohort 
studies,  HCV  incidence  as  a  result  of  injecting  drug  use  was  estimated;  (iii)  these 
estimates  of  HCV  incidence  due  to  injecting  drug  use  were  then  adjusted  in 
accordance  with  the  available  epidemiological  data  to  allow  for  HCV  infections 
through  other  transmission  routes,  including  receipt  of  blood  and  blood  products. 
Lack  of  data  on  the  prevalent  number  of  IDUs  in  Australia  at  the  time  of  the 
first  HCV  projection  report  meant  that  the  Delphi  technique  was  used  to  reach 
consensus  estimates80.  The  second  Australian  projection  report  was  able  to  refine 
these  estimates  based  on  data  obtained  through  modelling  of  overdose  deaths, 
methadone  maintenance  episodes  and  heroin  arrests81.  Law  et  al.  acknowledged  that 
the  incidence  of  HCV  infection  estimated  through  this  approach  was  particularly 
sensitive  to  assumptions  regarding  the  numbers  of  IDUs  and  HCV  incidence  rates 
among  IDUs  and  emphasised  the  need  to  corroborate  model  results  with  available 
epidemiological  data. 
1.5.1.3  Adjustment  of  surveillance  data  on  acute  HCV 
The  most  recent  model  developed  for  the  United  States  by  Davis  et  al.  84  estimated  the 
annual  incidence  of  HCV  infection  during  1982-1995  according  to  the  annual  number 
of  acute  HCV  infections  reported  to  the  Centre  for  Disease  Control  and  Prevention 
(CDC)  sentinel  surveillance  system,  with  adjustment  for  significant  underreporting 
and  the  recognition  of  only  symptomatic  acute  infection88'89.  The  annual  incidence  of 
infection  for  the  years  1950  to  1981  was  assumed  the  same  as  for  1982,  which  most 
likely  overestimated  infections  during  these  years. 
14 1.5.1.4  Calibration  of  HCV  seroprevalence  and  HCC  mortality  data 
Another  group  in  the  United  States  applied  a  model  fitting  approach  to  estimate  the 
past  incidence  of  HCV  infection  using  information  on  HCV  seroprevalence  and  HCC 
mortality  simultaneously.  A  comprehensive  and  complex  model  was  designed  to 
follow  the  entire  population  from  birth  to  death,  with  acquisition  of  HCV  assumed  to 
occur  through  three  major  routes:  mother-to-child  transmission,  transfusion-associated 
infection  and  community  infection,  including  injection  drug  use  and  sexual 
transmission.  Numerous  assumptions  were  explored  to  depict  the  HCV  incidence 
patterns  through  these  three  risk  categories.  A  review  of  the  literature  was  conducted 
to  define  plausible  ranges  around  model  parameters  (on  acquisition  of  infection, 
probability  of  persistence  and  risk  of  progression  to  end-stage  liver  disease),  and 
multiple  simulations  of  the  model  were  undertaken  using  sampled  values  from  these 
ranges.  Model  predictions  produced  by  each  set  of  sampled  values  were  compared 
with  data  on  HCV  seroprevalence  and  HCC  mortality  and a  range  of  HCV  incidence 
curves,  which  produced  consistent  results,  was  identified. 
1.5.1.5  Estimating  the  number  of  persons  currently  infected  with  HCV  by  stage 
of  disease 
Wong  et  al.  82  adopted  a  different  approach  for  the  United  States  to  those  described 
above;  using  national  household  survey  data,  this  entailed  the  estimation  of  the 
number  of  persons  infected  with  HCV  by  age  group  in  1991.  The  authors  accepted 
that  this  approach  had  likely  underestimated  infection  because  of  the  household 
survey's  non-representation  of  prisoners  and  homeless  people.  Further,  this  model  did 
not  consider  new  infections  occurring  after  1991.  Estimates  of  the  prevalent  number 
of  HCV  infected  persons  by  age  were  combined  with  liver  biopsy  data,  from  HCV- 
15 infected  patients  presenting  at  liver  clinics  for  treatment90,  to  determine  the  number  of 
persons  currently  infected  with  HCV  by  stage  of  liver  disease  (i.  e.  mild  hepatitis, 
moderate  hepatitis  and  cirrhosis).  Because  these  latter  patients  were  involved  in 
treatment  trials  and  subject  to  selection  bias,  the  authors  adjusted  the  proportion  of  the 
simulated  population  with  cirrhosis  so  that  the  simulated  number  of  HCV-related 
deaths  matched  that  estimated  from  other  sources82 
Sagmeister  et  al.  86  used  a  similar  approach  for  Switzerland,  which  combined 
(i)  HCV  antibody  prevalence  data  from  blood  donors  and  pregnant  women  to  estimate 
the  number  of  HCV-infected  persons  in  1998,  with  (ii)  liver  biopsy  data82  to  estimate 
disease  stage.  The  projection  models  developed  for  Canada85  and  Greece87  were  based 
also  on  the  estimated  number  of  persons  who  were  infected  with  HCV  in  1998  and 
1991,  respectively;  no  details  were  provided  of  the  methods  used  to  derive  these 
estimates.  The  Canadian  and  Greek  models  then  estimated  the  dates  of  HCV 
acquisition,  instead  of  the  current  stage  of  liver  disease,  for  their  currently  HCV- 
infected  populations;  this  was  achieved  by  assignment  of  infected  cases  to  either  age 
or  transmission  groups  and  assignment  of  duration  of  HCV  infection  intervals  to  each 
infected  case  on  the  basis  of  their  age  or  transmission  group,  according  to  data  from 
various  sources  but  mainly  from  patients  enrolled  in  treatment  studies.  The  Greek 
model  acknowledged  the  potential  under-representation  of  HCV-infected  IDUs  in  the 
treatment  studies  and  thus  performed  sensitivity  analyses  assuming  a  much  higher 
proportion  of  this  risk  group  87 
1.5.2  Accounting  for  mortality  from  causes  unrelated  to  HCV 
Seven  of  the  ten  previous  projection  models  applied  general  population,  some  age  and 
gender  specific,  rates  of  mortality  to  account  for  the  death  of  simulated  subjects  from 
16 causes  unrelated  to  HCV  (Table  1.3).  The  remaining  three  applications,  more 
appropriately,  have  taken  account  of  the  additional  non-HCV-related  mortality  risk  for 
individuals  who  acquire  HCV  infection  compared  to  the  general  population:  the  most 
recent  Australian  model  assumed  a  1%  annual  mortality  due  to  injecting  drug  use81; 
Wong  et  al.  explored  the  effect  of  an  excess  mortality  risk  for  persons  who  acquired 
their  HCV  through  injection  drug  use  (i.  e.  relative  risk  of  14,10  and  4  for  those  aged 
<21,21-30,  >30  years,  respectively,  compared  to  the  general  population)  and  blood 
transfusion  (i.  e.  additive  risk  of  0.15  per  year)82;  and  Salomon  et  al.  assumed  a2  to  5 
times  higher  risk  of  death  among  HCV-infected  persons  compared  to  the  general 
population83 
1.5.3  Assumptions  used  to  model  the  progression  of  HCV  disease 
Several  HCV  projection  models,  undertaken  in  the  United  States82'84,  Canada85  and 
Switzerland86,  based  their  assumptions  on  the  natural  history  of  HCV  on  an  early 
Markov  model  developed  by  Bennett  et  al.  to  determine  the  cost-effectiveness  of 
treating  chronic  HCV  infection  with  antiviral  therapy68.  In  this  model,  80%  of  newly 
HCV-infected  persons  developed  chronic  infection:  this  percentage  has  since  been 
shown  to  vary  between  60  and  90%3'4,  although  only  the  model  proposed  by  Salomon 
et  al.  83  accommodated  this  range. 
Bennett  et  al.  estimated  that  approximately  30%  of  HCV  chronically  infected 
persons  would  progress  to  cirrhosis  within  20  years  of  infection,  according  to  three 
cohort  studies  involving  only  126  patients91'9`.  The  disease  progression  parameters  in 
this  model  have  remained  largely  unchallenged,  and  have  been  applied 
elsewhere  82,84,85,86,  despite  an  improved  understanding  of  the  natural  history  of 
HCV93.  In  a  systematic  review  of  57  natural  history  studies,  estimates  of  progression 
17 to  cirrhosis  at  20  years  among  HCV  chronically  infected  persons  varied  considerably 
depending  on  the  methodology  employed:  24%  (95%  CI  11-37%),  22%  (18-26%),  7% 
(4-10%)  and  4%  (1-7%)  among  post-transfusion  cohorts,  liver  clinic  series, 
community-based  cohorts,  and  blood  donor  cohorts,  respectively  94.  The  community- 
based  studies  were  generally  longitudinal  with  known  time  of  HCV  infection, 
recruitment  was  not  based  on  presence  of  symptomatic  or  established  chronic  liver 
disease,  and  their  combined  epidemiological  characteristics  -  mean  age  of  26  years  at 
infection  and  injecting  drug  use  reported  in  57%  -  were  broadly  representative  of 
HCV-infected  populations  in  most  western  countries.  Thus,  estimates  of  disease 
progression  derived  from  the  community-based  studies  would  appear  to  be  the  most 
appropriate  for  population  level  HCV  natural  history  models93  and  have  been  used  to 
produce  HCV  projections  in  Australia81. 
Estimates  of  higher  liver  disease  progression  rates  may  be  seen  in  settings 
where  the  prevalence  of  cofactors  for  liver  disease  progression  are  higher  than  those 
observed  in  the  community-based  studies  included  in  the  systematic  review  (i.  e.  mean 
age  at  HCV  acquisition  was  26  years,  heavy  alcohol  intake  was  reported  in  10%,  and 
co-infection  with  HIV  was  uncommon)95.  In  particular,  settings  with  a  high 
prevalence  of  heavy  alcohol  intake  or  HIV  co-infection  would  be  expected  to  have 
higher  rates  of  HCV-related  morbidity  and  mortality,  and  therefore  population  level 
models  would  need  to  be  adjusted  in  line  with  prevalences  of  these  factors  and  their 
influence  on  disease  progression.  Deuffic  et  al.  found  that  progression  to  cirrhosis 
depended  strongly  on  age  at  HCV  infection  and  gender:  for  example,  risk  of 
progression  to  cirrhosis  was  300  times  higher  for  men  aged  61-70  years  than  for  those 
aged  21-40  years;  and  at  any  age,  risk  in  men  was  ten  times  higher  than  in  women78. 
Age  and  gender  adjusted  HCV  progression  rates  have  frequently  been  used  in  HCV 
18 projection  models78'79'83'87,  but  only  Wong  et  a1.82  explored  the  influence  of  heavy 
alcohol  use. 
Although  some  Markov  models  have  overestimated  rates  of  progression  to 
cirrhosis,  those  from  cirrhosis  to  advanced  liver  disease  complications  (i.  e. 
decompensated  cirrhosis  and  HCC)  may  be  more  accurate  because  estimates  are  less 
subject  to  clinic  referral  bias.  The  incidences  of  decompensated  cirrhosis  and  HCC 
among  people  with  compensated  cirrhosis  were  estimated  in  the  ranges  3-6%  and  0.5- 
4%  per  year,  respectively,  although  mortality  from  liver  failure  and  HCC  varied 
considerably  in  the  ranges  14-40%  and  30-90%  per  year,  respectively  (Table  1.3). 
Finally,  as  relatively  few  HCV  chronically  infected  persons  have  received  antiviral 
therapy  in  most  western  countries  (e.  g.  less  than  2.5%  in  Australia93),  the  impact  of 
current  treatment  uptake  has  not  been  a  major  feature  in  HCV  projection  models. 
1.5.4  Data  used  to  validate  model  results 
Several  countries  have  developed  models  to  forecast  the  future  course  of  their  HCV 
epidemic,  but  few  have  validated  their  predictions  by  fitting  model  outcomes  to  past 
epidemiological  trends  relating  to  HCV  and  its  consequences  (Table  1.3).  Two  of  the 
approaches  described  above  used  a  model  fitting  process  to  derive  HCV  projections: 
Deuffic  et  at.  back-calculated  from  HCV-related  HCC  deaths  data78'79  and  Salomon  et 
al.  calibrated  data  on  HCV  seroprevalence  and  HCC  mortality83.  Others  have  only 
compared  model  outcomes  with  data  on  the  prevalent  number  of  IDUs  and  HCV- 
infected  persons84'81.  Salomon  et  al.  suggested  that  in  the  development  of  future 
projections  of  HCV  epidemics,  a  minimal  requirement  might  be  that  models  use 
parameter  values  that  are  consistent  with  past  epidemiological  data83. 
19 1.6  Approach  to  HCV  projections  for  Scotland:  aims  and  overview  of  methods 
As  presented  in  this  thesis,  a  forward  estimation  and  projection  approach,  similar  to 
that  adopted  in  Australia  80'  81,  was  used  to  model  the  past,  current  and  future  burden  of 
HCV  disease  among  IDUs  in  Scotland.  The  modelling  focussed  on  the  IDU 
population  because,  as  established  in  Section  1.2,  the  overwhelming  majority  of  HCV 
infections  and  much  of  the  epidemiological  data  related  to  HCV  in  Scotland  have 
been  associated  with  this  risk  group. 
Development  of  an  HCV  projection  model  for  Scotland  was  guided  by  two 
fundamental  criteria:  (a)  that  the  model  should  accurately  reflect  both  the  knowledge 
and  uncertainty  about  major  parameters  relating  to  the  epidemiology  and  natural 
history  of  HCV  on  the  basis  of  the  best  available  local  and  international  data,  and  (b) 
that  modelled  outcomes  should  be  consistent  with  epidemiological  data  to  date 
describing  the  population  impact  of  the  HCV  epidemic  in  Scotland.  A  limitation  of 
the  majority  of  previous  modelling  efforts,  as  discussed  above  in  Section  1.4.4,  was 
the  absence  of  the  latter  constraint  in  checking  the  validity  of  model  predictions. 
The  overall  aim  is  to  estimate  the  number  of,  both  current  and  former,  IDUs 
who  have  acquired  HCV  infection  and  will  progress  to  mild,  moderate  and  severe 
HCV  disease  now  and  in  the  future.  Figure  1.1  outlines  the  division  by  chapters  of  the 
data  which  were  used  (a)  as  input  parameters  to  and  (b)  to  check  the  validity  of  the 
HCV  projection  model.  The  strategy  was  to  capture  the  essential  features  of  the  HCV 
epidemic  among  IDUs  initially  in  Glasgow,  because  more  epidemiological  data  exist 
for  this  region  than  elsewhere  in  Scotland,  and  calibrate  model  outcomes  with 
available  data  relating  to  HCV  and  its  consequences.  Insights  gained  from  the  model 
fitting  process  in  Glasgow  on  the  epidemiology  and  natural  history  of  HCV  were  used 
to  improve  the  basis  for  extending  the  model  to  the  rest  of  Scotland.  It  was  important 
20 to  distinguish  between  current  and  former  IDUs  not  only  for  purposes  of  modelling 
the  HCV  epidemic,  but  also  to  help  establish  the  number  of  HCV  chronically  infected 
IDUs  eligible  for  antiviral  therapy;  current  injecting  drug  use,  generally,  is  a 
contraindication  to  antiviral  therapy  because  of  poor  compliance  and  the  risk  of  re- 
infection  with  HCV. 
The  HCV  progression  model  was  designed  to  incorporate  both  the  knowledge 
and  uncertainty  about  major  parameters  relating  to  (i)  the  incidence  and cessation  of 
injecting  drug  use  and  mortality  from  causes  unrelated  to  HCV,  (ii)  the  incidence  of 
HCV  infection  among  current  IDUs,  and  (iii)  the  rate  of  HCV  disease  progression, 
including  the  influence  of  host  factors  (Figure  1.1(a)).  First,  the  incidence  and 
cessation  of  injecting  drug  use  in  Glasgow  were  derived  through  the  use  of  a  modified 
Delphi  approach,  which  combined  expert  opinion  with  capture-recapture  IDU 
prevalence  estimates,  as  described  in  Chapter  2.  Mortality  from  causes  unrelated  to 
HCV  among  current  and  former  IDUs  was  based  on  estimates  from  the  literature,  as 
detailed  in  Chapter  6.  Secondly,  stochastic  simulation  was  developed  to  model  the 
transmission  of  HCV  among  current  IDUs  in  Glasgow,  according  to  the  injecting  risk 
behaviours  and  the  characteristics  (i.  e.  transmissibility  and  chronicity)  of  the  virus, 
and  to  estimate  the  incidence  of  HCV  infection,  as  described  in  Chapter  3.  The 
transmission  model  detailed  in  Chapter  3  was  also  used  to  examine  the  impact  of 
changes  in  injecting  risk  behaviours  on  the  incidence  of  HCV  infection.  For  the  third 
component  of  the  projection  model,  the  worldwide  literature  was  reviewed  to  inform 
the  rate  of  HCV  disease  progression,  as  detailed  in  Chapter  6.  A  meta-analysis  was 
performed  to  quantify  the  effect  of  heavy  alcohol  use  on  progression  to  cirrhosis  in 
persons  with  chronic  HCV,  as  described  in  Chapter  5. 
21 Modelled  outcomes  were  fitted  to  epidemiological  data  on  the  prevalent 
number  of  current  IDUs  (based  on  published  capture-recapture  estimates  described  in 
Chapter  2),  the  prevalence  of  HCV  infection  among  current  IDUs  (based  on  survey 
data  described  in  Chapter  3),  and  the  number  of  IDUs  developing  HCV-related 
decompensated  cirrhosis  each  year  (Figure  1.1  (b)).  The  latter  data  on  the  occurrence 
of  HCV-related  liver  failure  were  obtained  through  record-linkage  of  Scotland's 
national  surveillance  system  of  all  persons  diagnosed  HCV  antibody  positive  with 
other  national  computerised  databases  on  hospital  discharges  and  deaths,  as  described 
in  Chapter  4.  Chapter  6  then  synthesizes  the  data  gathered  in  previous  chapters  to 
develop  a  comprehensive  model  to  estimate  the  number  of  current  and  former  IDUs 
who  had  acquired  HCV  infection  and  progressed  to  mild,  moderate  and severe  HCV 
disease  in  Glasgow  and  Scotland,  1960-2030.  Finally,  this  projection  model  was  used 
to  explore  the  impact  of  different  antiviral  treatment  strategies  on  the  future  incidence 
of  severe  HCV-related  disease. 
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N Chapter  2:  Estimating  the  prevalence,  incidence  and  cessation  of  injecting 
drug  use  in  Glasgow  1960-2000:  combining  expert  opinion  with  capture- 
recapture  prevalence  data 
2.1  Introduction 
Estimation  of  the  size,  and  trends  in  the  size,  of  injecting  drug  user  (IDU)  populations, 
locally  and  nationally,  is  fundamental  to  the  planning  and  development  of  health-care 
services  for  this  group'o2°'03  Detection  among  IDUs  of  high  prevalences  of  hepatitis  C 
virus  (HCV)  infection  (highlighted  in  Section  1.2),  which  can  lead  in  the  long-term  to 
cirrhosis  and  hepatocellular  carcinoma  104,  has  placed  even  greater  emphasis  on  the 
importance  of  quantifying  the  dynamics  of  this  population12'los  Data  on  the  incidence 
and  cessation  of  injecting  drug  use  are  essential  if  the  future  burden  of  HCV  disease  is 
to  be  predicted  through  statistical  modelling  initiatives. 
Epidemiological  studies  of  the  epidemic  spread  of  IDU  in  the  United  Kingdom 
(UK),  generally,  have  been  limited  to  those  which  use  indirect  methods  to  estimate 
prevalence  for  a  specific  calendar  year  106  Log-linear  modelling  of  capture-recapture 
data  was  first  applied  in  Glasgow102  to  estimate  the  prevalent  number  of  current  IDUs 
in  1989107  (central  estimate  9,420;  95%  Cl  6,960-11,880);  further  estimates  were 
generated  in  199018  (8,490;  7,490-9,720)  and  2000100  (7,190;  6,090-8,620).  The  city 
was  thereby  identified  as  being  home  to  approximately  a  third  of  Scotland's  IDUs'°8 
and  having  one  of  the  highest  IDU  prevalences  in  Europe'  9.  Few  studies  have 
attempted  to  derive  estimates  of  the  incident  number  of  IDUs  due  to  the  shortage  of 
appropriate  data  sources109,110,111,112 
Lacking  Scottish  or  UK  data  to  generate  an  IDU  epidemic  curve  for  the  past 
four  decades  (i.  e.  since  the  earliest  reports  of  IDU),  the  use  of  expert  opinion  to  elicit 
28 one  for  Glasgow  was  investigated  and  presented  in  this  chapter.  Such  elicitation  has 
been  used  to  gauge  the  prevalent  number  of  IDUs  in  Australia80,14  13  and  Canada' 
The  study  was  confined  to  the  Greater  Glasgow  Health  Board  area  because  of  the 
added  complexity  of  eliciting  expert  opinion  at  a  national,  rather  than  local,  level  and 
also  due  to  the  existence,  for  that  area,  of  published  data  on  IDU  prevalence  (as 
outlined  above)  to  anchor  experts'  estimates. 
2.2  Methods 
2.2.1  Design  and  data  collection 
A  modification  of  the  Delphi  technique,  originally  described  by  Dalkey115,  was  used 
to  reach  consensus  estimates  on  the  prevalent  and  incident  number  of  injectors  and 
percentage  ceasing  IDU.  Experts  were  defined  as  individuals  whose  extensive 
experience  and  knowledge  about  drug  use  was  specific  to  Greater  Glasgow.  Five  key 
informants,  from  different  professions  (academia,  drugs  service  work,  law 
enforcement,  medicine,  and  sociology),  were  initially  contacted  to  invite  their 
participation  and,  in  the  first  instance,  nomination  of  other  experts.  All  five  informants 
were  willing  to  participate  and  nominated  a  further  16  experts,  who  were  subsequently 
contacted  by  telephone,  where  possible,  or  email  to  explain  the  study  and  to  verify 
willingness  to  participate.  The  overall  volunteer  rate  of  experts  was  95%  (20/21):  the 
five  key  informants  and  15  of  the  16  informant-nominated  experts;  one  person  refused 
because  of  concerns  about  the  validity  of  the  Delphi  approach. 
The  20  experts  were  asked,  in  May  2001,  to  complete  anonymously  a  postal 
questionnaire  (attached  in  Appendix,  Section  2.5).  The  questionnaire  asked  for  central 
estimates,  and  90%  certainty  ranges,  per  quinquennium  during  1960-2000  of  (i) 
prevalence  (i.  e.  "the  number  of  people  injecting  drugs  during  each  year"),  (ii) 
29 incidence  (derived  from  two  questions,  which  asked:  (1)  "relative  to  an  arbitrary 
benchmark  of  1,000  initiates  into  IDU  in  1990,  estimate  the  number  of  initiates  in 
other  years",  and  (2)  "given  that  the  benchmark  of  1,000  initiates  was  chosen  for 
convenience,  estimate  the  actual  number  of  initiates  into  IDU  in  1990"),  and  (iii) 
cessation  of  injecting  (i.  e.  "out  of  1,000  injectors  at  the  start  of  a  calendar  year,  who 
survive  throughout  the  year,  estimate  the  number  who  would  have  permanently 
stopped  injecting  in  that  year").  In  addition,  participants  were  asked  to  return, 
separately  from  their  completed  questionnaire,  a  named  postcard,  indicating  that  they 
had  completed  and  returned  their  questionnaire,  which  allowed  reminders,  at  least  two 
in  the  form  of  letters  and  emails,  to  be  sent  to  non-responders  during  June-July  2001. 
As  a  mark  of  appreciation,  participating  experts  were  included  in  a  prize  draw,  by  way 
of  the  named  postcard,  for  a  £30  book  voucher.  Twelve  of  the  20  experts  (5/5 
informants  and  7/15  informant-nominees)  returned  questionnaires  by  the  end  of 
August  2001.  Unlike  the  classic  Delphi  technique  115,  an  iterative  process  was  not  used 
to  refine  these  experts'  opinions.  Instead,  results  were  compared  with  empirical 
estimates  of  the  prevalent  number  of  current  injectors  during  199018  and  2000100  and 
an  adaptation  of  rejection  sampling116  was  substituted  for  the  usual  iterative  process 
(described  in  Analyses  below). 
2.2.2  Background  on  experts 
The  professions  of  the  12  experts  who  returned  questionnaires  included  academia, 
drugs  service  work,  law  enforcement,  medicine  and  sociology.  Participating  experts 
reported  their  experience  of  the  drug  use  field  in  Glasgow  to  be  limited  during  the 
1960s  and  1970s,  and  knowledgeable  during  1985  onwards.  Key  data  sources  which 
experts  indicated  had  shaped  their  opinions  were:  (i)  early  reports  of  the  rise  in  drug 
30 use  117,118,119;  (ii)  capture-recapture  prevalence  estimates'8;  (iii)  hepatitis  B  virus 
reports  (from  the  early  1980s)120;  (iv)  registrations  of  new  attendances  at  drug  services 
(only  available  for  the  1990s  and  influenced  by  the  increased  capacity  to  treat  drug 
users  over  time)121;  and  (v)  their  own  observations  and  discussions  with  people 
working  in  the  field.  Prevalence  estimates  from  capture-recapture  studies  (ii)  were 
intrinsic  to  the  assessment  of  experts'  consensus  (described  below);  furthermore, 
comparisons  were  also  drawn  with  data  from  (i)  and  (iii)  (see  Discussion). 
2.2.3  Analyses 
Using  S-PLUS  software122,  data  analysis  consisted  of: 
(a)  An  examination  of  experts'  estimates  including  the  identification  of  outlying 
values;  an  expert's  set  of  responses  (i.  e.  central,  lower  and  upper  estimates)  to 
either  prevalence,  incidence  or  cessation  in  a  particular  calendar  year  was 
regarded  as  outlying  if  the  central  estimate  lay  beyond  the  median  90%  certainty 
range  for  all  experts  by  more  than  50%. 
(b)  Based  on  the  restricted  opinion  of  experts  (i.  e.  with  outlying  values  removed), 
their  estimates  were  used  to  provide  a  single  consensus  distribution,  which 
permitted  the  generation  of  an  overall  mean,  median,  and  lower  and  upper  90% 
certainty  limit  for  the  three  main  parameters  of  (i)  prevalence,  (ii)  incidence  and 
(iii)  cessation  in  each  quinquennium.  For  each  expert's  reported  range,  their 
central  value  was  assumed  to  be  their  most  likely  estimate  for  that  parameter  and, 
thus,  a  triangle  distribution  was  applied  to  each  expert's  set  of  responses  (i.  e. 
central,  lower  and  upper)  for  each  parameter.  A  triangle  distribution  was  used  in 
preference  to  other  standard  probability  distributions  (e.  g.  normal  or  log-normal) 
due  to  the  varying  skewness  of  parameter  estimates  between  experts.  A  consensus 
31 distribution  was  then  generated  for  each  parameter  by  sampling  1,000 
observations  randomly  from  available  experts'  triangle  distributions; 
(c)  To  examine  the  coherency  of  experts'  estimates,  prevalences  obtained  from 
experts  in  (b)(i)  and  externally  from  other  studies18,100  were  compared  with  a 
constructed  prevalence  distribution  derived  by  combining  expert  data  on 
incidence  from  (b)(ii)  and  cessation  from  (b)(iii)  and  accounting  for  1-2%  per 
annum  mortality  123  '  124  The  following  expressions  were  used: 
Aj 
P#,  -l,; 
+  q,  j-  ((r,  1+  s;  )  x  (pti-i,  i  +  qi)) 
for  i=1960;  j=1,...,  1000; 
for  i=1961,...,  2000;  j=1,...,  1000; 
where,  in  a  given  calendar  year  i  for  thejth  simulation,: 
p*;  j  represents  the  prevalent  number  of  injectors; 
P1960j  represents  the  prevalent  number  of  injectors  in  1960,  which  was  randomly 
sampled  from  the  prevalence  distribution  (b)(i)  for  1960; 
s;  j  represents  the  mortality  rate  per  annum,  which  was  sampled  from  a  uniform 
distribution  with  range  0.01  to  0.02; 
q  ;j  and  r  ;j  represent  the  incident  number  of  injectors  and  proportion  ceasing 
injecting,  respectively,  per  annum,  which  were  randomly  sampled  from  the 
respective  incident  and  cessation  distributions,  (b)(ii)  and  (b)(iii),  in  each 
quinquennial  year,  with  values  in  between  these  years  deduced  from  linear 
interpolation  (note:  variations  on  the  linear  assumption  were  explored); 
(d)  To  derive  coherent  estimates,  combinations  of  incidence  and  cessation  values 
were  sampled  from  the  consensus  distributions,  generated  in  (b),  and  those  which 
formed  prevalence  coherent  both  with  published  prevalence  estimates  (in  199018 
and  2000100)  and  with  experts'  consensus  on  prevalence  (in  the  remaining 
quinquennia)  were  retained.  Following  on  from  methods  described  in  (c),  values 
32 of  q,  r  and  s  were  therefore  rejected  if  the  formulated  prevalence  did  not  fall 
within  the  95%  confidence  limits  of  prevalence  reported  from  capture-recapture 
studies  in  1990  and  2000  and  within  the  90%  certainty  range  of  consensus 
distributions,  (a)(i),  generated  from  expert  opinion  in  years  1960,1965,1970, 
1975,1980,1985,  and  1995. 
2.3  Results 
2.3.1  Experts'  estimates:  compliance  and  outliers 
Prevalence,  incidence  and  cessation  estimates  were  provided  by  a  mean  of  9  (standard 
deviation  1.7),  9  (1.7),  and  6  (2.0)  experts,  respectively,  for  quinquennia  during  1960- 
2000.  Three  of  the  12  experts  consistently  provided  estimates  well  beyond  the  general 
consensus. 
2.3.2  Experts'  consensus  estimates  of  prevalence,  incidence  and  cessation 
Table  2.1(i)  and  (ii)  provide  a  summary  of  experts'  responses,  with  outlying  values 
removed.  According  to  expert  opinion,  prevalence,  incidence  and  cessation  of  IDU 
remained  relatively  low  and  stable  during  1960-1975,  rising  several  fold  between 
1975  and  1980  (3.3-4.0  times  based  on  median  prevalence;  5.5-8.8  times  for 
incidence;  and  5.0-6.0  times  for  cessation),  rising  again  between  1980  and  1985  (4.7- 
5.0  times  for  prevalence;  1.9-2.4  times  for  incidence;  and  1.2-1.3  times  for  cessation), 
and  thereafter  incidence  declined  marginally  but  prevalence  and  cessation  both  rose 
further. 
33 2.3.3  Examining  the  coherence  of  experts'  consensus  estimates  on  prevalence, 
incidence  and  cessation 
Figure  2.1  illustrates  that  the  prevalence  distribution  (3),  constructed  from  combining 
experts'  consensus  on  incidence  and  cessation,  corresponds  well  with  experts' 
consensus  on  prevalence  (1)  during  1960-1980,  but  then  underestimates,  during  1985- 
2000,  both  their  own  consensus  on  prevalence  (1)  and  also  capture-recapture 
estimates  (2). 
2.3.4  Deriving  coherent  estimates  on  prevalence,  incidence  and  cessation 
Figure  2.1  also  shows  the  coherence  prevalence  distribution  (4)  constructed  from 
experts'  consensus  on  incidence  and  cessation,  using  rejection  sampling  to  filter  out 
combinations  which  were  not  coherent  with  prevalence  estimates  from  experts  (1)  and 
capture-recapture  studies  (2). 
Table  2.1  summarises  these  data  and  highlights  that  experts  had  under- 
estimated  the  number  of  incident  injectors  in  1985,1990  and  2000  (median 
consensus:  1,120,1,095  and  948,  compared  to  median  coherence  distribution:  1,335, 
1,375  and  1,195,  respectively)  and  also  over-estimated  the  percentage  of  current 
injectors  permanently  ceasing  injecting  in  four  quinquennia  during  1985-2000 
(median  consensus:  14%,  10%,  15%  and  17%,  median  coherence  distribution:  6%, 
10%,  12%  and  15%,  respectively).  From  the  coherence  distributions,  the  incident 
numbers  of  injectors  obtained  in  2000  from  1,000  simulations  were  greater  than  those 
in  1990  and  1995  in  36%  and  69%  of  cases,  respectively.  Similarly,  the  percentages 
ceasing  injecting  during  2000  obtained  from  1,000  simulations  were  greater  than 
those  in  1990  and  1995  in  93%  and  67%  of  cases,  respectively. 
34 The  constraint  imposed  on  prevalence  in  the  rejection  sampling  process  for  the 
year  2000  was  altered  from  the  range  6,085-8,515,  based  on  capture-recapture  data  '°°9 
to  7,900-15,950  according  to  experts'  consensus.  This  produced  a  coherent  prevalence 
central  estimate  of  8,354  (90%  certainty  range  7,935-9,865)  for  2000,  which  was  still 
closer  to  that  of  the  capture-recapture  estimate  (7,187)  than  that  of  the  experts'  central 
consensus  (11,931). 
2.4  Discussion 
Models  to  estimate  the  future  burden  of  HCV  infection  among  injectors,  recently 
acknowledged  as  a  priority  for  future  work  in  the  Department  of  Health's  "Hepatitis  C 
Strategy  for  England"  125,  require  estimates  of  the  number  of  people  starting  and 
ceasing  to  inject  over  time80'108.  Whilst  the  importance  of  knowledge  on  incidence  and 
cessation  of  IDU  has  long  been  recognisedlos,  few  attempts  have  been  made  to 
estimate  these  in  the  UK110'111  because  of  the  limitations  of  available  data  sources 
which,  generally,  have  been  either  incomplete  in  years  or  not  representative  of  the 
whole  population121 
The  first  indication  of  an  injecting  epidemic  in  Glasgow  was  evident  in  the 
early  1980s  when  a  sharp  rise  was  reported  in  the  number  of  people  seeking  treatment 
at  hospitals  for  heroin  addiction"8.  Further  consideration  of  routine  statistics  and 
fieldwork  data  led  Haw  to  estimate  that there  were  approximately  5,000  problem  drug 
users  in  Glasgow  in  1983  1  19.  In  the  early  1990s,  Frischer  et  al.,  using  capture- 
recapture  methods  which  were  applied  to  data  from  treatment  centres,  needle/syringe 
exchange  schemes,  HIV  testing  laboratories  and  the  police  in  Glasgow,  estimated  a 
total  of  8,490  (95%  CI  7,490-9,720)  current  drug  injectors'8.  Glasgow,  a  city  with  an 
extensively  studied  drug  problem,  has  been  at  the  forefront  of  IDU  prevalence 
35 estimation102;  hitherto,  however,  no  consensus  had  been  sought  on  the  size  and  shape 
of  its  IDU  epidemic  curve. 
The  Delphi  approach,  essentially,  is  a  way  to  reach  a  consensus  or  a  range  of 
possible  values  for  an  uncertain  parameter.  The  reliability  of  Delphi  estimates, 
however,  can  only  be  judged  in  relation  to  other  observed  data.  In  previous  studies, 
IDU  prevalence  estimates  generated  through  the  elicitation  of  expert  opinion 
compared  well  with  estimates  derived  using  other  methods.  In  Australia,  Delphi 
estimates  of  the  number  of  dependent  injectors  in  199780  were  consistent,  allowing  for 
the  difference  in  population  groups,  with  estimates  of  the  number  of  dependent  heroin 
users,  obtained  through  the  use  of  three  different  methods  (i.  e.  back-projection, 
capture-recapture,  and  multiplier)'  13.  Similarly,  Delphi  estimates  of  the  injector 
numbers  in  Toronto,  Montreal  and  Vancouver  during  1996  were  of  the  same  order  as 
those  obtained  by  capture-recapture  methods114  All  of  these  applications,  however, 
relied  on  responses  from  relatively  small  groups  of  experts,  which  probably  reflects 
the  rarity  of  persons  working  in  this  field  with  sufficient  knowledge  and experience. 
This  study  was  similarly  weakened  by  the  modest  participation  rate  (12/21)  of 
nominated  experts,  which  illustrates  the  difficulty  or  reluctance  experts  had  in 
quantifying  parameters.  However,  this  study  differs  in  design  from  its 
predecessors  80'114,  which  did  not  report  on  elicitation  of  injector  incidence  and 
cessation,  thereby  enabling  a  check  to  be  made,  as  here,  on  internal  as  well  as  external 
coherence. 
Expert  consensus  on  IDU  prevalence  indicated  that  the  scale  of  the  injecting 
problem  in  Glasgow  had  been  minimal  between  1960  and  1975  and  epidemic 
throughout  the  1980s.  Whilst  these  findings  conform  with  the  reports  outlined 
above'  18,119,  it  must  be  highlighted  that  the  early  years,  in  particular  1960,1965  and 
36 1970,  encountered  the  most  non-responses  from  experts.  This  is  likely  to  have  been 
caused  by  either  limited  experience,  problems  with  recall  or  lack  of  empirical  data, 
which  admittedly  raises  concerns  about  the  reliability  of  the  Delphi  approach.  Experts 
revealed  that  their  estimates  had  also  been  shaped  according  to  the  rise  in  laboratory 
reports  of  hepatitis  B  virus  infections  during  the  early  1980s120.  Figure  2.2  illustrates 
the  sharp  rise  in  these  reports  among  those  aged  15  to  24  years  -  indicative  of  the  age 
at  which  IDUs  commence  injecting  -  during  the  early  to  mid  1980s,  which  aligns  well 
with  the  estimated  incident  number  of  IDUs  derived  from  this  study.  The  number  of 
HBV  reports  decreased  during  the  late  1980s  and  1990s  as  a  result  of  reduced 
injecting  risk  behaviours126  and  vaccination  against  HBV. 
For  2000,  experts  over-estimated  the  prevalence  of  IDU  (median  consensus 
11,930;  90%  certainty  range  7,900-15,950)  compared  to  that  derived  in  a  capture- 
recapture  study  (central  estimate  7,190,95%  CI  6,090-8,620)  published  in  September 
2001100.  Experts  were  unaware  of  the  findings  from  the  capture-recapture  study  for 
the  year  2000  when  they  provided  their  opinions.  The  wide  certainty  range 
surrounding  experts'  central  consensus  on  prevalence  in  2000  reflected  their  difficulty 
in  quantifying  this  unknown.  The  high  prevalence  reported  by  experts  for  2000  may 
also  have  been  influenced  by  a  Needs  and  Resources  Report  127  published  in  2000,  in 
which  the  number  of  Glasgow  problem  drug  misusers  (defined  by  the  regular  use  - 
either  injecting  or  non-injecting  -  of  heroin,  benzodiazepines,  cocaine  and/or 
amphetamines)  was  indicated,  based  on  limited  data  and  methods,  to  be  in  the  range 
12,400-15,400. 
The  collection  of  opinion  on  incidence  and  cessation  of  IDU  in  this  study, 
although  a  challenge  to  experts  (as  indicated  by  the  extent  of  non-responses  and  wide 
certainty  ranges  around  parameters),  provided  an  opportunity,  not  previously 
37 explored,  to  combine  these  data  and  examine  coherence  with  estimates  of  prevalence. 
Experts'  opinions  on  prevalence,  incidence  and cessation  were  neither  internally  nor 
externally  coherent,  but  coherence  was  enforced  by  an  adaptation  of  rejection 
sampling.  Through  this  process,  experts  were  shown  to  have  under-estimated  the 
number  of  incident  injectors  and  over-estimated  the  percentage  ceasing  injecting 
during  1985-2000.  The  simulations  also  indicated  that  whilst  cessation  of  IDU  had 
risen  throughout  the  1990s,  a  finding  which  is  in  keeping  with  the  expansion  of  the 
methadone  prescribing  and  other  drug  treatment  services  in  Glasgow128,  there  is 
however  cause  for  concern  at  the  rise  in  the  incident  number  of  injectors  in  the  year 
2000  compared  to  that  in  1995. 
The  external  point  estimates  and  confidence  intervals  on  prevalence  were 
essential  to  anchor  experts'  opinions,  although  wide  certainty  ranges  still  remain 
around  parameters;  ideally,  external  data  on  incidence  and  cessation  would  have  been 
incorporated,  if  available,  into  the  rejection  sampling  process.  Clearly,  further  efforts 
are  required  to  collect  data  which  will  allow  accurate  estimation  of  the  incidence  and 
cessation  of  IDU  both  regionally  and  temporally.  These  data  are  necessary  to  inform 
policy-making,  in  terms  of  determining  coverage  and  assessing  the  effectiveness  of 
preventive  measures  and  treatment  options  targeted  at  injectors. 
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3 Chapter  3:  Modelling  the  spread  of  hepatitis  C  virus  infection  among 
injecting  drug  users  in  Glasgow  1960-2000 
3.1  Introduction 
Injecting  drug  users  (IDUs)  are  at  high  risk  of  acquiring  hepatitis  C  virus  (HCV) 
infection  through  the  multi-person  use  of  injection  equipment,  principally 
needles/syringes129.  High  seroprevalences  of  HCV  antibodies,  in  the  range  50-90%, 
have  been  detected  in  surveys  of  IDUs  throughout  the  developed  world12'13o  HCV, 
generally,  has  a  long  and  variable  asymptomatic  incubation  period  before  it  causes 
severe  liver  disease  131.  The  enormous  health  and  economic  burden  this  infection 
presents  is  increasingly  being  recognised  80'82 
HCV  has  been  circulating  among  IDUs  in  Scotland  since  at  least  the  early 
1980s2°  when  there  were  reports  of  a  rapid  rise  in  the  number  of  IDUs  in 
Glasgow'  18'120,  Scotland's  largest  city.  In  1990,  Glasgow  had  approximately  8,500 
IDUs'8,  almost  half  of  Scotland's  injecting  population  108,  and  one  of  the  highest 
population  prevalences  (2.7%  of  20-29  year  olds)  in  Europe.  The  prevalence  of  HCV 
antibodies  among  IDUs,  having  reached  74%  by  1990-9147,  suggests  that  HCV  spread 
rapidly  throughout  this  population  during  the  1970s/1980s.  During  the  1990s,  an 
ecological  association  between  reductions  in  HCV  prevalence  and  the  development  of 
harm  reduction  initiatives  was  evident47'132;  nevertheless,  the  incidence  of  HCV 
remained  high  in  1999/200050 
Because  of  the  extent  of  the  past,  current  and  likely  future  burden  of  HCV  - 
and  the  wealth  of  available  epidemiological  data  -  it  was  considered  both  necessary 
and  feasible  to  model  the  relationship  between  needle/syringe  sharing  and  the 
incidence  of  HCV  among  IDUs  in  Glasgow  during  1960-2000.  This  model  would 
46 inform  on  the  past  incidence  of  HCV  infection  in  this  population  and  permit  the 
gauging  of  changes  in  risk  behaviours  required  to  effect  appreciable  reductions  in  the 
incidence  of  HCV  infection.  Such  insights  will  inform  those  responsible  for 
developing  new  ways  to  prevent  HCV  transmission  among  IDU  populations. 
3.2  Methods 
3.2.1  Overview 
Stochastic  modelling  was  used  to  simulate  (day  by  day)  the  transmission  of  HCV, 
during  1960-2000,  through  the  sharing  of  used  needles/syringes  among  current  IDUs, 
on  an  individual  basis,  from  their  onset  of  injecting  drug  use.  Individuals  were  given 
the  potential  to  progress  through  three  states  of  infection:  susceptibility,  acute  and 
chronic.  As  detailed  below,  the  models  were  designed  to  use  available  information  on 
(a)  the  incidence  and  cessation  of  injecting  drug  use  in  Glasgow  (population  factors), 
(b)  the  frequencies  with  which  Glasgow  IDUs  injected  and  shared  needles/syringes, 
and  the  numbers  of  different  persons  they  shared  with  (behavioural  factors)  and  (c) 
the  susceptibility,  transmissibility  and  carriage  of  HCV  infection  (viral  factors). 
Generated  outcomes  were  (i)  estimates  of  the  actual  prevalence  and  incidence  of  HCV 
infection  (from  needle/syringe  sharing)  during  1960-2000  and  (ii)  scenario  data  on  the 
prevalence  and  incidence  of  HCV  infection  during  1988-2000  assuming  that  there  had 
been  either  no  or  more  effective  interventions  to  reduce  needle/syringe  sharing. 
Models  were  developed  using  S-PLUS  software122 
47 3.2.2  Model  design 
3.2.2.1  Population  factors:  Incidence  and  cessation  of  injecting  drug  use 
Previously,  in  Chapter  2,  estimates  of  the  size  of  Glasgow's  active  IDU  pool  in  1960 
and  the  number  of  individuals  who  entered  (i.  e.  commenced  injecting)  and  who  left 
(i.  e.  either  permanently  stopped  injecting  or  died)  this  pool  each  calendar  year 
thereafter  till  2000  were  generated  through  a  modified  Delphi  approach  which 
combined  expert  opinion  with  capture-recapture  prevalence  data.  Figure  3.1  illustrates 
the  estimates  of  (a)  the  incident  number  of  IDUs  and  (b)  the  percentage  ceasing  to 
inject  in  Glasgow  per  annum  during  1960-2000  which,  together  with  an  assumed  1- 
2%  per  annum  mortality  rate123,  provided  estimates  of  the  prevalent  number  of  IDUs 
per  annum  as  shown  in  Figure  3.1(c).  Ten  percent  of  the  actual  population  size  was 
used  in  the  simulations  to  reduce  the  computer  time  required  to  process  data;  as  a 
sensitivity  check,  simulations  were  also  performed  at  30%  of  the  actual  population 
size  and  produced  comparable  findings.  We  assumed  that  individuals  entered  and  left 
the  IDU  pool  on  random  days  throughout  a  year;  IDUs  were  randomly  selected  with 
equal  probability  to  leave  the  pool. 
3.2.2.2  Behavioural  factors 
3.2.2.2.1  Sources  of  data 
Two  principal  sources  of  needle/syringe  sharing  data  were  available:  multi-site, 
community-wide  surveys  undertaken  in  Glasgow  during  1990-1994  and  199951,133 
and  those  performed  in  Edinburgh  -  Scotland's  capital  city,  70km  from  Glasgow  - 
during  1992-1993126.  The  former  provided  estimates  of  injecting  and  needle/syringe 
sharing  (injecting  with  needles/syringes  previously  used  by  someone  else)  frequency 
and  numbers  of  persons  shared  with  during  the  previous  six  months  (adjusted  to 
48 twelve  months,  explained  in  footnote  to  Figure  3.2),  while  the  latter  provided,  for 
every  year  since  1980,  estimates  of  the  proportions  of  injectors  who  had  shared  at 
least  once.  A  study  comparing  behaviours  among  IDUs  in  Edinburgh  and  Glasgow  134, 
undertaken  in  1985,  indicated  that  the  proportions  sharing  at  least  once  in  both  cities 
were  very  similar;  accordingly,  the  above  Edinburgh  data  were  used  as  a  surrogate  for 
sharing  behaviour  in  Glasgow  during  the  1980s  (note:  only  data  on  the  proportion 
sharing  at  least  once  were  used;  data  on  the  numbers  of  partners  were  not 
exchangeable  because  Edinburgh  IDUs  had  a  much  greater  number  than  Glasgow's 
IDUs134).  No  needle/syringe  sharing  data  were  available  for  the  period  prior  to  1980. 
The  following  behavioural  sections  describe  the  model  process  each  year  for 
generating  (a)  the  frequency  with  which  IDUs  injected  drugs,  (b)  the  percentage  of 
IDUs  who  had  shared  a  needle/syringe,  (c)  the  number  of  needle/syringe  sharing 
partners,  (d)  the  assignment  of  number  of  needle/syringe  sharing  partners  to  each 
IDU,  (e)  the  selection  of  actual  needle/syringe  sharing  partners  for  each  IDU,  and  (f) 
the  frequency  with  which  IDUs  shared  needles/syringes. 
3.2.2.2.2  Frequency  of  injecting 
Glasgow  IDUs  reported  a  high  and  consistent  frequency  of  injecting  (from  1990-1994 
surveys:  23%  injected  less  than  twice  a  day  and  77%  injected  at  least  twice  a  day'33). 
For  simplicity,  we  assumed  that  all  IDUs  injected  three  times  per  day  for  48  weeks 
per  year,  thus  accounting  for  four  weeks'  abstinence  from  injecting135;  abstinence  was 
increased  to  12  weeks  during  1995-2000,  an  adjustment  based  on  survey  data51,  which 
correlates  with  an  increased  prescribing  of  methadone  to  IDUs124.  On  a  given  day,  the 
number  of  times  an  individual  shares  needles/syringes  from  their  three  injections  was 
randomly  assigned  using  a  binomial  distribution  with  probability  equivalent  to  the 
49 proportion  of  their  injecting  episodes  spent  sharing  (see  "Frequency  of  needle/syringe 
sharing",  3.2.2.2.7  below).  Then,  for  each  sharing  occasion,  the  partner  from  whom 
they  receive  their  used  needle/syringe  was  randomly  selected  from  their  group  of 
sharing  partners;  if  the  selected  partner  was  an  HCV  carrier,  transmission  occurred 
with  probability  as  described  below  (see  "Transmissibility",  3.2.2.3.2  below). 
3.2.2.2.3  Percentage  of  ID  Us  per  year  who  had  shared  a  needle/syringe  at 
least  once 
The  percentage  of  IDUs  who  were  assigned  to  share  a  needle/syringe  at  least  once 
during  a  particular  calendar  year  in  the  model  was  generated  by  sampling  from  a 
uniform  distribution,  where  limits  were  varied  in  four  epochs:  1960-1976  (a  period  of 
minimal  injecting),  1977-1985  (a  period  of  injecting  epidemic  growth),  1986-1990  (a 
period  of  HIV  awareness  and  introduction  of  harm  reduction  initiatives),  and  1991- 
2000  (era  of  harm  reduction).  Based  on  observed  data  for  Glasgow  and  Edinburgh 
(Figure  3.2),  rates  in  the  ranges  70-89%  and  35-49%  were  used  for  the  respective 
periods  1977-1985  and  1991-1997,  and  a  linear  reduction  in  the  range  was  applied 
during  the  intermediate  epoch.  A  range  of  40-54%  was  applied  in  years  1998-2000  to 
reflect  the  recent  rise  in  needle/syringe  sharing  observed  in  Glasgow51.  Data  on  the 
behaviours  of  IDUs  during  the  1960s/1970s  were  not  available;  therefore,  a  broad 
range  of  50-89%  was  applied  to  encompass  the  prevalence  of  needle/syringe  sharing 
in  the  first  epoch  1960-1976. 
3.2.2.2.4  Number  of  needle/syringe  sharing  partners 
The  number  of  IDUs  with  whom  Glasgow  respondents  reported  needle/syringe 
sharing  at  least  once  in  the  previous  six  months  (referred  to  as  partners)  is  shown  in 
50 Figure  3.3;  very  few  respondents  reported  more  than  20  partners.  The  number  of 
partners  reported  by  respondents  was  heavily  skewed,  with  a  mean  of  3  and  2  partners 
reported  in  the  1990  and  1991-1994  surveys,  respectively;  a  survey  of  IDUs  attending 
general  practices  in  Glasgow  during  the  early  to  mid  1980s  revealed  a  mean  of  8 
partners  (range  1-30)134.  Geometric  distributions,  as  illustrated  in  Figure  3.3,  were 
used  to  generate  the  number  of  partners,  Xi,  k,  for  the  pool  of  needle/syringe  sharing 
IDUs  each  year  (see  Appendix  in  Section  3.5.1).  The  mean  number  of  partners 
amongst  IDUs  who  were  assigned  to  share  needles/syringes  each  year  was  assumed  to 
be  eight,  two  and  three  during  the  periods  1977-1985,1991-1997  and  1998-2000, 
respectively;  a  linear  reduction  in  the  mean  number  of  partners  was  employed  during 
1986-1990.  Due  to  the  low  prevalence  of  IDUs  in  the  earlier  period  1960-1976,  a 
conservative  mean  of  two  partners  was  applied. 
3.2.2.2.5  Assignment  of  number  of  needle/syringe  sharing  partners  to  each 
IDUper  annum 
In  any  given  year  k,  a  vector  for  the  number  of  partners,  denoted  as  Xi,  k,  was  generated 
(described  above)  and  each  element  of  X  ,k  was  assigned  to  a  person  in  the  pool  of  nk 
IDUs  through  a  process  of  either  random  (i.  e.  equal  probability)  or  weighted  selection. 
The  latter  refers  to  an  increased  likelihood  of  an  IDU  selecting  a  number  of  partners, 
in  a  given  year,  which  is  the  same  or  near  to  the  number  of  partners  they  had  been 
assigned  in  the  previous  year  (see  Appendix  in  Section  3.5.2). 
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year 
At  the  beginning  of  each  year  in  the  model,  for  individuals  who  were  assigned  a  lower 
number  of  partners  than  in  the  previous  year,  established  partnerships  would  be 
randomly  deselected.  The  remaining  established  partnerships  would  be  retained  for 
that  year,  and  others  formed  until  the  required  number  of  partnerships  was  reached. 
An  IDU  selects  their  actual  partner(s)  based  on  either  random  or  weighted  selection, 
where  the  latter  refers  to  an  increased  likelihood  of  an  IDU  selecting  a  partner  who 
has  the  same  or  near  to  the  same  "number  of  partners"  as  they  have  in  that  year  (see 
Appendix  in  Section  3.5.3). 
3.2.2.2.7  Frequency  of  needle/syringe  sharing 
The  frequency  with  which  Glasgow  IDUs  shared  needles/syringes  correlated  strongly 
with  the  number  of  sharing  partners  reported  (Figure  3.4).  For  each  calendar  year  in 
the  model,  individuals  were  randomly  assigned  a  frequency  of  sharing,  according  to 
the  number  of  partners  they  had,  based  on  the  Glasgow  1990-1994  data;  for  example, 
for  IDUs  with  one  sharing  partner,  49%,  33%,  4%,  2%,  2%,  1%,  0%,  1%,  0%,  0%  and 
8%  recipient-shared  needles/syringes  for  0.5%,  5%,  15%,  25%,  35%,  45%,  55%, 
65%,  75%,  85%  and  95%  of  their  injecting  episodes,  respectively. 
3.2.2.3  Viral  factors 
3.2.2.3.1  Susceptibility 
All  new  initiates  to  injecting  who  entered  the  IDU  pool  were  regarded  as  being 
susceptible  to  infection  (Figure  3.5).  HCV  has  been  circulating  for  many  decades; 
thus,  an  IDU  from  the  original  pool  in  1960  was  randomly  assigned  as  an  HCV  carrier 
52 allowing  them  to  transmit  the  virus  to  others.  A  susceptible  individual  was  considered 
to  have  been  exposed  to  HCV  only  when  he/she  injected  with  a  needle/syringe 
previously  used  by  an  individual  who  was  an  HCV  carrier.  Transmissions  through 
other  routes,  such  as  sexual  intercourse  136,  occur  relatively  infrequently  and  thus  these 
were  not  considered  in  the  model. 
3.2.2.3.2  Transmissibility 
Upon  exposure  to  HCV,  the  probability  of  an  individual  becoming  acutely  infected 
was  assumed  to  be,  on  average,  2-3%  (range  0-10%),  based  on  reported  rates  of 
transmission  occurring  among  health  care  workers  after  needle-stick  injuries137'13s  A 
beta  distribution  (mean  0.03,  variance  0.0001)  was  used  to  generate  probabilities  for 
transmission  after  each  exposure.  A  short  period  (6-8  weeks)  of  high  viraemia139 
follows  infection  with  HCV,  a  phenomenon  similar  to  that  observed  for  HIV;  using 
knowledge  which  exists  for  HIV140,141,  but  not  HCV,  the  effect  of  a  10-fold  increase 
in  infectivity  during  the  initial  high  viraemia  phase  was  explored.  During  acute 
infection,  HCV  RNA  -  indicating  infectiousness  -  has  been  detected  in  blood  within 
two  weeks  of  exposure  142;  accordingly,  in  the  model,  individuals  became  infectious 
two  weeks  post  infection. 
3.2.2.3.3  Carriage 
Of  individuals  with  newly  acquired  HCV,  between  15-40%  spontaneously  recover 
from  their  acute  infection,  generally  within  two  years3'4.  A  beta  distribution  (mean 
0.25,  variance  0.001)  was  used  to  generate  probabilities  for  viral  clearance  among 
newly  infected  individuals  and  a  geometric  distribution  (parameter  1/290  days)  was 
used  to  generate  intervals  from  infection  to  recovery.  Partial  immunity  against  HCV 
53 re-infection  and  persistence  may  be  acquired  in  individuals  who  have  had  previous 
infection  and  cleared  their  virus143'144  Thus,  in  the  model,  individuals  who  recover 
from  their  acute  HCV  infection  re-entered  the  susceptible  population,  but,  according 
to  Farci  et  al.  143,  were  half  as  likely  to  develop  new  viraemia  following  re-exposure 
and  were  twelve  times  less  likely  to  develop  chronic  infection  following  acute  status. 
Individuals  who  do  not  recover  from  their  acute  infection  develop  chronic  HCV  and 
remain  infectious. 
3.2.3  Model  outcomes 
3.2.3.1  Prevalence  of  HCV  infection 
The  prevalence  of  HCV  antibodies  among  current  IDUs  each  year  between  1960  and 
2000  was  simulated.  Different  models  were  specified  to  assess  the  effect  on  HCV 
seroprevalence  of  (i)  increasing  the  infectivity  of  newly  HCV  infected  individuals 
during  the  short  period  of  high  viraemia  following  seroconversion,  (ii)  weighting  the 
assignment  of  number  of  sharing  partners  to  each  IDU,  and  (iii)  weighting  the 
selection  of  actual  partners  for  each  IDU.  For  each  model,  100  simulation  runs  were 
performed;  HCV  seroprevalence  was  summarised  by  reporting  the  10th,  5  0th  and  90th 
percentiles  separately  for  each  year. 
The  fit  of  models  was  determined  by  comparing modelled  with  observed  HCV 
seroprevalences  at  different  calendar  years:  principally,  community-wide  surveys  of 
Glasgow  IDUs  reported  that  HCV  seroprevalence  declined  between  1990  (79%)  and 
1999  (61  %)47.  HCV  seroprevalence  estimates  were  also  available  from  IDUs  who  had 
tested  hepatitis  B  surface  antigen  positive  and  negative  in  1973-80  (81%  and  65%, 
respectively)  and  positive  in  1984  (65%)  (Personal  communication:  Sheila  Cameron, 
Glasgow  Regional  Virus  Laboratory). 
54 3.2.3.2  Incidence  of  HCV  infection 
The  incident  number  of  HCV  infections  each  year  was  obtained  from  the  models  for 
susceptible  current  IDUs  who  either  (i)  had  no  previous  infection  or  (ii)  had  cleared 
their  previous  infection;  for  (i),  the  incidence  was  calculated  as  the  number  of  new 
infections  during  the  year  divided  by  the  total  number  of  injector-years  contributed  by 
HCV  antibody  negative  IDUs. 
3.2.3.3  Potential  impact  of  harm  reduction  measures  on  the  prevalence  and 
incidence  of  HCV  infection 
Data  on  HCV  incidence  were  generated  by  applying  the  high  levels  of  needle/syringe 
sharing  from  the  early  to  mid  1980s  in  Glasgow  to  the  period  1988-2000.  By 
comparing  models  with  and  without  this  high  risk  behaviour,  estimates  of  the  number 
of  HCV  infections  averted  among  Glasgow  IDUs  during  the  period  of  harm  reduction 
(1988-2000)  were  obtained. 
3.2.3.4  Potential  impact  of  hypothetically  lower  risk  behaviours  on  the 
prevalence  and  incidence  of  HCV  infection 
The  impact  of  the  following  hypothetical  reductions  in  risk  behaviour,  for  the  period 
1988-2000,  on  the  prevalence  and  incidence  of  HCV  was  examined: 
(i)  the  percentage  of  IDUs  who  had  shared  per  year  was  reduced  to  1-10%,  11- 
20%,  21-30%,  31-40%,  and  41-50%  (from  the  estimated  actual  rates, 
described  above  in  3.2.2.2.3,  of  45-79%,  35-49%  and  40-54%  in  years  1988- 
1990,1991-1997  and  1998-2000,  respectively); 
55 (ii)  the  mean  number  of  needle/syringe  sharing  partners  per  annum  was  reduced  to 
1,1.5  and  2  (from  the  estimated  actual numbers,  described  above  in  3.2.2.2.4, 
of  3-6,2  and  3  in  years  1988-1990,1991-1997  and  1998-2000,  respectively); 
(iii)  the  percentage  of  injecting  episodes  shared  was  reduced  to  below  10%  (from 
that  illustrated  in  Figure  3.4). 
3.3  Results 
3.3.1  Modelled  prevalence  of  HCV  infection 
Significantly  more  simulations  generated  by  model  (a),  which  employed  a  ten-fold 
higher  infectivity  to  newly  HCV  infected  IDUs  during  the  short  period  of  high 
viraemia  following  seroconversion,  than  by  model  (b),  without  the  higher  infectivity 
constraint,  produced  HCV  seroprevalences  in  the  ranges  of  those  obtained  through 
community-wide  surveys  of  Glasgow  IDUs  in  years  1990-1993  (56-92%),  1994-1996 
(53-86%)  and  1999  (50-75%)  (Figure  3.6)  (87%  compared  to  55%  of  100  simulations, 
respectively;  p=0.0001).  The  best  fitting  model  (a)  was  used  below  to  estimate  the 
incidence  of  HCV  infection  and  to  examine  changes  in  this  with  different  scenarios  of 
higher  and  lower  risk  behaviour. 
The  process  of  assigning  sharing  partners  to  each  IDU  per  year  was  weighted 
(described  in  Methods  and  Appendix  3.5.2-3.5.3,  such  that  the  mean  z  score  for  years 
1977-1987  ranged  1.4-2.4  (versus  5.4-6.9)  under  weighted  (versus  random)  selection, 
and  for  years  1991-2001  ranged  0.4-0.8  (versus  1.1-1.9)),  but  the  effect  on  HCV 
seroprevalence  was  marginal:  for  years  1977-1987,  median  ranged  70-80%  (versus 
74-77%)  under  weighted  (versus  random)  selection;  and  for  years  1991-2000,  median 
ranged  57-61  %  (versus  62-69%)  under  weighted  (versus  random)  selection. 
56 3.3.2  Modelled  incidence  of  HCV  infection 
The  annual  incident  number  of  HCV  infections  among  current  IDUs  in  Glasgow  was 
estimated,  by  model  (a),  to  be  low  during  1960-1976  (median  new  infections  among 
IDUs  who  had  no  previous  infection  and  had  cleared  their  previous  infection:  10-60 
and  0-20  per  annum,  respectively),  rising  steeply  during  the  early  1980s  to  peak  in 
1985  (1,120  and  210,  respectively),  stabilising  during  1991-1997  (510-610  and  100- 
140,  respectively)  and  rising  again  during  1998-2000  (710-780  and  130-150, 
respectively)  (Figure  3.7). 
The  median  percentage  of  HCV  antibody  negative  IDUs  who  acquired  new 
HCV  infection  per  annum  was  estimated  to  be  in  the  ranges  5-27%,  43-48%  and  14- 
20%,  which  corresponds  to  incidences  of  6-40,78-89  and  18-30  per  100  susceptible 
injector-years,  during  periods  1960-1976,1977-1986  and  1990-2000,  respectively 
(Figure  3.8). 
3.3.3  Potential  impact  of  harm  reduction  measures  on  the  prevalence  and 
incidence  of  HCV  infection 
Carrying  forward  the  high  levels  of  needle/syringe  sharing  from  the  early  1980s  to 
1988-2000  generated  higher  prevalences  of  HCV  during  this  latter  period  (median  83- 
91%)  than  were  determined  through  model  (a)  with  the  lower  estimated  actual  levels 
of  needle/syringe  sharing  among  Glasgow  IDUs  (62-75%)  (Figure  3.6  (c)  and  (a), 
respectively).  The  median  cumulative  number  of  newly  HCV  infected  IDUs  during 
1988-2000  in  Glasgow  from  models  (c)  and  (a),  with  and  without  the  higher  levels  of 
risk  behaviour,  were  13,420  and  8,910  (10th  to  90th  percentiles:  11,370-16,290  and 
7,720-10,340),  respectively,  which  indicates  that  potentially  as  many  as  4,500  (2,400- 
7,700)  HCV  infections  had  been  prevented  as  a  result  of  established  harm  reduction 
57 measures  during  this  period  -  that  is,  around  half  as  many  prevented  as  actually 
occurred. 
3.3.4  Potential  impact  of  hypothetically  lower  risk  behaviours  on  the  prevalence 
and  incidence  of  HCV  infection 
Reductions  in  three  key  risk  parameters  -  (i)  the  percentage  of  IDUs  who  had  shared  a 
needle/syringe  per  year,  (ii)  the  mean  number  of  needle/syringe  sharing  partners  per 
year,  and  (iii)  the  percentage  of  injecting  episodes  shared  -  all  impacted  on  the 
prevalence  and  incidence  of  HCV  infection  by  varying  amounts  (Figure  3.9). 
Assigning  either  1-10%,  11-20%,  21-30%,  31-40%  or  41-50%  of  IDUs  to  have  shared 
a  needle/syringe  per  year  during  1988-2000  would  have  reduced  the  HCV  prevalence 
to  a  median  of  18%,  33%,  46%,  55%  and  63%,  respectively,  and  the  incidence  to  a 
median  of  1,7,14,20  and  28  infections  per  100  susceptible  injector-years, 
respectively,  by  the  year  2000;  while  the  median  cumulative  number  of  newly  HCV 
infected  IDUs  during  1988-2000  would  have  been  1,310,3,700,5,860,7,550  and 
8,960,  respectively. 
Alternatively,  assigning  the  mean  number  of  partners  per  annum  to  1.0,1.5 
and  2.0  during  1988-2000  among  needle/syringe  sharing  IDUs  would  have  reduced 
the  HCV  prevalence  to  a  median  of  33%,  48%  and  58%,  respectively,  and  the 
incidence  to  a  median  of  5,13  and  21  infections  per  100  susceptible  injector-years, 
respectively,  by  the  year  2000;  the  median  cumulative  number  of  newly  HCV  infected 
IDUs  during  1988-2000  would  have  been  3,650,6360  and  7,990,  respectively. 
Finally,  limiting  the  percentage  of  injecting  episodes  shared  to  less  than  10%  among 
needle/syringe  sharing  IDUs  during  1988-2000  would  have  resulted  in  a  median  HCV 
prevalence  of  48%  and  incidence  of  14  infections  per  100  susceptible  injector-years 
58 by  2000;  the  median  cumulative  number  of  newly  HCV  infected  IDUs  during  1988- 
2000  would  have  been  6,280.  As  changes  in  one  risk  parameter  will  likely  correlate 
with  changes  in  another,  these  findings  may  have  under-estimated  the  collective  effect 
of  reduced  risk  behaviours  on  HCV  prevalence  and  incidence. 
3.4  Discussion 
This  chapter  presents  the  findings  of  a  model  designed  to  estimate  the  impact  of 
established,  and  hypothesised,  harm  reduction  interventions  on  HCV  incidence  by 
simulating  the  transmission  of  HCV  among  Glasgow  IDUs  according  to  their  self- 
report  of  needle/syringe  sharing.  Since  the  introduction,  in  the  late  1980s,  and 
continual  expansion,  during  the  1990s,  of  needle/syringe  exchanges  and  other  harm 
reduction  interventions  targeted  at  IDUs,  reductions  in  both  needle/syringe  sharing145 
and  the  incidence  of  HCV47'50  have  been  evident  in  Glasgow.  It  is  possible  that  some 
of  the  behaviour  change  resulted  independently  of  the  harm  reduction  activities; 
however,  with  several  studies  undertaken  in  Glasgow  and elsewhere  demonstrating  a 
strong  association  between  HCV  prevalence  reduction  and  harm  reduction 
initiatives  146,  it  is  plausible  that  such  interventions  were  responsible  for  averting, 
during  1988-2000,  many  of  the  4,500  HCV  infections  (10th  and  90th  percentiles: 
2,400-7,700)  indicated  by  scenario  analysis. 
Full  advantage  of  available  behavioural  and  epidemiological  data  was  taken  to 
model  the  heterogeneity  typical  of  an  entire  IDU  population.  Inevitably  with  a  model 
designed  to  reproduce  a  complex  process,  there  were  limitations  which  need  to  be 
considered:  (i)  biases  may  exist  as  a  result  of  IDUs'  under-  or  over-reporting  risk 
behaviour,  although  previous  studies  have  found  IDUs  to  be  generally  reliable  in  their 
self-report  of  this'  47,148,149,  and  findings  from  the  Glasgow  surveys  have  been 
59 corroborated  by  other  investigations  150;  (ii)  a  broad  range  for  needle/syringe  sharing 
was  applied  in  the  1960/1970s  epoch  to  allow  for  the  absence  of  data,  but  this  did  not 
hinder  the  estimation  of  the  incident  number  of  HCV  infections  because  so  few 
individuals  were  injecting  during  this  period;  (iii)  previous  infectious  disease  models 
among  IDUs  have  been  limited  by  the  lack  of  data  on  the  changing  size  of  this 
population151;  whilst  this  model  was  designed  to  allow  individuals  to  enter  and  leave 
the  current  IDU  population,  further  data  are  needed  to  corroborate  our  estimates  on 
the  incidence  and  cessation  of  injecting  drug  use;  (iv)  IDUs  were  all  posed  with  an 
annual  mortality  rate  in  the  range  of  1-2%,  although  recent  work  has  indicated  that 
IDUs'  mortality  is  higher  for  males  and  increases  with  age152;  (v)  behavioural  data 
specifically  on  the  change  in  needle/syringe  sharing  partners  from  one  timeframe  to 
the  next  and  the  propensity  to  share  with  different  partners  are  needed  to  refine  the 
model;  importantly,  weighted  selection  employed  to  minimize  the  change  in  number 
of  partners  from  one  year  to  the  next  per  IDU  did  not  affect  model  results.  Future 
modelling  also  needs  to  consider  differences  in  risk  behaviour  in  the  initial  versus 
subsequent  years  following  onset  of  injecting  drug  use133;  (vi)  individuals  were  only 
exposed  to  HCV  through  the  sharing  of  needles/syringes;  it  has  been  suggested  that 
HCV  can  be  contracted  through  other  injecting  equipment  153,  but  only  limited 
evidence  of  transmission  efficiency  for  this  existslsa,  iss  Since  infections  occurring 
through  means  other  than  needle/syringe  sharing,  including  unprotected  sexual 
intercourse  and  tattooing,  were  judged  to  be  relatively  small  and  the  behavioural  data 
for  these  were  not  available,  they  were  not  considered  in  this  model  (as  in  previous 
HCV  transmission  models  among  IDUs'56"57);  (vii)  the  cleaning  of  used 
needles/syringes  and  its  influence  on  HCV  transmission,  believed  to  be  considerably 
less-effective  than  with  HIV157,  was  not  considered;  (viii)  while  the  aim  was  to 
60 capture  the  behavioural  heterogeneity  of  IDUs,  it  is  appreciated  that  the  detailed  data 
requirements  of  the  model  will  influence  its  generalizability. 
Despite  these  limitations,  modelled  data  on  HCV  prevalence  agreed  well  with 
observed  trends  among  current  IDUs  in  Glasgow.  The  model  which  discounted  the 
effect  of  higher  infectivity  among  newly  HCV  infected  IDUs,  a  criticism  of  previous 
HCV  transmission  models158,  under-estimated  the  prevalence  of  HCV  during  the 
1990s  compared  to  data  from  community-wide  surveys  of  Glasgow  IDUs.  The  lower 
than  expected  HCV  prevalences  could  be  explained  by  the  omission  of  transmissions 
occurring  through  other  routes  such  as  indirect  sharing  of  injecting  equipment. 
Alternatively,  considering  higher  infectivity  during  acute  viraemia  after  infection  in 
the  model  produced  HCV  prevalences  consistent  with  survey  data,  and  suggests  that 
this  phenomenon  is  an  important  factor  in  the  spread  of  HCV,  as  recognised  with 
HIV  140,141 
Further  validation  of  the  behavioural  assumptions  used  in  the  model  was 
attained  by  adapting  the  viral  characteristics  to  monitor  the  spread  of  HIV  among 
IDUs  in  Glasgow  (details  provided  in  Appendix,  Section  3.5.4).  This  showed  that  the 
prevalence  of  HIV  remained  low  and  stable  (median  of  0.4-1.0%  during  years  1983- 
2000;  1  0th  and  90th  percentiles  ranged  0-0.3%  and  2.3-7.9%,  respectively);  a  finding 
that  is  consistent  with  detected  rates  among  Glasgow  IDUs159.  Corroborating  a 
previous  modelling  application  in  Australia15',  these  results  demonstrate  that  the  ten- 
fold  higher  infectivity  of  HCV  compared  to  HIV129,160  largely  explains  the  difference 
in  the  spread  of  these  two  viruses  among  IDUs. 
Observed  data  on  HCV  incidence  among  IDUs  in  Scotland  are  confined  to  the 
1990s  and  have  been  derived  from  cross-sectional  (centrally  estimated  20-27  per  100 
person-years  among  recent-onset  IDUs108)  and  cohort  studies  in  selected  populations 
61 (28  per  100  person-years;  95%  Cl  16-51161),  which  compare  favourably  with  our 
modelled  estimates  of  HCV  incidence  during  the  same  period  (18-30  per  100 
susceptible  injector-years).  The  incident  numbers  of  IDU-related  HCV  infections 
estimated  historically  are  central  to  the  development  in  Chapter  6  of  models  to  project 
the  number  of  people  likely  to  progress  to  HCV  disease  in  the  future80'108 
HCV  transmission  thus  continues  to  occur  at  an  alarming  rate  among 
Glasgow's  IDUs.  The  main  public  health  message  -  "not  to  share  needles/syringes"  - 
used  in  this  population  to  control  HIV  transmission  has  proved  inadequate  for  the 
control  of  HCV.  A  previous  study  had  indicated  that  improving  IDUs'  access  to 
sterile  injecting  equipment  is  likely  to  result  in  reductions  in  sharing'33;  accordingly, 
research  is  underway  in  Glasgow  to  determine  the  effect  on  behaviours  of  removing 
government  restrictions  on  the  numbers  of  needles/syringes  distributed.  We  cannot 
ignore,  however,  that  some  IDUs  share  needles/syringes  despite  having  sufficient 
access  to  harm  reduction  services.  Our  model  indicates  directions  for  public  health 
strategies  to  reduce  the  incidence  of  HCV  infection.  Incidence  can  be  more 
successfully  reduced  if  IDUs  who,  unavoidably,  share  needles/syringes  confine  their 
borrowing  of  used  equipment  to  one  person,  ideally  someone  they  know  well  and  who 
has  recently  tested  HCV  antibody  negative;  with  this  strategy  alone  (i.  e.  reducing  the 
mean  number  of  partners  to  one  during  1988-2000),  an  estimated  5,300  HCV 
infections  (10th  and  90th  percentiles:  4,100-6,700)  could  have  been  averted  during 
1988-2000  among  Glasgow  IDUs.  Alternatively,  permitting  only  11-20%  of  the  IDU 
population  to  share  a  needle/syringe  annually  during  1988-2000  would  have  similarly 
averted  an  estimated  5,200  HCV  infections  (10th  and  90th  percentiles:  4,200-6,600). 
Determining  the  most  effective  means  of  communicating  risk  reduction  strategies  to 
IDUs  should  be  a  priority  in  HCV  prevention  plans.  The  ability  of  existing  HCV 
62 testing  and  counselling  practices  to  change  behaviour  and  prevent  further  transmission 
among  IDUs  remains  unclear'6a'163  A  thorough  evaluation  of  such  services164  is 
required  to  determine  if  the  HCV  testing  of  current  IDUs  should  be  promoted. 
Based  on  a  study  which  examined  the  direct  medical  costs  associated  with 
HCV  infection  among  IDUs  in  Australia76,  the  estimated  550  to  920  new  HCV 
infections  among  IDUs  in  Glasgow  during  2000  could  equate  to  approximately  three 
to  five  million  pounds  in  health  care  spending  in  the  future  as  sequelae  become 
manifest.  A  serious  commitment  to  model  in  advance,  implement  and  audit  strategies, 
which  could  achieve  appreciable  reductions  in  risk  behaviours  and  HCV  transmission 
among  IDUs,  is  urgently  needed  to  influence  the  future  course  of  this  epidemic. 
Otherwise  the  mounting  HCV  burden  of  illness  and  cost  will  continue.  Meanwhile, 
"off-injecting"  remains  a  key  public  health  message  both  for  HCV  prevention  and 
treatment.  Behavioural  surveillance  of  IDUs  should  also  be  expanded  to  keep  abreast 
of  potential  changes  in  blood-borne  virus  transmission  and  inform  HCV  prevention 
efforts. 
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I1I  III 3.5  Appendix 
3.5.1  Generating  the  number  of  needle/syringe  sharing  partners  per  year 
The  following  expression  was  applied: 
Xj,  k  =  G(1/pd  +1  for  i=  1) 
....  ,  sk;  where  k=  1960, 
...., 
2000; 
0  for  i=  sk+,,  ....,  nk;  where  k=  1960, 
...., 
2000; 
to  generate  a  vector,  Xi,  k,  of  the  number  of  partners  to  assign  to  nk  IDUs,  in  a  given 
year  k,  where  sk  was  the  number  of  the  nk  IDUs  who  had  been  determined  to  share 
needle/syringes  on  at  least  one  occasion  during  year  k,  and  G(1/pk)  were  non-negative 
integers  randomly  generated  from  the  geometric  distribution  with  probability  1/pk, 
where  Pk  was  the  mean  number  of  partners  for  year  k. 
3.5.2  Weighting  the  probability  of  assigning  a  number  of  needle/syringe  sharing 
partners  to  each  IDU  per  annum  according  to  the  number  of  partners  assigned 
in  the  previous  year 
The  following  expression  was  used  to  weight  the  probability  of  selecting  each  element 
of  X  ,k 
for  the  jth  person  in  the  pool  of  nk  IDUs: 
w;  j  k=  1/6x;  k-  yj,  k_J1+1)2  for  i=1, 
...,  nk  and  j=1, 
...,  nk;  where  k=1960,...,  2000,  - 
,, 
where  Xi,  k  represents  the  number  of  partners  to  assign  to  each  person  in  the  pool  of  nk 
IDUs  for  year  k  and Yj,  k_I  represents  the  number  of  partners  the  jth  IDU  had  been 
assigned  in  the  previous  year. 
As  a  simplified  example:  for  a  given  year,  say  1990,  in  a  pool  of  four  IDUs 
(i.  e.  n=  4),  where  the  first  IDU  had  been  assigned  zero  partners  in  the  previous  year 
(i.  e. 
,y1,1989 
=  0),  if  a  vector  x,,  1990-(0,0,2,2O) 
(i.  e.  X1,1990-0,  X2,1990-0,  x3,1990-2,  and 
X4,1990=20)  had  been  generated  for  the  number  of  partners  to  assign  to  these  four  IDUs 
73 in  1990,  then  the  weights  associated  with  the  first  IDU  selecting  elements  of  x;,  1990 
would  be: 
WJ,  J,  J990  =  1/(I0-01+1)2  =  1;  W2,  J,  1990  =  1/(IO-OI+1)2  =  1; 
W3,1,1990  =  1/(12-0l+1)2  =  1/9;  w4,1,1990  =  1/(120-0I+1)2  =  1/441. 
Normalizing  these  weights  (1,1,1/9,1/441)  produces  a  vector  of  probabilities  (0.473, 
0.473,0.052,0.001)  associated  with  the  first  IDU  selecting  elements  of  x;,  199o,  under 
random  selection,  the  vector  of  selection  probabilities  would  have  been  (0.25,0.25, 
0.25,0.25).  If  we  assume  that  x],  1990  was  assigned  to  the  first  IDU  under  weighted 
selection,  this  selection  process  would  continue  for  the  second  IDU  without  replacing 
the  chosen  number  of  partners  in  the  vector  (i.  e.  x;,  1990  would  reduce  to  (0,2,20)). 
The  following  expression  was  calculated  at  the  start  of  each  year  to  compare 
the  average  change  in  the  number  of  partners  assigned  to  IDUs  between  random  and 
weighted  selection: 
nk 
Y 
j,  k-1  Y 
j,  k 
Zk  for  j=1, 
...,  nk;  where  k=1961,...,  2000; 
nk 
where  yj,  k_J  and  yj,  k  represent  the  number  of  partners  the  jth  IDU,  from  a  total  of  nk 
IDUs,  had  been  assigned  in  years  k-1  and  k. 
3.5.3  Weighting  the  probability  of  selecting  actual  needle/syringe  sharing 
partners  for  each  IDU  per  year  according  to  the  number  of  partners  each  IDU 
has  been  assigned 
The  expression  1/(]x;,  k-xj,  kH+l)2  was  applied  to  weight  the  probability  of  the  jh  IDU 
selecting  as  a  partner  the  ith  IDU  of  the  remaining  pool  of  sharing  individuals  where 
XJ,  k  and  Xj,  k  represent  the  number  of  partners  assigned  to  these  respective  individuals  in 
a  given  year  k. 
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Further,  to  validate  the  model  findings,  the  transmission  of  HIV  infection  was  also 
simulated  among  the  current  IDUs  in  Glasgow  by  applying  the  same  population  and 
behavioural  factors  as  described  in  Sections  3.2.2.1  and  3.2.2.2,  respectively,  and 
accommodating  the  following  viral  characteristics: 
(i)  The  first  case  of  HIV  among  Glasgow  IDUs  was  introduced  in  1983165; 
(ii)  Individuals  were  only  exposed  to  HIV  through  the  sharing  of  needles/syringes. 
Sexual  transmission  of  HIV  is  more  common  than  HCV,  however 
needle/syringe  sharing  is  generally  regarded  as  the  most  important  means  of 
spread  between  IDUs141'151 
(iii)  The  transmission  probability  for  HIV  was  assumed  to  be  ten  times  lower  (i.  e. 
mean  0.3%)  than  that  of  HCV129,16o  A  short  period  (6-8  weeks)  of  high 
viraemia139,142  follows  infection  with  HIV,  and  has  been  related  to  increased 
infectivity  14o  It  was  therefore  assumed  that  infectiousness  increased  10-fold 
during  this  initial  high  viraemia  phase  '51,141; 
(iv)  The  latency  period  for  HIV  was  taken  to  be  50  days166; 
(v)  All  individuals  who  acquired  HIV  developed  chronic  infection  and  remained 
infectious  129 
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infection  in  Scotland,  1991-2001:  record-linkage  study 
4.1  Background 
Progression  to  severe  sequelae  of  hepatitis  C  virus  (HCV)  infection,  namely 
hepatocellular  carcinoma  (HCC)  and  decompensated  cirrhosis,  generally  takes  several 
decades  and  varies  according  to  age,  gender,  alcohol  consumption  and  co-infection 
with  other  blood-borne  viruses5.  An  epidemic  of  severe  liver  disease  has  been 
predicted  in  Australia  and  the  United  States  as  a  consequence  of  the  large  numbers  of 
people  who  became  infected  with  HCV  through  injecting  drug  use  in  the  1970s  and 
1980s8183,167.  To  monitor  the  emergence  of  such  a  problem  requires  national 
surveillance  systems,  currently  lacking  in  the  UK  and  elsewhere,  which  detect  not 
only  advanced  liver  disease  but  also  the  aetiological  factors. 
Numerous  studies  have  examined  national  trends  in  HCC  but  few  have 
provided  data  on  the  underlying  cause.  The  increasing  burden  of  HCV  infection  is  a 
likely  explanation  for  the  rise  in  HCC  incidence  over  the  past  two  to  three  decades 
reported  in  Japan  168,  North  America  169,170,  Australia171  and  parts  of  Europe172'173 
Alcohol  was  discounted  as  the  predominant  risk  factor,  except  in  Japan174,  because  of 
declining  rates  in  consumption169'l70'»1'1'2'173  One  study,  confined  to  US  veterans, 
deduced  HCV  from  medical  history  records  to  be  the  most  important  underlying  cause 
for  the  increase  in  hospitalisation  for  primary  liver  cancer175.  In  80  patients  presenting 
to  a  Scottish  hospital,  who  had  available  stored  serum  samples,  HCV  infection  was 
identified  as  a  major  risk  factor  for  the  development  of  HCC39.  Moreover,  the  age- 
specific  incidence  of  HCC  has  progressively  shifted  toward  younger  people169 
76 It  has  also  been  suggested  that  HCV  has  played  a  role  in  the  rise  in  alcohol 
related  deaths,  mostly  due  to  liver  damage,  in  England  between  1983  and  1999176 
Disproportionately  high  prevalences  of  HCV  infection  have  been  found  in  alcoholic 
patients  with  liver  disease  (43%  from  two  studies  with  61177  and  40178  patients), 
compared  to  those  without  liver  disease  (2%  (1/45)  177  and  10%  (6/60)178, 
respectively).  Further,  the  prognosis  among  patients  with  high  alcohol  consumption 
and  HCV  antibodies  was  significantly  worse  than  for  those  without  HCV 
antibodies  179,180,181  Among  patients  hospitalised  in  Japan  with  liver  cirrhosis,  a 
considerably  higher  percentage  of  those  with  both  HCV  and  alcohol  present  had 
developed  HCC  (51%,  151/297)  compared  to  those  with  only  one  of  these  two  risk 
factors  (HCV-alone:  37%,  156/420;  alcohol-alone:  17%,  20/119)182.  In  direct  contrast, 
a  recent  study  of  213  patients  reported  that  survival  in  alcoholic  cirrhosis  patients  was 
not  influenced  by  the  presence  (72)  or  absence  (141)  of  HCV  infection  183.  This 
apparent  discrepancy  may  have  been  due  to  confounding  factors'  84.  Determining  the 
extent  to  which  alcohol  and other  factors,  such  as  HIV,  influence  the  course  of  HCV 
epidemics  will  inform  (i)  the  development  of  appropriate  interventions  and  (ii)  models 
to  forecast  the  future  burden  of  severe  disease. 
There  is  thus  an  urgent  need  in  Scotland  and  elsewhere185  to  provide  accurate, 
up-to-date  information  about  the  current  burden  of  HCV-related  severe  disease  to  help 
policymakers  prioritise  health  interventions  and  allocate  resources  accordingly.  To 
improve  our  understanding  of  the  epidemiology  of  HCV  infection  in  Scotland,  a 
nationwide  surveillance  system  was  established  to  collect  laboratory  data  on  all 
persons  diagnosed  HCV  antibody  positive'  86.  The  existence  of  this  and  other  high- 
quality  national  computerised  databases  on  hospital  discharges,  cancer  registrations 
77 and  deaths'87  afforded  an  opportunity  to  adopt  a  record-linkage  approach  to  examine 
the  occurrence  of  liver  failure  and  cancer  associated  with  HCV  infection  in  Scotland. 
4.2  Aims 
The  aims  of  the  work  presented  in  this  chapter  were  to: 
(i)  estimate  the  annual  number  of  new  diagnoses  for  decompensated  cirrhosis  and 
HCC  related  to  HCV  infection  in  Scotland; 
(ii)  examine  the  epidemiological  characteristics,  in  particular  the  presence  of  alcohol 
and  HIV  infection,  of  HCV-related  decompensated  cirrhosis  and  HCC  cases  in 
Scotland; 
(iii)  determine  the  influence  of  epidemiological  risk  factors  on  the  development  of 
decompensated  cirrhosis  and  HCC  among  HCV  diagnosed  persons  in  Scotland; 
(iv)  determine  the  mortality  rate  following  hospitalisation  with  decompensated 
cirrhosis  and  HCC  among  HCV  diagnosed  cases  in  Scotland; 
(v)  estimate  the  prevalence  of  diagnosed  HCV  infection  among  all  decompensated 
cirrhosis  and  HCC  cases  in  Scotland. 
Estimates  of  (i)  were  also  produced  for  Greater  Glasgow  to  allow  validation  of 
the  model,  in  Chapter  6,  designed  to  estimate  and  project  the  burden  of  HCV-related 
disease  among  IDUs  in  this  area.  Data  from  (ii),  (iii)  and  (iv)  provide  a  Scottish 
perspective  on  the  natural  history  of  HCV  infection.  Data  from  (v)  will  provide  an 
understanding  of  the  contribution  of  HCV  in  the  rising  incidence  of  severe  liver 
disease  reported  in  the  UK  and  in  other  developed  countries. 
78 4.3  Methods 
4.3.1  Design  overview 
Scotland's  database  of  HCV  diagnosed  persons  was  linked  with  other  nationally  held 
databases  on  hospital  admissions,  cancer  registrations  and  deaths  to  determine  HCV 
diagnosed  patients'  development  of,  and  mortality  from,  severe  sequelae  (namely 
HCC  and  decompensated  cirrhosis)  during  1991-2001.  Not  all  instances  of  the  above 
severe  disease  outcomes  related  to  HCV  infection  would  be  detected  through  this 
approach  -  for  example,  due  to  undiagnosed  HCV  infection  -  and  thus  hospital  data 
were  adjusted  to  account  for  this  (described  below).  Data  on  epidemiological  risk 
factors  -  in  particular  excessive  alcohol  use  and  coinfection  with  HIV  -  acquired 
through  the  record-linkage  process,  were  assessed  in  relation  to  the  development  of 
decompensated  cirrhosis  and  HCC.  The  mortality  rate  following  hospitalisation  with 
HCV-related  decompensated  cirrhosis  and  HCC  cases  in  Scotland  was  also 
determined.  Finally,  the  numbers  of  new  hospitalisations  and  deaths  from  HCC  and 
decompensated  cirrhosis  related  to  diagnosed  HCV  infection  were  compared  with  all 
new  hospitalisations  and  deaths  from  these  causes  (i.  e.  regardless  of  HCV  status)  in 
Scotland  during  1996-2001  to  estimate  the  prevalence  of  diagnosed  HCV  infection  in 
end-stage  liver  disease. 
4.3.2  Study  population 
The  study  population  comprised  all  persons  who  had  been  diagnosed  HCV  antibody 
positive  in  Scotland  up  to  the  31st  December  2001.  Epidemiological  data  on 
laboratory  reported  HCV  diagnoses  are  held  at  the  Scottish  Centre  for  Infection  and 
Environmental  Health  (SCIEH)'  86;  laboratory  under-reporting  is  not  an  issue  because 
diagnoses  are  confirmed  by  virology  laboratories  in  which  dedicated  surveillance  staff 
79 collate  and  forward  the  data  to  SCIEH.  The  database  consists  of  cases  who  were 
diagnosed  since  testing  first  began  in  1991  and  a  minority  (<I%)  who  were 
retrospectively  tested  HCV  antibody  positive  prior  to  this.  Data  collected  include  date 
of  the  earliest  positive  specimen,  source  of  specimen  (e.  g.  hospital,  general  practice, 
genito-urinary  medicine  clinic,  prison),  risk  information  and  a  limited  set  of  personal 
identifiers  ((a)  forename  initial,  (b)  surname  initial,  (c)  surname  soundex'88,  (d)  date 
of  birth,  (e)  gender  and  (f)  postcode  district  of  residence  at  diagnosis)  to  eliminate 
repeat  tests;  full  names  are  not  held  to  preserve  patient  confidentiality188.  Records  are 
updated  (but,  regrettably,  date  of  updating  is  not  registered)  if  missing  data  on  risk  or 
other  relevant  epidemiological  information  become  available  from  subsequent  tests. 
At  the  end  of  December  2001,  records  from  13,519  persons  in  Scotland  diagnosed 
with  HCV  were  held  on  the  database189 
4.3.3  Data  sources  used  to  identify  information  on  disease  outcomes  and  other 
epidemiological  risk  factors 
4.3.3.1  Scotland's  hospital  discharge,  cancer  and  deaths  databases 
The  Information  and  Statistics  Division  (ISD)  in  Edinburgh  holds  national 
computerised  data  on  (i)  hospital  (general  acute  inpatient  and  day  case)  discharge 
records  for  non-psychiatric,  non-obstetric  specialties  190,  (ii)  cancer  registrations  190  and 
(iii)  Registrar  General's  death  records  191  Diagnoses  pertinent  to  either  the  patient's 
hospital  stay,  cancer  registration  or  cause  of  death  were  coded  according  to  the 
International  Classification  of  Diseases  (ICD)  Ninth192  (in  years  1980-1995  for 
hospital  discharges  and  1980-1999  for  deaths  records)  and  Tenth  Revisions193  (in 
years  1996-2001  for  hospital  discharges,  1980-1998  for  cancer  and  2000-2001  for 
deaths  records;  data  were  only  available  up  to  1998  for  cancer  registrations  and 
80 therefore  were  merely  used  to  assess  the  reliability  of  hospital  discharge  data). 
Records  on  these  databases  contained  full  identifying  information,  including  the 
limited  set  of  identifiers  listed  (a)-(f)  above,  required  to  link  to  the  HCV  diagnoses 
database.  A  measure  of  a  patient's  deprivation  status  was  also  available  with  each 
record  and  had  been  derived  from  their  postcode  of  residence  based  on  the  Carstairs 
and  Morris  index,  which  combines  four  census  indicators  (overcrowding, 
unemployment,  social  class  and  car  ownership),  judged  to  represent  material 
disadvantage  in  the  population,  into  a  single  composite  seven-point  score,  ranging 
from  very  affluent  (1)  to  very  deprived  (7),  for  each  postcode  sector  in  Scotland'  94,195 
4.3.3.2  Scotland's  HIV  test  database 
SCIEH  holds  epidemiological  non-named  data  on  all  persons  who  have  had  a  personal 
HIV  antibody  test  in  Scotland  since  1989196.  These  data  are  collected  through  the  use 
of  a  national  HIV  test  request  form,  which  accompanies  the  blood  specimen  sent  for 
HIV  testing  to  the  appropriate  laboratory'  97.  Data  retained  at  SCIEH  include  date  of 
specimen,  HIV  antibody  test  result,  risk  category  associated  with  HIV  test  and 
identifiers  (a)-(f)  listed  above. 
4.3.4  Record-linkage  process 
The  HCV  diagnoses  database  was  linked  to  (i)  hospital  discharge  records,  (ii)  cancer 
registrations  and  (iii)  death  records  by  ISD's  Record  Linkage  Team  using  a  previously 
developed  probability  matching  approach'87.  The  identifier  fields  used  in  the  linkage 
process  were  as  listed  (a)-(f)  above.  ISD  have  estimated  that  both  the  false  negative 
rate  (the  proportion  of  truly  matched  pairs  which  the  system  fails  to  link)  and  the  false 
positive  rate  (the  proportion  of  linked  pairs  of  records  which  do  not  refer  to  the  same 
81 individual)  with  this  approach  to  be  less  than  5%187,  similar  to  that  found  recently  in 
an  independent  assessment  of  matching  using  non-name-based  case  registries19ß.  ISD 
also  performed  an  internal  linkage  of  records  on  the  HCV  diagnoses  database  to 
identify  any  overlooked  duplicate  cases  (see  Results).  These  linkages  were  approved 
by  the  Privacy  Advisory  Committee,  which  oversees  issues  of  confidentiality 
involving  data  on  National  Health  Service  patients  in  Scotland.  Once  these  linkages 
were  completed,  ISD  provided  SJH  with  data  from  the  hospital,  cancer  and  deaths 
registries  on  HCV  diagnosed  persons  for  subsequent  analyses  as  described  below. 
To  secure  further  data  on  the  injecting  and  HIV  positive  status  of  HCV 
diagnoses,  a  linkage  of  the  HCV  diagnoses  database  with  a  subset  of  the  HIV  test 
database  (on  records  of  those  who  had  indicated  that  they  had  injected  drugs  or  who 
had  tested  HIV  positive)  was  performed  by  SJH.  The  surname  soundex  of  HIV  tested 
persons  was  incomplete  and  thus  excluded  from  the  linkage  process.  Individuals  who 
matched  exactly  on  forename  initial,  surname  initial,  date  of  birth  and  gender  were 
assumed  to  be  the  same  person;  the  sensitivity  and  specificity  of  matching  based  only 
on  these  identifiers  was  assumed  to  be  in  excess  of  95%198. 
4.3.5  Definition  of  disease  outcomes  and  other  epidemiological  risk  factors 
4.3.5.1  Hepatocellular  carcinoma  (HCC) 
HCC  was  identified  on  the  hospital  discharge,  cancer  and  deaths  databases  by  a 
diagnosis  of  primary  liver  cancer  (ICD-9  code  155.0;  ICD-10  code  C220).  The  cancer 
database  was  also  able  to  identify  those  who  had  histologically  confirmed  HCC. 
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Decompensated  cirrhosis  was  defined  as  ascites,  oesophageal  varices  with  bleeding, 
hepatic  encephalopathy,  chronic  hepatic  failure  and  alcoholic  hepatic  failure 
(identified  as  ICD-9  codes:  456.0,571.3,572.2,572.8,789.5;  ICD-10  codes:  1850, 
1982,  K704,  K709,  K721,  K729,  R18). 
4.3.5.3  Epidemiological  risk  factors 
For  each  HCV  diagnosed  case,  their  linked  hospital  discharge  and  death  records  were 
searched  for  mention  of  alcohol  (as  defined  by  ICD-9  codes:  291,303.9,305.0,571.0- 
571.3;  ICD-10  codes:  F  10,  K70),  hepatitis  B  virus  (HBV)  (ICD-9  codes  070.2,070.3; 
ICD-10  codes:  B  16,  B  170,  B  180,  B  181)  and  opiate  dependence  (ICD-9  codes:  304.0, 
304.7;  ICD-10  codes:  F  11).  A  second  variable  for  alcohol  abuse  (as  defined  by  ICD-9 
codes:  291,303.9,305.0;  ICD-10  codes:  F10)  was  also  created  which  excluded 
alcoholic  liver  disease.  Data  on  opiate  use  (from  a  hospital  admission  or  death  record) 
and  injecting  drug  use  (with  a  HIV  test)  were  used  to  establish  the  IDU  risk  status  of 
HCV  diagnosed  persons  for  whom  no  risk  factor  information  were  available.  The 
maximum  Carstairs  and  Morris  deprivation  score  recorded  in  patients'  linked  hospital 
discharge  and  death  records  was  used  to  establish  if  HCV  diagnosed  persons  had 
resided  in  an  area  of  high  deprivation  (represented  by  scores  6  and  7). 
4.3.6  Analyses 
4.3.6.1  Characteristics  of  HCV  diagnosed  persons 
A  comparison  of  HCV  diagnoses'  characteristics  (i.  e.  year  and  age  at  diagnosis, 
gender,  risk  group,  health-board  of  residence,  referral  source)  was  made  between 
those  who  had  sufficient  and  insufficient  identifiers  for  linkage  with  other  databases; 
83 insufficient  identifiers  amounted  to  absence  of  date  of  birth  or  both  forename  and 
surname  initials.  Uni-factorial  and  multi-factorial  logistic  regression  were  used  to 
determine  the  factors  significantly  associated  with  non-linkage  of  HCV  diagnosed 
cases. 
4.3.6.2  Epidemiological  risk  factors  of  HCV  diagnosed  persons 
The  HIV  diagnosis,  deprivation,  alcohol  and  HBV  status  of  HCV  diagnosed  persons 
were  obtained  from  examining  their  HIV  test,  hospital  discharge  and  death  records. 
The  IDU  status  of  HCV  diagnosed  persons  was  sourced  from  four  databases  (i.  e. 
HCV  diagnoses,  HIV  test,  hospital  discharge  and  death  databases;  data  on  opiate  use, 
instead  of  IDU,  was  only  available  from  the  latter  two  databases).  Log-linear 
modelling199  was  then  used  to  analyse  the  overlaps  in  the  number  of  HCV  diagnosed 
IDUs  among  the  four  data-sources  and  estimate  the  total  (including  hidden)  number  of 
HCV  diagnosed  IDUs.  Stepwise  regression  was  used  to  find  a  model  which 
adequately  described  the  data  with  as  few  parameters  as  possible;  retention  of 
interaction  terms  was  further  assessed  by  comparison  of  the  residual  deviance  with  the 
x2  distribution. 
4.3.6.3  Characteristics  of  HCC  and  decompensated  cirrhosis  cases  among 
HCV  diagnosed  persons 
The  epidemiological  characteristics  of  new  diagnoses  (first  hospital  admissions)  and 
deaths  (both  underlying  and  all  causes)  from  HCC  and  decompensated  cirrhosis 
during  1991-2001  were  examined.  In  particular,  the  proportion  of  deceased  cases  with 
each  condition  (i.  e.  HCC  and  decompensated  cirrhosis)  who  had  also  been 
hospitalised  with  this  condition  was  determined  (for  purposes  of  adjusting  observed 
84 data,  as  described  below).  Additionally  for  HCC,  the  proportions  of  hospitalised  and 
deceased  cases  who  had  been  registered  on  the  cancer  database  (complete  to  1998) 
were  also  determined. 
4.3.6.4  Annual  numbers  of  new  diagnoses  for  HCC  and  decompensated 
cirrhosis  related  to  HCV  infection 
The  annual  number  of  first  hospital  admissions  for  HCC  and  decompensated  cirrhosis 
among  individuals  who  were  already  HCV  diagnosed  prior  to  hospitalisation  or  within 
14  days  were  adjusted  to  account  for  (i)  the  inability  to  link  a  proportion  of  HCV 
diagnosed  cases  due  to  insufficient  identifiers,  (ii)  the  non-hospitalisation  of  HCC  and 
decompensated  cirrhosis  cases  (estimated  from  the  proportion  of  deaths  not 
previously  hospitalised  for  these  conditions),  and  (iii)  the  non-diagnosis  of  HCV 
infection  among  HCC  and  decompensated  cirrhosis  cases  (estimated  from  the 
proportion  of  those  hospitalised  for  decompensated  cirrhosis  who  were  not  diagnosed 
with  HCV  infection  until  >14  days  after  their  hospitalisation);  details  given  in 
footnote  to  Table  4.6.  No  adjustment  was  made  for  the  high  sensitivity  and  specificity 
of  the  record-linkage  process.  Adjusted  annual  diagnoses  for  HCC  and 
decompensated  cirrhosis  were  restricted  to  the  period  1996-2001,  due  to  limited  HCV 
testing  prior  to  this  period. 
4.3.6.5  Risk  factors  for  development  of  HCC  and  decompensated  cirrhosis 
among  HCV  diagnosed  persons 
Cox  proportional  hazards  regression200  was  used  to  assess  the  influence  of 
epidemiological  factors  on  the  development  of  outcomes  (i)  HCC  and  (ii) 
decompensated  cirrhosis  among  diagnosed  HCV  positive  persons  in  Scotland.  The 
85 period  of  observation  used  in  calculating  the  risk  of  either  outcome  began  at  the  date 
of  first  HCV  positive  specimen  and  ended  at  the  date  of  hospitalisation  for  the 
relevant  outcome  (either  HCC  or  decompensated  cirrhosis),  date  of  death,  or  the  end 
of  December  2001,  whichever  came  first.  Covariates  examined  included  baseline 
characteristics  at  the  time  of  HCV  diagnosis  (i.  e.  gender,  risk  group,  health-board  of 
residence  and  referral  source)  and  time-dependent  covariates  (i.  e.  current  age,  first 
hospitalisation  for  alcohol  abuse  and  HBV,  and  diagnosed  HIV  infection).  Analysis 
was  confined  to  persons  who  were  outcome  free  at  the  start  of  follow-up  and  thus 
cases  who  were  admitted  to  hospital  for  the  relevant  condition  (i.  e.  HCC  or 
decompensated  cirrhosis)  prior  to  or  within  14  days  of  HCV  diagnosis  were  excluded; 
furthermore,  those  who  had  been  retrospectively  diagnosed  with  HCV  and  had  their 
first  positive  test  result  prior  to  1991  were  also  excluded  from  analyses.  Models  were 
assessed  for  HCV  diagnosed  cases  referred  from  all  settings  and  separately  on  cases 
referred  only  from  non-hospital  settings.  In  an  additional  analysis,  the  risk  period  was 
defined  in  terms  of  age  (i.  e.  from  age  at  first  HCV  positive  specimen  to  age  at  end  of 
follow-up)  to  examine  the  influence  of  other  characteristics  on  the  development  of 
decompensated  cirrhosis  as  age  advances. 
4.3.6.6  Mortality  related  to  HCC  and  decompensated  cirrhosis  among  HCV 
diagnosed  persons 
Following  first  hospitalisation  for  HCC,  the  number  of  deaths  from  all  causes  and 
from  HCC  (given  as  the  underlying  cause  or  contributing  cause  with  the  underlying 
cause  stated  as  liver  or  HCV  related)  and  the  number  of  cases  who  had  been  in 
hospital  for  a  liver  transplant  (ICD-9  code:  V42.7;  ICD-10  codes:  Z94.4),  according  to 
gender  and  age  at  time  of  hospitalisation  for  HCC,  were  determined.  The  person-years 
86 at  risk  were  calculated  as  time  in  years  from  date  of  first  hospitalisation  for  HCC  to 
date  of  death,  date  of  liver  transplant  or  the  end  of  December  2001,  whichever  came 
first;  cases  who  had  either  (i)  died  on  the  same  day  as  or  (ii)  received  a  liver  transplant 
prior  to  first  admission  with  HCC  were  excluded  (i.  e.  for  HCC:  (i)  0  and  (ii)  2  cases 
excluded;  also  for  decompensated  cirrhosis:  (i)  2  and  (ii)  5  cases  excluded).  Cox 
proportional  hazards  regression  was  used  to  assess  the  influence  of  gender  and  age  on 
mortality  from  (i)  HCC  and  (ii)  all  causes  following  first  hospitalisation  with  HCC; 
the  probability  of  death  from  (i)  and  (ii)  at  one  and  two  years  since  first  hospitalisation 
with  HCC  were  also  estimated.  The  number  of  deaths,  liver  transplants,  person-years 
and  mortality  associated  with  cases  hospitalised  for  decompensated  cirrhosis  were 
similarly  assessed. 
4.3.6.7  Prevalence  of  diagnosed  HCV  infection  among  all  HCC  and 
decompensated  cirrhosis  cases  in  Scotland 
Data  on  all  first  hospital  admissions  and  deaths  associated  with  HCC  and 
decompensated  cirrhosis  in  Scotland  during  1996-2001  by  gender,  age,  history  of 
alcohol  abuse  and  HCV  diagnoses  status  (sourced  from  hospital  discharge  records, 
death  records  and  linkage  with  SCIEH's  HCV  diagnoses  database)  were  examined. 
Decompensated  cirrhosis  was  defined  as  above  (ascites,  oesophageal  varices  with 
bleeding,  hepatic  encephalopathy,  chronic  hepatic  failure  and  alcoholic  hepatic 
failure)  except  that  cases  without  mention  of  liver  disease  (ICD-9  codes  570-573; 
ICD-10  codes:  K70-K77)  or  hepatitis  (ICD-9  codes  070;  ICD-10  codes:  B  16-B  18) 
were  excluded,  to  discount  non-liver-related  conditions  associated  with  ascites  and 
oesophageal  varices,  from  this  analyses. 
87 4.4  Results 
4.4.1  Characteristics  of  HCV  diagnosed  persons 
Of  the  13,535  entries  on  the  HCV  diagnoses  database  as  at  the  end  of  2001,164 
(1.2%)  were  recognised  as  duplicate  records  based  on  probability  matching  methods 
carried  out  by  ISD.  A  further  1,275  (9.5%)  of  the  remaining  13,371  records  on  the 
database  either  had  date  of  birth  (277)  and/or  both  forename  and  surname  initials 
(1,034)  identifiers  missing  so  that  linkage  was  inhibited. 
Table  4.1  shows  the  characteristics  of  the  12,096  HCV  diagnosed  cases  who 
had  sufficient  identifiers  for  record-linkage  compared  with  those  of  the  remaining 
1,275  cases  who  had  insufficient  identifiers  and  were  not  linked.  The  majority  of  all 
diagnosed  cases  were  first  tested  positive  in  1998-2001  (56%),  male  (69%),  aged  20- 
34  years  (63%),  IDUs  (90%  of  known  risk  cases)  and  47%  were  referred  from 
hospital  settings.  Referrals  from  GUM  and  drug/counselling  clinics  were  significantly 
more  likely  than  hospital  referred  patients  to  have  insufficient  identifiers  for  record- 
linkage  (unadjusted  odds  ratios:  31.0  and  3.5;  95%  CI  25.9-37.1  and  2.9-4.2, 
respectively).  The  completeness  of  identifier  information  varied  by  health-board  of 
residence  -  highest  in  Lothian  (94%),  Tayside  (93%),  then  Glasgow  (91%)  and  lower 
in  the  rest  of  Scotland  (88%).  Persons  diagnosed  recently  in  years  1998-2001 
(compared  to  pre  1994)  and  those  aged  20-34  years  (compared  to  35  years  and  older) 
were  significantly  more  likely  to  have  insufficient  identifiers  recorded  and  thus  were 
less  represented  in  the  subsequent  record-linkage  exercise. 
Table  4.2(a)  shows  the  characteristics  of  the  12,096  HCV  diagnosed  cases  who 
had  sufficient  identifiers  for  record-linkage  by  risk  group.  Those  who  reported  a  non- 
IDU  risk  were  more  likely  to  have  been  diagnosed  pre  1994  and  resided  outside 
Glasgow  than  either  IDUs  or  not  known  risk  groups.  Those  who  reported  IDU  were 
88 more  likely  to  be  male  and  younger  than  those  belonging  to  non-IDU  and not  known 
risk  groups.  Finally  those  for  whom  a  risk  could  not  be  ascribed  were  more  likely  than 
the  reported  IDUs  and  non-IDUs  to  have  been  referred  from  a  hospital  setting. 
4.4.2  Epidemiological  risk  factors  of  HCV  diagnosed  persons 
Of  the  12,096  HCV  diagnosed  cases,  17%  and  6%  had  alcohol  and  HBV  mentioned 
on  either  a  hospital  discharge  or  death  record,  respectively,  and  3%  were  diagnosed 
HIV  positive  (Table  4.2).  Over  half  of  linked  cases  (5469/9813)  had  resided  in  an  area 
of  high  deprivation  (measured  by  Carstairs  score  6-7). 
Sixty-eight  percent  (8244/12096)  of  HCV  diagnosed  persons  had  IDU  (or 
opiate  use)  mentioned  with  at  least  one  of  their  (i)  HCV  diagnosis,  (ii)  HIV  test,  (iii) 
hospital  discharge  or  (iv)  death  records  (Table  4.3).  Log-linear  modelling  estimated 
that there  were  a  further  2,404  HCV  diagnosed  persons  who  had  not  been  identified  as 
IDUs  from  these  four  data-sources.  The  model  yielded  an  overall  estimate  of  10,648 
HCV  diagnosed  IDUs  (95%  Cl  9,753-12,047),  which  represents  88%  (95%  Cl  81- 
100%)  of  all  12,096  diagnosed  cases.  An  additional  analysis,  which  excluded  persons 
who  reported  a  non-IDU  risk  with  their  HCV  diagnosis,  provided  a  similar  estimate  of 
the  total  number  of  HCV  diagnosed  IDUs  (10,578  (95%  CI  9,682-11,978)). 
4.4.3  Characteristics  of  HCC  and  decompensated  cirrhosis  cases  among  HCV 
diagnosed  persons 
During  1991-2001,71  HCV  diagnosed  persons  were  hospitalised  for  the  first  time 
with  HCC  (Table  4.4),  of  whom  58  (82%)  had  also  died  during  this  period  (43  from 
underlying  cause  HCC,  5  contributing  cause  HCC  and  10  other  causes).  In  total,  67 
persons  died  with  HCC  as  their  underlying  (59)  or  contributing  cause  (8),  of  whom  50 
89 (75%)  had  been  hospitalised  with  HCC  previously  (48  during  1991-2001  and  2  pre 
1991)  and  17  (25%)  had  not  been  identified  as  having  been  hospitalised  with  HCC 
(24%  (14/59)  and  38%  (3/8)  of  deceased  cases  with  HCC  as  underlying  or  only  as 
contributing  cause,  respectively).  Of  the  eight  who  had  died  with  contributing  cause 
HCC,  five  (63%)  had  liver  disease  or  HCV  as  their  underlying  cause.  For  those  who 
had  been  hospitalised  or  died  with  HCC  during  1991-1998,95%  (40/42)  and  91% 
(39/43),  respectively,  were  registered  with  HCC  on  the  cancer  database;  24%  (13/54) 
of  HCC  cases  on  the  cancer  database  had  not  been  hospitalised  with  this  diagnosis. 
During  1991-2001,514  HCV  diagnosed  persons  were  hospitalised  for  the  first 
time  with  decompensated  cirrhosis,  of  whom  312  (61%)  had  also  died  during  this 
period  (65  and  98  from  underlying  and  contributing  cause  decompensated  cirrhosis, 
respectively,  27  HCC,  36  from  other  diseases  of  the  liver,  15  HCV  and  71  other 
causes).  In  total,  196  persons  died  with  decompensated  cirrhosis  as  their  underlying 
(75)  or  contributing  cause  (121),  of  whom  168  (86%)  had  been  hospitalised  with 
decompensated  cirrhosis  previously  (163  during  1991-2001  and  5  pre  1991)  and  28 
(14%)  had  not  been  identified  as  having  been  hospitalised  with  decompensated 
cirrhosis  (9%  (7/75)  and  17%  (21/121)  of  deceased  cases  with  decompensated 
cirrhosis  as  underlying  or  only  as  contributing  cause,  respectively;  of  note,  a  high 
proportion  (24%:  5/21)  of  the  latter  group  had  been  diagnosed  with  HIV  antibodies). 
Of  the  121  who  had  died  with  contributing  cause  decompensated  cirrhosis,  7  (6%)  had 
HCC  and  60  (50%)  had  liver  disease  or  HCV  as  their  underlying  cause.  A  further  73 
deaths  with  underlying  cause  liver  disease  or  HCV  and  without  either  decompensated 
cirrhosis  or  HCC  were  identified  during  1991-2001. 
The  majority  of  HCC  (73%),  and  less  so  decompensated  cirrhosis  (52%), 
hospitalisations  were  among  HCV  diagnosed  cases  without  a  risk  group.  A  higher 
90 proportion  of  HCC  than  decompensated  cirrhosis  first  hospitalisations  were  aged  50 
years  or  more  (82%  vs  31%,  respectively)  and  were  male  (85%  vs  75%,  respectively). 
Only  6%  of  HCV-related  HCC  hospitalisations  were  not  diagnosed  with  HCV 
antibodies  until  after  14  days  following  first  admission  with  HCC,  compared  to  17% 
(90/514)  of  HCV-related  decompensated  cirrhosis  hospitalisations.  Of  these  latter  90 
cases,  55  (61%)  were  diagnosed  with  HCV  within  a  year  of  their  first  hospital 
admission  for  decompensated  cirrhosis  and  of  the  remaining  35,31%  were  HCV 
diagnosed  within  14  days  of  a  subsequent  hospital  re-admission  for  decompensated 
cirrhosis.  Further,  81%  of  the  90  cases  had  either  alcoholic  hepatic  failure  or  ascites 
(but  not  hepatic  encephalopathy,  chronic  hepatic  failure  or  varices)  recorded  with 
their  first  hospitalisation  for  decompensated  cirrhosis  (compared  to  58%  (245/424)  of 
those  who  were  diagnosed  with  HCV  before  or  within  14  days  of  their  first 
decompensated  cirrhosis  hospitalisation). 
Alcohol  use  was  associated  with  41  %  of  HCC  hospitalisations  and  deaths,  and 
71%  of  decompensated  cirrhosis  hospitalisations  rising  to  97%  of  deaths  with 
underlying  cause  decompensated  cirrhosis.  HIV  and  HBV  were  associated  with  only  a 
small  proportion  of  HCC  (0%  and  9%,  respectively)  and  decompensated  cirrhosis  (5% 
and  13%,  respectively)  hospitalisations. 
4.4.4  Annual  numbers  of  new  diagnoses  for  HCC  and  decompensated  cirrhosis 
related  to  HCV  infection 
Table  4.6  shows  the  estimated  numbers  of  new  diagnoses  for  HCC  and 
decompensated  cirrhosis  related  to  HCV  infection  according  to  region  (as  described  in 
footnote  to  Table  4.6,  by  accounting  for  (i)  the  inability  to  link  a  proportion  of  HCV 
diagnosed  cases  due  to  insufficient  identifiers,  (ii)  the  non-hospitalisation  of  HCC  and 
91 decompensated  cirrhosis  cases,  and  (iii)  the  non-diagnosis  of  HCV  infection  among 
HCC  and  decompensated  cirrhosis  cases).  There  was  a  30%  increase  in  the  estimated 
number  of  new  diagnoses  for  decompensated  cirrhosis  related  to  HCV  infection  from 
230  (95%  CI  220-250)  in  1996-1998  to  300  (280-320)  cases  in  1999-2001  for  all 
Scotland.  In  contrast,  there  was  no  change  in  HCC  new  diagnoses  related  to  HCV 
infection  in  Scotland:  52  (95%  CI  46-60)  cases  in  1996-1998  and  49  (42-57)  in  1999- 
2001. 
4.4.5  Risk  factors  for  the  development  of  HCC  and  decompensated  cirrhosis 
among  HCV  diagnosed  persons 
The  relative  hazards  in  Tables  4.7  and  4.8  show  the  change  in  risk  of  HCC  and 
decompensated  cirrhosis,  respectively,  for  each of  the  epidemiological  factors.  The 
highest  risk  for  the  development  of  HCC  was  associated  with  cases  aged  50  years  and 
above,  which  remained  the  only  significant  factor  in  the  multi-factorial  model 
restricted  to  referrals  for  HCV  diagnosis  from  non-hospital  settings  (relative  hazard 
(RH)  35  with  95%  CI  7-169).  Cases  hospitalised  with  alcohol  abuse  (3.4),  referrals  for 
HCV  diagnosis  from  hospital  (2.8)  and  males  (2.6)  were  also  significantly  associated 
with  an  increased  risk  of  HCC  in  the  multi-factorial  model  for  all  diagnosed  cases. 
Increasing  age  was  also  highly  associated  with  a  raised  risk  of  decompensated 
cirrhosis  in  the  multi-factorial  model  restricted  to  referrals  from  non-hospital  settings 
(RH  4.6  (95%  Cl  2.2-9.6),  8.8  (3.5-22.0)  and  10.7  (3.1-37.5)  for  those  aged  30-49,50- 
69  and  70+  years,  respectively,  compared  to  those  aged  <30  years).  Significantly 
increased  risk  of  decompensated  cirrhosis  was  also  found  with  hospitalisation  for 
alcohol  abuse  and  HBV,  diagnosis  with  HIV  infection  and  non-IDU  risk  for  HCV 
infection  (RHs  6.1  (95%  Cl  4.0-9.1),  2.0  (1.1-3.6),  3.9  (2.2-7.0)  and  2.4  (1.4-4.2), 
92 respectively).  Broadening  to  referrals  from  all  settings,  cases  with  unknown  risk  for 
HCV  infection,  referrals  for  HCV  diagnosis  from  hospital  and  residents  of  Lothian 
also  had  significantly  increased  risk  of  progression  to  decompensated  cirrhosis;  males 
did  not  have  a  significantly  different  risk  from  females. 
Figure  4.1  illustrates  the  development  of  decompensated  cirrhosis  among 
HCV  diagnosed  cases  according  to  age  and  alcohol  abuse.  Development  of 
decompensated  cirrhosis  by  50  years  of  age  increased  from  14%  (95%  Cl  10-17%)  to 
46%  (37-54%)  among  cases  without  and  with  a  history  of  hospitalisation  with  alcohol 
abuse,  respectively;  restricting  to  non-hospital  referrals  for  HCV  diagnosis,  these 
proportions  reduced  marginally  to  11%  (7-15%)  and  44%  (29-55%),  respectively. 
4.4.6  Mortality  related  to  HCC  and  decompensated  cirrhosis  among  HCV 
diagnosed  persons 
Tables  4.9(a)  and  4.9(b)  examine  the  mortality  of  HCV  diagnosed  patients  following 
first  hospitalisation  for  HCC  and  decompensated  cirrhosis  during  1991-2001  in 
Scotland,  respectively.  The  probability  of  death  from  HCC  and  all  causes  following 
first  hospitalisation  with  HCC  was  57%  and  68%  at  1  year  increasing  to  63%  and  79% 
at  2  years,  respectively;  the  risk  of  death  following  first  hospitalisation  with  HCC  was 
higher  among  patients  aged  50  years  or  more  and  men  but  neither  reached  statistical 
significance.  The  probability  of  death  from  decompensated  cirrhosis  and  all  causes 
following  first  hospitalisation  with  decompensated  cirrhosis  was  18%  and  42%  at  1 
year  increasing  to  39%  and  72%  at  5  years,  respectively.  The  risk  of  all  cause  death 
following  first  hospitalisation  with  decompensated  cirrhosis  was  significantly  higher 
among  those  aged  50  years  or  older  at  hospitalisation  compared  to  younger  patients 
(RH  1.85;  95%  CI  1.46-2.35,  p<0.0001).  The  probability  of  having  a  liver  transplant 
93 within  the  first  two  years  following  first  hospitalisation  for  decompensated  cirrhosis 
was  4.2%  (95%  Cl  1.5-6.9%). 
4.4.7  Prevalence  of  diagnosed  HCV  infection  among  all  HCC  and  decompensated 
cirrhosis  cases  in  Scotland 
Seven  hundred  first  hospital  admissions  and  617  deaths  from  HCC  occurred  during 
1996-2001  in  Scotland  (Table  4.10),  of  which  9.7%  (68/700)  and  8.1%  (50/617)  were 
determined  as  known  to  be  infected  with  HCV,  respectively.  Of  the  68  known  HCV 
infected  persons  hospitalised  with  HCC,  51  (75%)  were  determined  as  HCV  infected 
according  to  both  their  SCIEH  and  either  hospital  or  death  records,  6  (9%)  from  only 
their  SCIEH  record  and  11  (16%)  from  either  their  hospital  or  death  records;  39 
(78%),  5  (10%)  and  6  (12%)  were  similarly  recognised  as  known  HCV  infected 
among  the  50  HCC  deaths.  Prevalence  of  known  HCV  infection  was  highest  among 
HCC  cases  aged  30-49  years  (39%  of  44  new  hospitalisations  and  40%  of  25  deaths). 
The  aetiological  factors  potentially  responsible  for  HCC  were  only  explained  by  either 
(a)  alcohol,  (b)  HBV  or  (c)  HCV  recorded  in  38%  of  hospitalised  cases  (a:  178;  b:  13; 
c:  33;  a&b:  5;  a&c:  28;  b&c:  3;  and  a,  b&c:  4)  and  38%  of  deaths  (a:  169;  b:  12; 
c:  28;  a&b:  3;  a&c:  21;  anda,  b&c:  1) 
New  hospital  admissions  and  deaths  from  decompensated  cirrhosis  occurred  in 
10,588  and  3,936  cases,  respectively,  during  1996-2001  in  Scotland  (Table  4.10),  of 
which  4.2%  (442/10588)  and  3.4%  (134/3936),  respectively,  were  determined  as 
known  to  be  infected  with  HCV.  Of  the  442  known  HCV  infected  persons 
hospitalised  with  decompensated  cirrhosis,  286  (65%)  were  determined  as  HCV 
infected  according  to  both  their  SCIEH  and  either  hospital  or  death  records,  64  (14%) 
from  only  their  SCIEH  record  and  92  (21%)  from  either  their  hospital  or  death 
94 records;  84  (63%),  23  (17%)  and  27  (20%)  were  similarly  recognised  as  known  HCV 
infected  among  the  134  decompensated  cirrhosis  deaths.  Prevalence  of  known  HCV 
infection  was  highest  among  decompensated  cirrhosis  cases  aged  under  50  years  (9% 
of  new  hospitalisations  and  8%  of  deaths).  Alcohol  was  identified  as  a  factor  in  83% 
of  all  decompensated  cirrhosis  new  hospitalisations  (other  aetiological  factors:  alcohol 
(a):  8412;  HBV  (b):  28;  HCV  (c):  105;  a&b:  53;  a&c:  278;  b&c:  17;  and  a,  b&c: 
42)  and  89%  of  deaths  (a:  3378;  b:  12;  c:  26;  a&b:  16;  a&c:  88;  b&c:  4;  and  a,  b& 
c:  16). 
4.5  Discussion 
To  help  policymakers  to  prioritise  HCV-related  interventions  and  research  and  to 
allocate  healthcare  resources  accordingly,  accurate  information  about  the  current 
burden  of  this  disease  is  essential.  The  greatest  burden  from  HCV  infection  will  come 
from  the  long-term  complications  of  this  chronic  liver  disease,  namely  decompensated 
cirrhosis  and  HCC.  In  the  United  States,  examination  of  trends  in  deaths  from  non-A, 
non-B  viral  hepatitis  and  the  frequency  of  inpatient  care  for  HCV-related  diagnoses 
highlighted  that  the  mortality  and  healthcare  utilisation  associated  with  long-standing 
HCV  infection  had  increased  over  the  past  decade'85'2oi  These  data,  however,  relied 
on  the  accurate  reporting  of  hepatitis  C  on  death  and  hospital  records  and  thus,  likely, 
under-estimated  the  true  mortality  and  morbidity  burden.  Unless  countries  introduce 
national  surveillance  systems  for  registration  of  HCV-related  decompensated  cirrhosis 
and  HCC,  akin  to  that  for  AIDS  diagnosis,  the  record-linkage  approach  developed 
here  is  the  only  means  to  ascertain  these  data.  The  laboratory  reporting  of  diagnostic 
positive  tests  for  HCV  antibodies  in  Scotland  linked  electronically  to  clinical  data 
95 gathered  from  hospital  and  death  records  therefore  provided  a  unique  national 
epidemiological  dataset  on  diagnosed  HCV  infection. 
Approximately  500  and  200  diagnosed  HCV  antibody  positive  persons  in 
Scotland  had  developed  and  died  of  liver  failure,  respectively,  by  the  end  of  2001.  The 
number  of  persons  with  newly  developed  HCV-related  decompensated  cirrhosis  in 
Scotland  was  estimated  to  increase  by  30%  from  230 (95%  CI  220-250)  in  1996-1998 
to  300  (280-320)  cases  in  1999-2001.  The  number  of  confirmed  HCV  antibody 
positive  persons  who  had  presented  to  hospital  with  decompensated  cirrhosis  and 
HCC  by  2001  was,  however,  a  small  fraction  -  only  4.2%  (514/12,096)  and  0.6% 
(71/12,096),  respectively  -  of  the  total  HCV  diagnosed  population  in  Scotland.  This 
observation  may  be  reassuring  for  a  patient  newly  diagnosed  with  HCV,  but 
represents  a  growing  significant  burden  on  healthcare  resources. 
Estimates  of  the  proportion  of  chronic  liver  disease  attributable  to  HCV 
infection  vary  considerably,  ranging  from  8-15%  in  the  United  States201  and  New 
Zealand202  to  62-74%  in  Italy203  and  Egypt204.  Back-calculation  models  in  France 
assumed  that  36%,  and  more  recently  27%,  of  HCC  deaths  were  attributable  to 
HCV78'79.  Much  higher  prevalences  of  HCV  antibodies  were  reported  among  selected 
HCC  patients  in  Japan  (60-95%)  205,206  and  other  parts  of  Europe  (45-75%)  207,208 
except  in  England  (22%  of  37)  and  Greece  (14%  of  56)209.  Australian  projections 
estimated  that  7%  (5-8%)  of  HCC  cases  in  1998  were  due  to  HCV  infection81.  HCV 
was  detected  in  30%  of  80  HCC  patients,  with  stored  serum  samples,  presenting  to  a 
single  hospital  in  the  East  of  Scotland  between  1985  and  199439 
In  comparison,  low  prevalences  of  diagnosed  HCV  infection  were  found 
among  individuals  with  HCC  and  decompensated  cirrhosis  (DC)  presenting  to 
hospital  (10%  and  4%,  respectively)  or  having  died  (8%  and  3%,  respectively)  in 
96 Scotland  during  1996-2001.  The  underlying  prevalence  of  HCV  in  these  groups  could 
be  higher  at  13%  (i.  e.  hospitalised  with  HCC),  6%  (hospitalised  with  DC),  11%  (died 
with  HCC)  and  5%  (died  with  DC),  respectively,  after  accounting  for  infections  which 
were  not  identified  through  record-linkage,  because  (i)  10%  of  HCV  diagnosed 
persons  could  not  be  included  in  the  record-linkage  due  to  insufficient  identifiers,  and 
(ii)  a  proportion  (estimated  to  be  17.5%,  based  on  the  proportion  who  were  HCV 
diagnosed  after  hospitalisation  with  decompensated  cirrhosis)  of  HCV-infected  HCC 
and  decompensated  cirrhosis  cases  were  not  tested  and  diagnosed  with  HCV. 
Estimates  were  restricted  to  1996-2001  to  minimise  the  influence  of  the  sharp  increase 
in  HCV  antibody  testing  of  patients  with  liver  disease  during  the  early  1990s. 
Misclassification  of  the  ICD  code  on  the  hospital  or  death  record  represents  a  further 
source  of  error,  although  this  appears  to  be  minor  given  that  95%  and  91%  of  HCV 
diagnosed  individuals  who  had  been  hospitalised  or  had  died  with  HCC,  respectively, 
were  also  registered  with  HCC  on  the  cancer  database.  HCC  and  hepatic 
decompensation  -  as  manifested  by  ascites,  hepatic  encephalopathy  or  gastrointestinal 
bleeding  -  generally  necessitate  inpatient  hospital  care.  However,  25%  and  14%  of 
deaths  from  HCC  and  decompensated  cirrhosis,  respectively,  were  not  identified  with 
these  conditions  in  the  hospital  register  and  therefore  the  hospital  morbidity  data  alone 
may  under-estimate  the  incidence  of  severe  HCV-disease. 
The  extent  of  alcohol-  compared  to  HCV-  related  hepatic  failure  is  sobering, 
with  hospitalisations  associated  with  the  former  outnumbering  the  latter  20-fold,  and 
underlines  alcohol  as  the  major  cause  of  chronic  liver  disease  currently  in  Scotland; 
although,  HCV  is  forecast  to  become  a  more  prominent  cause  in  the  future  (as 
suggested  from  projections  derived  in  Chapter  6).  Alcohol  was  also  a  prominent 
feature  among  HCV  diagnosed  persons  who  either  died  or  were  hospitalised  with 
97 decompensated  cirrhosis  during  1996-2001  (78%  and  72%,  respectively).  The 
younger  age  of  decompensated  patients  presenting  to  hospital  with  both  HCV  and 
alcohol  (78%  <50  years  old)  suggests  that  the  combined  effect  of  these  two  factors 
accelerates  liver  disease  progression  more  than  with  only  one  (HCV:  48%;  alcohol: 
33%)  or  none  of  these  factors  (17%).  In  multiple  regression  analysis,  a  history  of 
hospitalisation  with  an  alcohol-related  diagnosis  was  associated  with  a  5-  to  6-  fold 
increased  risk  of  developing  decompensated  cirrhosis  among  HCV  diagnosed 
antibody  positive  individuals  in  Scotland.  A  limitation  of  the  hospital  data  was  the 
absence  of  information  on  the  quantity  of  alcohol  consumed  by  patients.  Heavy 
alcohol  consumption,  particularly  above  350g  per  week,  has  previously  been 
correlated  with  increased  liver  disease  progression  in  individuals  infected  with 
HCV95'21°  and  is  the  focus  of  further  study  in  Chapter  5.  In  keeping  with  the  literature 
on  the  natural  history  of  HCV  diseases,  the  proportional  hazards  multifactorial 
regression  also  identified  older  age,  HIV  and  HBV  co-infection  as  factors  associated 
with  higher  risk  of  decompensated  cirrhosis. 
Injecting  drug  use  represents  the  most  common  risk  factor  for  HCV  infection 
throughout  the  industrialised  world211.  However  a  substantial  proportion  of  persons 
who  test  positive  for  HCV  antibodies  report  no  risk  factors  for  infection.  Thirty 
percent  of  persons  with  acute  HCV  in  the  United  States  during  1991-1995  denied  a 
specific  exposure  associated  with  acquiring  infection  during  the  six  months  preceding 
onset  of  their  illness,  although  over  half  of  these  reported  a  previous  history  of  drug 
use212.  In  England  and  Wales,  43%  of  confirmed  HCV  infections  during  1992-1996 
lacked  risk  factor  information  213.  It  follows  that  either  the  potential  risk  factors  for 
HCV  acquisition  were  not  carefully  elicited  or  that  there  may  be  a  significant 
undefined  source  of  viral  transmission.  A  study  in  the  United  States  showed  that  the 
98 route  of  HCV  acquisition  could  be  delineated  in  88%  of  HCV  chronically  infected 
patients  using  a  systematic  interview  approach;  in  nearly  all  cases,  the  initially 
unreported  risk  factor  for  HCV  transmission  was  a  remote  history  of  injecting  drug 
use214.  This  application  in  Scotland  of  capture-recapture  methodology  is  the  first  to 
demonstrate  the  use  of  log-linear  modelling,  based  on  record-linkage  data  from  four 
sources  (i.  e.  HCV  diagnoses,  HIV  test,  hospital  and  death  records),  to  estimate  the 
proportion  of  IDUs  among  HCV  diagnosed  persons.  Of  12,096  HCV  antibody 
positive  persons  studied,  61%  reported  injecting  drug  use  with  their  HCV  diagnosis 
and  a  further  27%,  yielding  a  total  of  88%,  were  established  as  IDUs  through  log- 
linear  modelling. 
This  study  provided  the  first  estimates  of  the  current  morbidity  and  mortality 
associated  with  diagnosed  HCV  infection  in  Scotland,  which  is  of  particular 
importance  in  terms  of  validating  HCV  projections  in  Chapter  6,  and  highlighted  the 
impact  of  alcohol  on  the  course  of  this  epidemic.  The  extent  of  heavy  drinking  among 
IDUs  -  reported  from  other  countries  to  be  in  the  range  of  20%  to  50%215,216,217,218  _ 
has  received  insufficient  attention  in  the  treatment  and  care  of  this  client  group. 
Further  research  is  required  to  assess  the  influence  on  drinking  behaviour  of  testing 
IDUs,  including  those  who  have  ceased  injecting,  for  HCV  antibodies  and  counselling 
them  about  the  consequences  of  alcoho1219.  In  light  of  the  apparent  synergistic  effect 
between  alcohol  and  HCV,  limiting  the  alcohol  consumption  of  chronically  infected 
individuals  is  essential  to  help  prevent  future  morbidity  and  mortality  related  to  HCV 
infection. 
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Table  4.1:  Characteristics  of  HCV  diagnosed  individuals  in  Scotland  up  to  the  end  of  2001:  comparison  between 
12,096  and  1,275  cases  who  had  sufficient  (linked)  and  insufficient  (non-linked)  identifiers,  respectively,  as 
required  to  allow  record-linkage  with  other  data  sources. 
HCV  diagnosed  persons  Odds  Ratio  for  non-linked 
N  (%)  (95%  CI) 
Linked  Non-linked  Uni-factorial  Multi-factorial 
N=12,096  N=1,275 
Year  of  HCV  diagnosis  Pre  1994  1187(10%)  52  (4%)  0.35  (0.27-0.47)  0.24  (0.14-0.40) 
1994-1997  4257(35%)  396  (31%)  0.75  (0.66-0.85)  0.87  (0.73-1.05) 
1998-2001  6652(55%)  827  (65%)  1.00  (Baseline)  1.00  (Baseline) 
Gender  Male  8345  (69%)  831  (71%)  1.00  (Baseline)  1.00  (Baseline) 
(129  not  known)  Female  3723  (31%)  343  (29%)  0.93  (0.81-1.05)  0.90  (0.75-1.09) 
Age  at  HCV  diagnosis  (years)  <  20  563  (5%)  59  (6%)  1.05  (0,80-1.39)  0.93  (0.63-1.37) 
(277  not  known)  20-34  7507  (62%)  747  (75%)  1.00  (Baseline)  1.00  (Baseline) 
35-49  3154(26%)  179(18%)  0.57  (0.48-0.67)  0.51  (0.41-0.64) 
2  50  872  (7%)  13  (1%)  0.15  (0.09-0.26)  0.23  (0.13-0.42) 
Risk  group  IDU  7327(61%)  716  (56%)  1.00  (Baseline)  1.00  (Baseline) 
Non-IDU  895  (7%)  45  (4%)  0.52  (0.38-0.70)  1.19  (0.76-1.86) 
None  reported  3874(32%)  514  (40%)  1.36  (1.20-1.53)  2.82  (2.32-3.42) 
Healthboard  of  residence  Greater  Glasgow  4513  (37%)  445  (35%)  1.00  (Baseline)  1.00  (Baseline) 
for  HCV  diagnosis  Lothian  1859  (15%)  112  (9%)  0.61  (0.50-0.76)  0.51  (0.38-0.69) 
Grampian  1360(11%)  209  (16%)  1.56  (1.31-1.86)  1.97  (1.48-2.62) 
Tayside  986  (8%)  72  (6%)  0.74  (0.57-0.96)  0.84  (0.57-1.22) 
Rest  of  Scotland  3378(28%)  437  (34%)  1.31  (1.14-1.51)  2.30  (1.86-2.85) 
Referral  source  for  HCV  diagnosis  Hospital  5755  (49%)  311  (25%)  1.00  (Baseline)  1.00  (Baseline) 
(384  not  known)  GP  2633  (22%)  67  (5%)  0.47  (0.36-  0.61)  0.57  (0.38-  0.85) 
Drug/Counselling  Clinic  1047  (9%)  195  (16%)  3.45  (2.85-  4.17)  11.68  (9.09-  15.01) 
Prison  1054  (9%)  55  (4%)  0.97  (0.72-  1.30)  1.60  (1.12-  2.30) 
GUM  clinic  316  (3%)  529  (42%)  30.98  (25.87-37.09)  124.94  (96.47-161.80) 
Other  933  (8%)  92  (7%)  1.82  (1.43-  2.33)  1.03  (0.61-  1.74) 
100 %0 
Table  4.2:  Epidemiological  characteristics  of  HCV  diagnosed  individuals  in  Scotland,  who  were  linked  to 
hospital  admission,  deaths  and  HIV  testee  databases,  by  risk  group. 
Risk  Group  reported  with  HCV  diagnosis 
IDU  Non-IDU  None  reported 
N  =7327  N=895  N=3874 
(a)  Characteristics  extracted  from  the  HCV  diagnosis  record 
Year  of  HCV  diagnosis  Pre  1994  534  (7%)  327  (37%)  326  (8%) 
1994-1997  2467  (34%)  315  (35%)  1475  (38%) 
1998-2001  4326  (59%)  253  (28%)  2073  (54%) 
Gender  Male  5245  (72%)  583  (65%)  2517  (65%) 
(28  not  known)  Female  2075  (28%)  31  1  (35%)  1337(35%) 
Age  at  HCV  diagnosis  (years)  <  20  346  (5%)  107  (12%)  110  (3%) 
20-34  5344(73%)  344(38%)  1819(47%) 
35-49  1577  (22%)  290(32%)  1287(33%) 
>_  50  60  (1%)  154(17%)  658(17%) 
Healthboard  of  residence  Greater  Glasgow  2845  (39%)  253  (28%)  1415  (37%) 
For  HCV  diagnosis  Lothian  1182(16%)  208(23%)  469(12%) 
Grampian  978  (13%)  74  (8%)  308  (8%) 
Tayside  618  (8%)  99(11%)  269  (7%) 
Rest  of  Scotland  1704  (23%)  261  (29%)  1413  (36%) 
Referral  source  for  HCV  diagnosis  Hospital  2936(41%)  322(37%)  2497(67%) 
(358  not  known)  GP  1901  (27%)  177  (20%)  555  (15%) 
Drug/Counselling  Clinic  865  (12%)  33  (4%)  149  (4%) 
Prison  890(12%)  8  (1%)  156  (4%) 
GUM  clinic  263  (4%)  28  (3%)  25  (1%) 
Other  308  (4%)  305  (35%)  320  (9%) 
(b)  Characteristics  extracted  from  matched  records  on  the  hospital  admission  and  deaths  databases 
Matched  to  hospital  &  deaths  No  1274  (17%)  148  (17%)  799  (21%) 
databases  Only  deaths  31  (<I%)  1  (<I%)  11  (<I%) 
Only  hospital  5259  (72%)  630  (70%)  2520  (65%) 
Both  hospital  and  deaths  763  (10%)  116(13%)  544  (14%) 
Deprivation  status  High  3655  (61%)  281  (38%)  1533  (50%) 
on  matched  records  (62  missing)  Low-Medium  2360(39%)  455  (62%)  1529(50%) 
Alcohol  mentioned  Yes  1251  (21%)  99  (13%)  657  (21%) 
on  matched  records  No  4802  (79%)  648  (87%)  2418  (79%) 
Hepatitis  B  virus  mentioned  Yes  558  (9%)  36  (5%)  188  (6%) 
on  matched  records  No  5495  (91%)  711  (95%)  2887  (94%) 
(c)  Characteristics  extracted  from  matched  records  on  the  HIV  testee  database 
Diagnosed  HIV  positive  Yes  354  (5%)  42  (5%)  15  (<1%) 
No  6973  (95%)  853  (95%)  3859  (100%) 
*  The  highest  deprivation  score  recorded  on  any  matched  hospital  admission  or  death  record,  where  deprivation  was  assigned  according  to  carstairs 
seven-point  scale  with  high  categorised  as  score  6-7  and  low-medium  as  score  1-5. 
101 Table  4.3:  IDU  status  of  12,096  HCV  diagnosed  individuals  in  Scotland  according  to  4  data-sources  (HCV 
diagnoses,  HIV  test,  hospital  discharge  and  death  databases)  and  the  estimated  number  of  HCV  diagnosed  IDUs 
from  log-linear  modelling. 
IDU  identified  from  4  data  sources 
(Y=yes;  N=no) 
Observed 
number  of 
Estimated  number  of  HCV 
diagnosed  IDUs 
(A) 
HCV 
Diagnoses 
(B) 
HIV  test 
(C) 
Hospital 
Discharge 
(D) 
Death 
HCV 
diagnosed 
persons 
from  log-linear  model* 
Y  Y  Y  Y  50  53 
N  y  y  Y  11  8 
Y  N  Y  Y  23  24 
N  N  Y  Y  8  7 
Y  Y  N  Y  117  113 
N  Y  N  Y  18  22 
Y  N  N  Y  40  40 
N  N  N  Y  34  34 
Y  Y  Y  N  1027  1024 
N  Y  Y  N  142  145 
Y  N  Y  N  859  858 
N  N  Y  N  248  249 
Y  Y  N  N  2383  2387 
N  Y  N  N  456  452 
Y  N  N  N  2828  2828 
N  N  N  N  -  2404 
Total  number  of  HCV  diagnosed  IDUs  identified  from  data-sources  8244  8244 
Total  number  of  HCV  diagnosed  IDUs,  including  those  not  identified  from  data-sources 
(95%  confidence  interval) 
10648 
(9753  -  12047) 
*  Log-linear  model  (residual  deviance  of  2.6  on  3  df)  included  main  effects  for  data-sources  (A)  HCV  diagnoses,  (B)  HIV  test, 
(C)  hospital  discharge  and  (D)  deaths  (model  coefficients  (standard  errors):  A  -0.63  (0.03);  B  0.05  (0.04);  C  0.58  (0.04);  D  1.73 
(0.04)),  with  interactions  between  data-sources  A  and  B  (0.28  (0.03));  A  and  C  (0.17  (0.03));  B  and  C  (0.11  (0.04));  B  and  D 
(0.23  (0.04));  C  and  D  (0.10  (0.04));  A,  B  and  C  (0.10  (0.03));  and  B,  C  and  D  (0.07  (0.03)). 
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cirrhosis 
HCV  diagnosed 
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Year  of  HCV  diagnosis  for  cases  diagnosed  after 
hospital  admission 
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1996  42  39  0  3  0  0  0  3 
1997  58  53  -  1  0  3  1  5 
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1999  78  74  -  -  -  2  2  4 
2000  66  59  -  -  -  -  7  7 
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.  -ý Chapter  5:  Influence  of  alcohol  on  the  progression  of  hepatitis  C  virus 
infection:  a  meta-analysis 
5.1  Introduction 
Cohort  studies  of  hepatitis  C  virus  (HCV)  infection  in  community-based  settings  have 
reported  a  generally  slow  course  of  liver  disease94,  although  several  viral,  host  and 
environmental  factors  appear  to  accelerate  this  progression5'22°.  Elucidation  of  the 
factors  that  influence  progression  to  severe  HCV  disease  is  essential,  both  at  an 
individual  level,  to  counsel  those  affected  and  help  make  decisions  regarding  antiviral 
therapy,  and at  a  population  level,  to  accommodate  covariate  influences  in  projection 
models  aimed  at  estimating  the  future  burden  of  disease.  An  understanding  of  the 
parameters  affecting  the  natural  history  of  HCV  would  also  inform  models  of  the  cost- 
effectiveness  of  preventive  and  therapeutic  interventions  220. 
Characteristics  commonly  associated  with  an  increased  risk  of  progression  to 
cirrhosis  include  male  sex,  older  age  at  HCV  acquisition  and  co-infection  with 
HIVS'22°.  A  recent  meta-analysis  estimated  the  overall  relative  risk  of  decompensated 
liver  disease  or  histological  cirrhosis  to  be  2.9  (95%  CI  1.7-5.0)  in  HIV  and  HCV  co- 
infected  patients  compared  to  those  with  only  HCV  infection221.  Similar  relative  risks 
for  cirrhosis  have  been  reported  in  studies  of  HCV  chronically  infected  persons  with 
heavy  alcohol  consumption,  defined  at  different  thresholds:  2.9  (95%  CI  1.6-5.4)  222 
and  2.8  (1.1-7.4)223  with  at  least  560g  and  20  units  (equivalent  of  approximately  240g) 
of  alcohol  per  week,  respectively.  Some  studies  however  have  failed  to  identify  a 
significant  correlation  between  heavy  alcohol  consumption  (defined  in  the  range  of  at 
least  240  to  560g  per  week)  and  development  of  severe  HCV  disease  210'224'225'226,227 
Meanwhile,  a  case-control  study  (involving  285  cases  with  liver  decompensation  and 417  controls  with  acute  diseases  unrelated  to  alcohol)  has  demonstrated  the  combined 
multiplicative  effect  of  alcohol  and  HCV  infection,  with  a9  (95%  CI  2-43),  15  (7-32) 
and  147  (42-514)  times  higher  odds  of  developing  cirrhosis  in  HCV-infected  patients 
who  had  never  consumed  alcohol  and  in  HCV-uninfected  and  HCV-infected  patients 
with  lifetime  daily  alcohol  intake  of  at  least  175g,  respectively,  compared  to  HCV- 
uninfected  patients  who  had  never  consumed  alcohol  180 
The  long-term  follow-up  of  acute  non-A,  non-B  hepatitis  cases  in  the  United 
States  provided  an  early  indication  of  the  importance  of  alcohol  in  progression  to 
cirrhosis,  with  almost  four-fifths  of  liver  disease  deaths  (14/18)  associated  with 
alcoholism228.  The  record-linkage  of  12,096  HCV  diagnosed  positive  persons  in 
Scotland  to  hospital  admission  data,  presented  in  Chapter  4,  identified  alcohol  as  a 
factor  in  71%  of  514  cases  developing  HCV-related  liver  failure  during  1991-2001. 
Populations  in  which  heavy  alcohol  consumption  is  relatively  common  -  such  as 
injecting  drug  users  (IDUs)215'216'217'218,  the  group  most  affected  by  HCV  infection  in 
resource-rich  countries  -  will  therefore  likely  experience  a  higher  burden  of  advanced 
liver  disease  among  those  with  chronic  HCV  than  estimated  from  community-based 
studies  (with  10%  heavy  alcohol  intake)  93 
A  convincing,  yet  inconsistent,  pattern  has  emerged  which  demonstrates 
increased  progression  of  HCV-related  liver  disease  with  heavy  alcohol  use.  The  aim 
in  this  chapter  was  to  perform  a  meta-analysis  of  published  studies  that  explored  the 
relationship  between  advanced  liver  disease  and  the  consumption  of  alcohol  among 
HCV  chronically  infected  persons.  Estimation  of  the  relative  risk  of  cirrhosis 
associated  with  heavy  alcohol  use  will  inform  the  design  of  the  HCV  projection  model 
described  in  Chapter  6.  Further,  the  effect  of  potential  sources  of  heterogeneity  - 
112 particularly,  the  threshold  used  to  define  heavy  alcohol  use  -  on  the  pooled  relative 
risk  estimate  was  examined  to  help  explain  the  inconsistency  between  study  findings. 
5.2  Methods 
5.2.1  Literature  search 
A  literature  search  was  performed  via  the  MEDLINE  database  of  English-language, 
peer-reviewed  publications  covering  the  period  January  1989  to  March  2004.  A 
search  for  terms  "alcohol",  "cirrhosis"  and  either  "hepatitis  C"  or  "HCV"  in  titles, 
abstracts  or  key  words  was  used  to  identify  articles,  which  had  examined  the 
association  between  alcohol  use  and  cirrhosis  risk  among  persons  infected  with  HCV. 
The  references  of  articles  obtained  from  the  MEDLINE  search  and  review 
papers  229,230,231,232  were  also  examined  for  relevant  studies. 
5.2.2  Criteria  for  inclusion  of  articles 
Twenty  articles,  identified  through  the  literature  search,  were  included  in  the  meta- 
analysis,  which  fulfilled  the  following  criteria: 
(i)  study  members  were  infected  with  chronic  HCV,  as  determined  by  a  positive  result 
in  serum  from  a  first-,  second-  or  third-generation  enzyme-linked  immunosorbent 
assay  and  confirmed  by  means  of  recombinant  immunoblot  assay  or  polymerase  chain 
reaction233; 
(ii)  study  outcomes  included  a  histopathological  diagnosis  of  cirrhosis  (graded  based 
234,235,236,237,238,239,240,241 
on  established  scoring  systems  ),  decompensated  cirrhosis 
(defined  clinically  by  the  presence  of  bleeding  oesophageal  varices,  ascites,  hepatic 
encephalopathy,  or  hyperbilirubinemia),  or  advanced  fibrosis  (which  includes  both 
, 
240,241 
bridging  fibrosis  with  many  septa  and  cirrhosis237,238  ); 
113 (iii)  sufficient  information  was  presented  in  the  article  to  estimate  the  relative  risk 
(RR)  or  odds  ratio  (OR)  of  the  outcome,  and  its  variance,  associated  with  a  category 
of  high  compared  to  low  alcohol  consumption. 
Eighteen  articles,  which  were  identified  through  the  literature  search  and  had 
reported  on  the  alcohol  intake  and  liver  disease  progression  of  persons  infected  with 
HCV,  were  excluded  from  the  meta-analysis  because  either  (a)  the  study  outcome 
included  moderate  fibrosis  242,243,244,245,  (b)  the  study  was  confined  to  patients  with 
minimal  or  mild  chronic  hepatitis246,  (c)  the  study  outcome  was  analysed  as  a  rate  of 
change  in  fibrosis  progression  247,248,249,250,  (d)  heavy  alcohol  (defined  as  at  least 
280g251,252  and  350g253  per  week)  users  were  excluded,  (e)  alcohol  had  not  been 
analysed  in  terms  of  categories  2sa,  255,2s6,  zsý  g,  or  (f)  members  of  the  study  were  included 
in  another  article  selected  (with  the  most  relevant  data)  for  the  meta-analysis25s,  259 
5.2.3  Extraction  of  data  from  articles 
The  unadjusted  and/or  adjusted  RRs  or  ORs,  with  95%  CIs  or  P  values,  for  the 
outcome  (either  cirrhosis,  decompensated  cirrhosis  or  advanced  fibrosis)  associated 
with  categories  of  alcohol  consumption  were  extracted  directly  from  the  article; 
unadjusted  risk  ratios  were  not  presented  in  eleven 
articles  224,260,2  but  were  calculated  based  on  available  crude 
data.  Serfaty  et  al.  270  conducted  a  case-control  study  matched  for  age,  gender,  route 
and  duration  of  HCV  infection,  and  the  OR  for  cirrhosis  extracted  from  this  article 
was  taken  as  an  adjusted  value.  Alcohol  consumption  measures  were  converted  into 
grams  (g)  per  week  (assuming  that  one  unit  or  drink  of  alcohol  equalled  12g252).  Three 
articles21o,  263,27o  analysed  alcohol  consumption  in  terms  of  more  than  two  categories 
(e.  g.  low,  medium  and  high),  and  the  risk  estimate  used  in  the  meta-analysis  from 
114 these  studies  was  the  one  that  had  compared  the  highest  with  the  lowest  or  baseline 
category  of  alcohol  intake.  Given  the  reported  higher  alcohol  intake  and  generally 
faster  HCV  disease  progression  among  men  compared  to  women271'272,  it  was  also  of 
interest  to  examine  the  differential  risk  of  severe  HCV  disease  by  sex  in  these  studies 
that  had  considered  the  effect  of  excessive  drinking;  thus,  risk  ratios  associated  with 
males  compared  to  females  were  similarly  extracted  from  these  articles. 
5.2.4  Statistical  analyses 
To  derive  pooled  risk  estimates,  the  RRs  or  ORs  from  each  study  were  first 
transformed  to  the  natural  log  scale  and  the  associated  variances  calculated  from 
either  the  published  95%  CIs  or  P  values273.  Random-  or  fixed-  effect  methods, 
described  by  DerSimonian  and  Laird274,  were  used  to  obtain  pooled  relative  risk 
estimates  from  the  included  studies,  dependent  on  whether  the  test  for  heterogeneity 
(Q-statistic)  was  or  was  not  significant  at  the  5%  level,  respectively  273 
Sensitivity  analyses  were  carried  out  to  examine  the  effect  on  the  pooled 
relative  risk  estimate  of  the  following  possible  sources  of  heterogeneity:  analysis  scale 
(i.  e.  odds  ratio  or  relative  risk),  disease  outcome  (advanced  fibrosis,  cirrhosis  or 
decompensated  cirrhosis),  and  threshold  for  heavy  alcohol  intake  (210-260,280-504 
or  560  grams  per  week;  the  middle  category  included  one  study  which  had  defined 
heavy  alcohol  intake  as  >280g  for  women  and  >420g  for  men266).  In  addition, 
weighted  linear  regression  models  were  performed  to  determine  the  significance  of 
the  effect  of  these  study  characteristics  (i.  e.  analysis  scale,  disease  outcome,  and 
threshold  for  heavy  alcohol  intake)  on  the  risk  estimate  (i.  e.  log  RR  or  OR),  weighted 
according  to  the  precision  of  the  risk  estimate  (i.  e.  inverse  of  the  variance).  S-PLUS 
software  was  used  for  all  analyses  122,275 
115 5.3  Results 
5.3.1  Characteristics  of  studies 
The  characteristics  of  the  twenty  articles  that  fulfilled  the  inclusion  criteria  for  the 
meta-analysis  are  shown  in  Table  5.1.  Thirteen  studies  were  carried  out  in  European 
countries  (one  of  these  also  included  participants  from  the  United  States),  three  in 
North  America,  two  in  Australia,  one  in  South  America  and  one  in  Japan.  The  studies 
ranged  in  size  from  59  to  5,789  participants  and  together  totalled  15,187  HCV 
chronically  infected  individuals.  Of  this  total,  2,716  (18%)  had  progressed  to 
advanced  liver  disease,  defined  as  cirrhosis  in  13  studies  (77%:  2,090/2,716), 
advanced  fibrosis  in  four  studies  (19%:  527/2,716),  decompensated  cirrhosis  in  two 
studies  (3%:  74/2,716)  and  cirrhosis/HCC  in  one  (1%;  this  study  involved  20  subjects 
with  cirrhosis  only,  4  with  both  cirrhosis  and  HCC  and  one  with  HCC  only267). 
HCV  infection  was  attributed  to  injecting  drug  use  and  transfusion  in  45%  and 
35%,  respectively,  of  all  subjects  included  in  these  studies.  In  the  range  of  42%  to 
100%,  and  overall  64%,  of  studies'  participants  were  male  and  their  average  age  at 
recruitment  to  the  clinic  or  biopsy  ranged  between  31  and  61  years  (Table  5.1).  Six 
studies  210,264,266,269,270,276  excluded,  and  one  study277  was  confined  to,  HIV  antibody 
positive  individuals.  Overall,  15%  of  13,181  participants,  from  studies  that  reported 
data,  were  co-infected  with  HIV.  Of  the  six  studies  that  reported  a  prevalence  of  HIV 
infection  above  5%,  all  except  that  by  Thomas  et  a!.  263  found  a  significantly  increased 
risk  of  severe  disease  with  HIV  positivity  (Table  5.2). 
The  threshold  for  heavy  alcohol  consumption  used  in  the  analyses  of  these 
twenty  studies  ranged  from  210g  to  560g  per  week;  the  latter  threshold  was  the  most 
commonly  applied  in  eight  studies,  followed  by  350g  per  week  used  in  three  studies. 
116 Wiley  et  a!.  266  and  Roudot-Thoraval  et  al.  260  defined  different  levels  of  heavy  alcohol 
intake  between  males  (>420g  and  >504g  per  week,  respectively)  and  females  (>280g 
and  >420g  per  week,  respectively).  Uptake  of  alcohol  ranged  from  only  5% 
consuming  >350g  per  week  in  the  study  by  Poynard  et  a1.276  to  51  %  consuming  >420g 
and  >290g  among  men  and  women,  respectively,  per  week  by  Wiley  et  al.  266.  An 
estimated  3,123  HCV  chronically  infected  persons  (21%  of  the  total  15,187)  were 
analysed  as  heavy  alcohol  users  (though  heterogeneously  defined)  in  the  twenty 
studies. 
5.3.2  Studies'  risk  estimates  of  severe  HCV  disease  associated  with  heavy  alcohol 
consumption 
The  extracted  risk  estimates,  and  confidence  intervals,  of  severe  HCV  disease 
associated  with  the  consumption  of  alcohol  from  the  twenty  studies  are  presented  in 
Table  5.2  (i).  The  matched  case-control  study  by  Serfaty  et  a!.  270  found  a  raised,  but 
not  significant,  risk  of  cirrhosis  with  >560g  of  alcohol  per  week.  Adjusted  RR 
estimates  of  severe  disease  associated  with  heavy  alcohol  intake  (defined  in  the  range 
of  at  least  240g  to  560g  per  week),  presented  in  the  other  ten  articles,  were  all 
significant  at  the  5%  level  and  ranged  from  1.6  to  11.8.  Of  the  remaining  nine  studies, 
eight  failed  to  identify  a  significant  association  between  heavy  alcohol  consumption 
(defined  in  the  range  of  at  least  240g  to  560g  per  week)  and  development  of  severe 
HCV  disease  210,224,225,226,227,265,268,269'  only  unadjusted  risk  estimates  of  this  association 
were  reported  in  these  nine  studies  and  were  included  with  the  adjusted  results  from 
the  other  eleven  studies  in  the  following  meta-analysis. 
117 5.3.3  Meta-analysis  of  the  risk  of  severe  HCV  disease  associated  with  heavy 
alcohol  consumption 
The  pooled  RR  estimate  of  severe  disease  (i.  e.  advanced  fibrosis,  cirrhosis  or 
decompensated  cirrhosis)  associated  with  heavy  alcohol  intake  (defined  in  the  range 
of  at  least  210  to  560g  per  week)  from  the  twenty  studies  was  2.14  (95%  CI  1.61- 
2.85)  by  the  random  effects  model,  as  the  test  for  heterogeneity  was  highly  significant 
(p<0.0001).  Table  5.3  shows  the  pooled  RR  estimates  of  severe  disease  associated 
with  heavy  alcohol  intake  according  to  three  possible  sources  of  heterogeneity: 
analysis  scale  (i.  e.  odds  ratio  or  relative  risk),  disease  outcome  (advanced  fibrosis, 
cirrhosis  or  decompensated  cirrhosis),  and  threshold  for  heavy  alcohol  intake  (210- 
260,280-504  or  560  grams  per  week).  The  four  studies  that  examined  the  association 
between  heavy  alcohol  intake  and  advanced  fibrosis  produced  the  lowest  pooled  RR 
estimate  (1.63;  95  %  Cl  1.22-2.17),  compared  to  those  studies  that  examined  the  risk 
of  cirrhosis  (2.14;  1.45-3.17)  or  decompensated  cirrhosis  (3.54;  2.14-5.85). 
Figure  5.1  shows  the  individual  study  risk  ratios  and  pooled  RR  (2.33;  95%  CI 
1.67-3.26)  from  the  sixteen  studies  that  examined  the  association  between  heavy 
alcohol  intake  and  development  of  cirrhosis  or  decompensated  cirrhosis.  No 
difference  in  risk  of  cirrhosis  or  decompensated  cirrhosis  was  found  between  studies 
that  calculated  either  relative  risks  (pooled:  2.3  1;  95%  CI  1.33-4.02)  or  odds  ratios 
(2.36;  1.52-3.65)  (Table  5.3).  Surprisingly,  the  pooled  RR  estimates  for  cirrhosis  or 
decompensated  cirrhosis  decreased  with  a  higher  threshold  of  alcohol  intake:  3.54 
(95%  Cl  2.14-5.85),  2.30  (1.18-4.47)  and  1.94  (1.26-2.99)  with  at  least  210-260,280- 
504  and  560  grams  of  alcohol  per  week,  respectively.  However,  the  three 
studies  263,267,278  that  used  the  threshold  of  210-260g  of  alcohol  per  week  had  assessed 
the  outcome  of  decompensated  cirrhosis  and  therefore  their  relative  risk  estimates  are 
118 not  directly  comparable  with  those  from  the  other  thirteen  studies  that  examined  the 
outcome  of  cirrhosis. 
5.3.4  Studies'  risk  estimates  of  severe  HCV  disease  for  men  compared  to  women 
Table  5.2  (ii)  shows  the  risk  ratios  of  severe  HCV  disease  for  men  compared  to 
women  extracted  from  eleven,  of  the  twenty,  studies.  Serfaty  et  al.  270  matched  for 
gender  in  their  case-control  study  and  Khan  et  al.  268  confined  theirs  to  males;  thus 
both  were  unable  to  examine  the  risk  of  severe  disease  by  this  factor.  In  the  remaining 
seven  studies,  three  222,260,279  reported  no  significant  difference  in  prevalence  of 
cirrhosis  between  men  and  women,  but  no  data  were  presented  to  calculate  the  risk  of 
severe  disease  by  gender.  Seven  of  the  eleven  studies,  which  reported  risk  ratios, 
failed  to  identify  a  significantly  different  risk  of  severe  HCV  disease  between  men 
210,225,226,227,261,266,269  and  women  Unadjusted  and  adjusted  RR  point  estimates  of 
severe  disease  for  men  compared  to  women  (presented  in  nine  and  four  articles, 
respectively)  ranged  from  0.6  to  3.6  and  1.0  to  2.6,  respectively.  Unadjusted  risk 
ratios  associated  with  gender,  from  articles  that  had  not  presented  adjusted  estimates, 
were  combined  with  adjusted  results  in  the  following  meta-analysis. 
5.3.5  Meta-analysis  of  the  risk  of  severe  HCV  disease  for  men  compared  to 
women 
The  pooled  RR  estimate  of  severe  disease  (i.  e.  advanced  fibrosis,  cirrhosis  or 
decompensated  cirrhosis)  for  men  compared  to  women  from  the  nine  studies  was  1.38 
(95%  Cl  1.13-1.69)  by  the  fixed  effects  model,  as  the  test  for  heterogeneity  was  not 
significant  (p=0.1).  Table  5.4  shows  the  RR  estimates  of  severe  disease  for  men 
compared  to  women  pooled  according  to  the  analysis  scale  and  disease  outcome  used 
119 in  studies;  results  were  not  pooled  in  this  analysis  according  to  the  threshold  of  heavy 
alcohol  intake  applied  because  only  a  minority  of  studies  had  adjusted  gender  effect 
estimates  for  alcohol  consumption.  A  significantly  higher  pooled  estimate  was 
obtained  from  studies  that  calculated  relative  risks  (2.31;  95%  CI  1.51-3.52)  rather 
than  odds  ratios  (1.18;  0.94-1.49).  The  three  studies  that  used  the  outcome  of 
advanced  fibrosis  produced  a  lower  pooled  estimate  (1.13;  95%  CI  0.82-1.57)  than 
those  studies  that  examined  the  risk  of  cirrhosis  (1.39;  1.05-1.84)  or  decompensated 
cirrhosis  (2.94;  1.53-5.65). 
A  pooled  RR  of  1.56  (95%  CI  1.21-2.03)  for  men  compared  to  women  was 
generated  from  the  eight  studies  that  examined  the  outcome  of  cirrhosis  or 
decompensated  cirrhosis.  A  higher,  but  not  significantly  different,  risk  of  cirrhosis  or 
decompensated  cirrhosis  was  found  with  the  studies  that  calculated  relative  risks 
(pooled:  2.31;  95%  CI  1.51-3.52)  compared  to  odds  ratios  (1.24;  0.89-1.72)  (Table 
5.4). 
5.4  Discussion 
In  chronic  HCV,  progression  to  cirrhosis  is  almost  always  the  precursor  to 
development  of  complications  such  as  HCC  and  liver  failure6.  Thus,  determining  the 
factors  that  accelerate  the  rate  of  progression  to  cirrhosis  is  a  priority  for  HCV  natural 
history  research.  Excess  alcohol  consumption  is  likely  to  result  in  more  severe  hepatic 
injury,  promoting  pathologic  progression  to  cirrhosis  among  patients  with  chronic 
HCV280.  This  meta-analysis  estimates  the  pooled  RR  of  cirrhosis,  including 
decompensated  cirrhosis,  associated  with  heavy  alcohol  intake  (defined  in  the  range 
of  at  least  210  to  560g  per  week)  to  be  2.33  (95%  Cl  1.67-3.26),  derived  from  sixteen 
studies  involving  a  total  of  13,706  HCV  chronically  infected  persons. 
120 Studies  investigating  the  risk  of  HCV-related  cirrhosis  with  alcohol  involved 
subjects  who  had  presented  to  liver  clinics,  with  the  exception  of  those  recruited 
during  the  Dionysos  general  population  survey267,  and  had  undergone  a  liver  biopsy. 
This  biased  accrual  will  tend  to  dampen  the  estimated  regression  effect  of  prognostic 
indicators  as  recruited  subjects  will  likely  have  more  advanced  liver  disease,  causing 
them  to  present  for  clinical  assessment,  and  be  more  prognostically  alike  than  other 
members  of  the  HCV  chronically  infected  populations  where  they  resided.  Moreover, 
heavy  alcohol  users  could  have  been  under-represented  in  some  studies,  as  patients 
consuming  alcohol  at  toxic  levels  may  have  been  precluded  from  biopsy265  and  those 
with  histological  features  of  alcoholic  hepatitis  were  excluded  from  some 
analyses 
265,266 
Such  selectivity  may  have  under-estimated  the  regression  effect  of 
alcohol  on  progression  to  cirrhosis  in  the  meta-analysis. 
The  extent  of  alcohol  consumption  in  these  studies  is  necessarily  based  on 
self-reporting,  since  no  other  marker  is  able  to  establish  past  intake231.  Responses 
could  therefore  be  affected  by  patients'  inability  to  recall  past  consumption  levels, 
unwillingness  to  admit  true  intake  and  changes  in  drinking  habits281.  Questionnaires 
asking  about  recent  and  lifetime  alcohol  ingestion  nevertheless  appear  to  have 
satisfactory  test-retest  reliability2g2'2g3'284.  Lifetime  alcohol  consumption,  or  that 
overlapping  with  duration  of  HCV  infection,  has  been  suggested  as  the  most 
appropriate  measure  to  assess  the  dose  determining  liver  damage'  80,255  Most 
investigators  have  instead  measured  alcohol  intake  over  short  periods  of  time,  such  as 
during  the  one  to  five  years  prior  to  HCV  diagnosis  or  histological  examination.  None 
of  the  studies  included  in  the  meta-analysis  analysed  alcohol  use  as  a  time-dependent 
covariate  to  accommodate  the  changing  behaviour  of  patients,  particularly  in  response 
121 to  medical  advice  following  HCV  diagnosis,  and  explore  the  impact  of  curtailed 
drinking  on  liver  disease  progression. 
Studies  varied  widely  in  their  definition  of  significant  alcohol  intake,  ranging 
between  210  and  560g  per  week,  and  so  the  true  threshold  above  which  alcohol 
accelerates  HCV  disease  progression  remains  uncertain231.  The  same  levels  of  intake 
have  been  reported  with  an  increased  risk  of  alcoholic  liver  disease285.  In  a  large 
population-based  prospective  study  of  13,285  individuals,  the  risk  of  alcohol-induced 
liver  disease  increased  significantly  from  as  low  as  84-156g  per  week  for  women  and 
168-324g  per  week  for  men,  and  continued  to  increase  with  higher  levels  of  alcohol 
intake272.  In  contrast,  the  meta-analysis  found  a  slightly  lower  pooled  RR  estimate  for 
HCV-related  cirrhosis  with  a  higher  threshold  of  alcohol  intake:  2.30  (95%  CI  1.18- 
4.47)  and  1.94  (1.26-2.99)  with  at  least  280-504  and  560g  of  alcohol  per  week, 
respectively.  It  is  possible  that  some  studies  chose  the  threshold  of  heavy  alcohol  use 
in  the  range  of  280-504g  per  week  during,  rather  than  prior  to,  the  analyses  stage  as  a 
result  of  a  significant  association  with  cirrhosis;  the  product  of  which  would  have 
inflated  the  pooled  RR  for  this  group. 
Analyses  of  different  endpoints  of  severe  disease  have  also  made  it  difficult  to 
compare  findings  on  the  relationship  between  alcohol  and chronic  HCV.  The  risk  of 
HCV-related  disease  associated  with  heavy  alcohol  intake  increased  with  the  severity 
of  the  outcome:  the  lowest  (1.63;  95%  CI  1.22-2.17)  and  highest  (3.54;  2.14-5.85) 
pooled  RR  estimates  were  obtained  for  advanced  fibrosis  and  decompensated 
cirrhosis,  respectively. 
Chronic  HCV  has  been  shown  to  be  histologically  milder  in  women  than 
men276. 
Wiley  et  al. 
266  indicated  that  the  difference  in  risk  of  HCV-related  cirrhosis 
between  the  sexes  could  be  explained  by  the  higher  consumption  of  alcohol  among 
122 men  compared  to  women.  A  complicating  factor  is  that  there  is  also  evidence  to 
suggest  that  women  may  be  more  susceptible  to  the  adverse  effects  of  alcohol  at  lower 
levels  of  consumption  than  men.  The  population-based  Dionysos  study  found  the  risk 
of  cirrhosis  was  twice  as  high  in  women  as  in  men  with  the  same  amount  of  alcohol 
intake286.  Poynard  et  al.  276  and  Harris  et  al.  278  both  reported  a  significantly  increased 
risk  of  HCV-related  severe  disease  (cirrhosis  and  decompensated  cirrhosis, 
respectively)  for  men  compared  to  women  (risk  ratios:  2.0,95%  CI  1.2-3.3;  and  2.6, 
1.1-5.9,  respectively),  after  adjustment  for  heavy  alcohol  intake  (defined  as  >350  and 
?  240g  per  week,  respectively)  and other  factors.  Overall,  a  lower  RR  estimate  (1.56, 
95%  Cl  1.21-2.03)  comparing  men  to  women  was  obtained  from  the  eight  studies  that 
examined,  in  either  unadjusted  or  adjusted  analyses,  the  outcomes  of  cirrhosis  and 
decompensated  cirrhosis.  Unfortunately,  only  three  266'276'278  of  these  eight  studies 
presented  risk  estimates  of  HCV-related  cirrhosis  by  gender  from  multi-factorial 
analyses,  and  so  it  was  not  possible  to  fully  assess  if  the  raised  risk  for  males 
diminished  after  adjusting  for  the  influence  of  heavy  alcohol  use. 
In  conclusion,  studying  the  relationship  between  HCV  and  alcohol  is 
inherently  problematic  because  of  difficulties  in  obtaining  an  accurate  history  of 
alcohol  use  and  clinic-recruitment  biases.  The  role  of  alcohol  in  HCV-related  cirrhosis 
may  therefore  be  under-estimated.  Nevertheless,  the  evidence  overwhelmingly  shows 
a  worsened  outcome  for  those  with  chronic  HCV  and  concurrent  alcohol  use.  The 
amount  of  alcohol  that  can  be  safely  consumed  by  patients  with  HCV  is  unclear; 
published  data  show  that  even  moderate  intake  can  increase  the  severity  of  liver 
disease231.  Alcohol  consumption  should  be  minimised  as  much  as  possible  in  those 
who  have  chronic  HCV  until  a  safe  threshold  is  more  definitively  determined. 
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N Table  5.3:  Pooled¶  relative  risk  estimates  of  the  outcome  (advanced  fibrosis,  cirrhosis  or 
decompensated  cirrhosis)  associated  with  heavy  alcohol  intake  compared  to  less  than  heavy  alcohol 
intake  among  HCV  chronically  infected  patients:  results  of  a  meta-analysis. 
Study  characteristics  Number  of  Pooled  Relative  Risks  Heterogeneity  Significance  of 
studies  (95%  Cl)  Q-statistic  (P-value)  characteristic: 
P-value 
ALL  STUDIES 
Total  20  2.14  (1.61-2.85)  70.1  (<0.0001)  - 
Analysis  scale  Odds  ratio  14  2.08  (1.48-2.94)  49.3  (<0.0001)  Baseline 
Relative  risk  6  2.31  (1.33-4.02)  17.2  (0.004)  0.34 
Outcome  Advanced  fibrosis  4  1.63  (1.22-2.17)  3.9  (0.3)  0.14 
Cirrhosis  13  2.14  (1.45-3.17)  55.3  (<0.0001)  Baseline 
Decompensated  cirrhosis  3*  3.54  (2.14-5.85)  0.4  (0.8)  0.54 
Threshold  for  heavy  210-260  4  2.38  (1.61-3.52)  6.4  (0.1)  Baseline 
alcohol  intake  (g/week)  280-504  8  2.07  (1.30-3.30)  39.7  (<0.0001)  0.75 
560  8  1.94  (1.26-2.99)  14.7  (0.04)  0.46 
STUDIES  WHICH  ANALYSED  OUTCOMES:  COMPENSATED  AND  DECOMPENSATED  CIRRHOSIS 
Total  16  2.33  (1.67-3.26)  57.0  (<0.0001)  - 
Analysis  scale  Odds  ratio  10  2.36  (1.52-3.65)  32.9  (<0.0001)  Baseline 
Relative  risk  6  2.31  (1.33-4.02)  17.2  (0.004)  0.19 
Threshold  for  heavy  210-260  3  3.54  (2.14-5.85)  0.4  (0.8)  Baseline 
alcohol  intake  (g/week)  280-504  5  2.30  (1.18-4.47)  27.2  (<0.0001)  0.76 
560  8  1.94  (1.26-2.99)  14.7  (0.04)  0.18 
￿  Pooled  estimate  was  derived  using  random  or  fixed  effects  methods  according  to  whether  the  test  for 
heterogeneity  was  significant  at  the  5%  level  or  not,  respectively. 
*  Included  the  study  by  Bellentani  et  al.  287  that  analysed  the  combined  outcome  of  cirrhosis  and  HCC. 
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Figure  5.1:  Individual  study  adjusted*  and  pooled  relative  risk  estimates  of  cirrhosis  associated  with 
heavy  alcohol  intake  compared  to  less  than  heavy  alcohol  intake  among  HCV  chronically  infected 
patients:  results  of  meta-analysis  (excludes  four  studies  which  estimated  the  risk  for  advanced 
fibrosis). 
Author,  year  of  publication 
Strasser,  1995* 
Serfaty,  1997 
Roudot-Thoraval,  1997 
Verbaan,  1988 
Pol,  1998a 
Pol,  1998b 
Khan,  1998* 
Wiley,  1998 
Bellentani,  1999* 
Khan,  2000; 
Loguercio,  2000* 
Thomas,  2000 
Poynard,  2001 
Di  Martino,  2001 
Harris,  2002 
Monto,  2004* 
Pooled 
0.25  1.00  3.25  11.50  45.75 
Relative  Risk  (95%  CI) 
*  Studies  that  reported  only  the  unadjusted  relative  risk,  which  are  presented  above. 
129 Table  5.4:  Pooled¶  relative  risk  estimates  of  the  outcome  (advanced  fibrosis,  cirrhosis  or 
decompensated  cirrhosis)  associated  with  male  compared  to  female  HCV  chronically  infected  patients: 
results  of  a  meta-analysis. 
Study  characteristics  Number  of  Pooled  Relative  Risks  Heterogeneity  Significance  of 
studies  (95%  CI)  Q-statistic  (P-value)  characteristic: 
P-value 
ALL  STUDIES 
Total  11  1.38  (1.13-1.69)  17.1  (0.1)  - 
Analysis  scale  Odds  ratio  8  1.18  (0.94-1.49)  8.5  (0.3)  Baseline 
Relative  risk  3  2.31  (1.51-3.52)  1.2  (0.5)  0.03 
Outcome  Advanced  fibrosis  3  1.13  (0.82-1.57)  1.0  (0.6)  0.45 
Cirrhosis  6  1.39  (1.05-1.84)  9.4  (0.1)  Baseline 
Decompensated  cirrhosis  2  2.94  (1.53-5.65)  0.2  (0.7)  0.11 
STUDIES  WHICH  ANALYSED  OUTCOMES:  COMPENSATED  &  DECOMPENSATED  CIRRHOSIS 
Total  8  1.56  (1.21-2.03)  13.9  (0.1)  - 
Analysis  scale  Odds  ratio  5  1.24  (0.89-1.72)  7.4  (0.1)  Baseline 
Relative  risk  3  2.31  (1.51-3.52)  1.2  (0.5)  0.11 
U  Pooled  estimate  was  derived  using  random  or  fixed  effects  methods  according  to  whether  the  test  for  heterogeneity  was 
significant  at  the  5%  level  or  not,  respectively. 
130 Chapter  6:  Modelling  the  current  and  future  disease  burden  of  hepatitis  C 
among  injecting  drug  users  in  Scotland 
6.1  Introduction 
Hepatitis  C  virus  (HCV)  is  a  slowly  progressive  disease:  a  systematic  review  of  the 
worldwide  literature  indicated  that  4%-10%  of  those  with  active  viraemia  develop 
cirrhosis  after  twenty  years  of  infection94.  Studies  have  demonstrated  considerable 
variability  in  rates  of  HCV  disease  progression  because  of  the  biased  selection  of 
cohorts  with  respect  to  disease  stage  and  host  characteristics.  Factors  most  commonly 
shown  to  accelerate  natural  history  include  alcohol,  co-infection  with  HIV,  older  age 
at  HCV  acquisition  and  male  gender288. 
In  most  resource-rich  countries,  the  majority  of  those  with  HCV  acquired  their 
infection  in  the  late  1970s  and  1980s167,  before  the  identification  of  the  virus  and  the 
availability  of  diagnostic  tests.  Given  that  chronic  HCV  does  not  result  in  major 
morbidity  for  many  years,  the  impact  of  this  infection  on  health  care  systems  is  only 
now  becoming  apparent.  For  example,  HCV  has  become  the  leading  cause  of  liver 
transplantation  in  the  United  States15.  There  are  also  concerns  over  the  burgeoning 
medical  costs  of  treating  chronic  HCV.  In  2001,  UK  consensus  guidelines  on  the 
clinical  management  of  HCV  infection  recommended  that  antiviral  treatment  should 
be  offered  to  patients  without  contraindications  such  as  continued  injecting  who  were 
shown  to  have  moderate  disease  according  to  histological  appearances289.  Persons 
who  are  HCV  seropositive  but  who  are  otherwise  healthy  are  likely  to  represent  a 
growing  number  of  candidates  for  treatment. 
In  Scotland,  a  total  of  14,390  persons  had  been  diagnosed  with  HCV 
antibodies  by  the  end  of  June  200221.  Among  those  for  whom  at  least  one  risk  factor 
131 was  known,  almost  90%  (8719/9728)  had  injected  drugs,  6%  (584/9728)  had  received 
blood  or  blood  products  and  4%  reported  occupational  needlestick  injuries,  tattoos, 
body  piercings  or  sexual  contact.  By  the  end  of  2000,  less  than  10%  of  HCV 
diagnosed  persons  in  Scotland  had,  however,  received  antiviral  therapy52  and  a  further 
70-80%  of  the  total  HCV  infected  female  population  remained  undiagnosed53.  To  plan 
an  appropriate  public  health  response  to  this  HCV  epidemic,  in  terms  of  both 
treatment  needs  and  preventive  measures,  quantitative  estimates  of  the  current  and 
future  burden  of  HCV  disease  are  required. 
In  this  chapter,  the  objectives  were  to  develop  a  comprehensive  model  to 
estimate  the  numbers  of,  both  current  and  former,  injecting  drug  users  (IDUs)  in 
Greater  Glasgow  and  Scotland  belonging  to  different  stages  of  HCV  disease  now  and 
in  the  future.  Modelling  was  confined  to  the  IDU  population  because  much  of  the 
epidemiological  data  available  to  date  and  the  overwhelming  majority  of  HCV 
transmissions  in  Scotland  have  been  associated  with  this  risk  group.  To  determine  the 
benefit  of  treating  HCV  chronically  infected  patients,  the  impact  of  different  antiviral 
treatment  strategies  on  the  incidence  of  severe  HCV-related  disease  was  explored. 
6.2  Aims 
The  primary  aims  were  to  develop  a  model  to  estimate: 
(i)  the  number  of  IDUs  (categorised  according  to  current  and  former  status)  who 
acquired  HCV  infection  and  progressed  to  mild,  moderate  and  severe  HCV 
disease  in  Glasgow  and  Scotland  between  1960  and  2030; 
(ii)  the  number  of  cases  of  severe  HCV-related  disease  (i.  e.  decompensated  cirrhosis 
and  HCC)  among  IDUs  that  could  be  prevented  in  the  future  through  a  range  of 
antiviral  treatment  strategies. 
132 6.3  Methods 
6.3.1  Overview 
The  study  involved  three  stages:  (a)  the  development  of  an  HCV  disease  progression 
model  for  the  IDU  population  in  Greater  Glasgow  (a  region  which  has  approximately 
a  third  of  all  IDUs  in  Scotland108  and  a  wealth  of  epidemiological  data);  (b)  using  the 
model  developed  in  (a),  a  comparison  of  the  impact  of  different  antiviral  treatment 
scenarios  on  severe  sequelae  of  HCV  infection;  and  (c)  the  extension  of  the  model 
developed  for  Greater  Glasgow  in  (a)  to  the  entire  Scottish  IDU  population. 
The  progression  model  (a)  was  designed  to  incorporate  both  the  knowledge 
and  uncertainty  about  major  parameters  relating  to  (i)  the  IDU  population  (i.  e. 
incidence  and  cessation  of  injecting  and  mortality),  (ii)  the  characteristics  of  the  IDU 
population  affecting  HCV  progression  (i.  e.  gender,  age,  co-infection  with  HIV  and 
heavy  alcohol  intake),  (iii)  the  incidence  of  HCV  infection  among  current  IDUs,  and 
(iv)  the  rate  of  HCV  disease  progression  (including  the  influence  of  host  factors  and 
the  current  uptake  of  antiviral  therapy).  Local  data  were  used  to  inform  parameters  (i), 
(ii)  and  (iii),  available  up  to  2000  (estimates  from  this  year  were  applied  in  subsequent 
years,  2001-2030),  and  the  world-wide  literature  was  reviewed  to  inform  on  (iv). 
Modelled  outcomes  were  fitted  to  available  epidemiological  data  on  the  prevalent 
number  of  current  IDUs,  the  prevalence  of  HCV  infection  among  current  IDUs,  and 
the  incident  number  of  HCV-related  decompensated  cirrhosis  cases  among  IDUs. 
6.3.2  Model  structure 
In  annual  cycles  between  1960  and  2030,  Markov  modelling  was  used  to  simulate 
individuals'  progression  from  commencement  of  injecting  drug  use  through 
133 predefined  HCV  disease  states  until  death  (Figure  6.1).  Progression  annually  from  one 
state  to  another  was  based  on  transition  probabilities  derived  from  a  comprehensive 
review  of  the  literature  (described  below).  The  model  distinguishes  between  HCV 
uninfected,  chronically  infected,  and  previously,  but  no  longer,  infected  persons.  Once 
chronically  infected,  cases  had  the  potential  to  progress  sequentially  to  moderate 
disease,  compensated  cirrhosis,  and  then  either  decompensated  cirrhosis  or  HCC.  For 
example,  each  year,  former  IDUs  with  mild  chronic  HCV  infection  could  either 
develop  moderate  disease,  remain  stable  with  mild  disease  or  die  from  causes 
unrelated  to  HCV.  Transplantation  was  also  a  possibility  for  decompensated  cirrhosis 
cases. 
Persons  belonging  to  the  group  with  moderate  disease  benefit  most  cost- 
effectively54  from,  and  should  therefore  be  offered,  antiviral  therapy  as  recommended 
by  the  Royal  College  of  Physicians  of  London  and  the  British  Society  of 
Gastroenterology289  (i.  e.  those  with  histological  appearances  of  3-5/6  on  fibrosis  score 
and/or  >  3/18  on  necroinflammatory  score240).  In  the  model,  persons  were  further 
characterised  according  to  age,  gender,  heavy  alcohol  use  and  co-infection  with  HIV 
(described  below)  to  explore  the  influence  of  these  factors  on  progression  from 
chronic  HCV  infection  to  cirrhosis.  Persons  exit  the  model  upon  death  from  causes 
unrelated  (specified  separately  for  current  and  former  IDUs)  and  related  to  HCV  (i.  e. 
decompensated  cirrhosis,  HCC  and  post-transplantation).  By  tracking  individuals' 
development  of  HCV-related  complications  each  year,  during  1960-2030,  the  model 
estimates  past,  current  and  future  HCV-related  morbidity  and  mortality.  The  software 
used  to  generate  simulations  was  SPLUS122. 
134 6.3.3  Model  parameters 
6.3.3.1  The  IDU  population:  incidence  and  cessation  of  injecting  and  mortality 
Estimates  of  the  incidence  and  cessation  of  injecting  and  mortality  among  current 
IDUs,  each  calendar  year  between  1960  and  2000  in  Glasgow,  were  derived  through 
the  use  of  (i)  a  modified  Delphi  approach,  which  combined  expert  opinion  with 
capture-recapture  IDU  prevalence  estimates  (Figure  3.1),  and  (ii)  an  annual  rate  of 
mortality,  from  overdose  and other  causes  (unrelated  to  HCV  and  HIV),  in  the  range 
of  1-2%I23,124,290,291  In  the  HCV  progression  model,  current  IDUs  were  assumed  to 
have  ceased  injecting  by  50  years  of  age,  because  individuals  newly  attending  drug 
services  in  Glasgow,  who  report  injecting  in  the  past  month,  were  almost  all  aged 
under  50  years  (99.9%  of  8,362  during  years  1995-2001;  Scottish  Drug  Misuse 
Database,  ISD,  Edinburgh).  The  annual  mortality  of  former  IDUs  from  causes 
unrelated  to  HCV  and  HIV  was  also  accounted  for,  and  assumed  to  be  two  to  five 
times  higher83'292  than  the  average  annual  age-  and  gender-specific  rates  for  the 
general  Scottish  population293 
6.3.3.2  The  characteristics  of  the  IDU  population  affecting  HCV  progression 
6.3.3.2.1  Gender  and  age 
The  gender  and  age  distributions  of  newly  initiated  IDUs  were  based  on  those 
reported  among  representative  samples  of  current  IDUs  surveyed  in  Glasgow  during 
the  1990s110:  27.5%  (standard  deviation  of  2.5%)  were  assumed  to  be  female 
(generated  according  to  the  normal  distribution)  and  the  mean  age  at  commencement 
of  injecting  was  assumed  to  be  17.5  years  up  until  the  mid  1980s,  increasing  linearly 
thereafter  to  23.5  years  by  2000  (generated  according  to  the  lognormal  distribution, 
with  a  standard  deviation  on  the  logarithm  scale  of  0.2). 
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The  majority  of  HIV  infections  among  IDUs  in  Scotland  occurred  during  1983-85  (an 
estimated  1,000  of  whom  only  15%  resided  in  the  Greater  Glasgow  area294).  Mortality 
among  HIV  infected  IDUs  was  based  on  data  generated  by  the  Collaborative  Group 
on  AIDS  Incubation  and  HIV  Survival295,  and  adjusted  down  (i.  e.  hazard  rate  reduced 
by  75%)  for  the  period  after  1995  to  allow  for  increased  survival  due  to  the  impact  of 
Highly  Active  Anti-Retroviral  Therapy. 
6.3.3.2.3  Heavy  alcohol  use 
Heavy  alcohol  intake,  such  as  that  above  50g  per  day  (or  350g  per  week),  increases 
the  rate  of  liver  disease  progression  in  the  HCV  chronically  infected  person9s,  2io5 
some,  but  not  all,  studies  have  found  even  lower  thresholds  to  be  associated  with  an 
increased  rate  of  progression  270,263  Alcohol  consumption  among  current  and  former 
IDUs  in  Scotland,  however,  has  not  been  well  studied.  Studies  of  drug  users  receiving 
drug  treatment  in  England  have  reported  prevalences  in  the  range  of  15- 
45%218,219,296,297  for  either  problem  drinking  or  drinking  above  the  recommended  safe 
limits  of  14  units  (168g)  per  week  for  women  and  21  units  (252g)  for  men;  further,  no 
change  in  alcohol  intake  was  detected  among  276  opiate  users  pre  and  post  initiation 
to  methadone  treatment298.  To  accommodate  this  range  of  uncertainty,  three  rates 
(0%,  20%  and  40%)  of  heavy  alcohol  use  were  explored  in  the  HCV  projection 
model. 
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Estimates  of  the  percentage  of  (i)  uninfected  current  IDUs  who  acquired  HCV  and  did 
not  clear  their  infection  (i.  e.  chronic  infection),  (ii)  uninfected  current  IDUs  who 
acquired  HCV  and  spontaneously  cleared  their  infection,  and  (iii)  previously  infected 
(but  cleared  their  infection)  current  IDUs  who  were  re-infected  with  HCV  and  did  not 
clear  their  re-infection  (i.  e.  chronic  infection),  each  calendar  year  between  1960  and 
2000  in  Glasgow,  were  generated  (Figure  3.7).  Briefly,  stochastic  simulation  had  been 
used  to  model  the  transmission  of  HCV  according  to  the  needle/syringe  sharing 
behaviours  of  current  IDUs  in  Glasgow  and  the  characteristics  (i.  e.  transmissibility 
and  chronicity)  of  HCV  infection;  of  note,  15-40%  of  current  IDUs  with  newly 
acquired  HCV  were  assumed  to  recover  from  their  acute  infection  spontaneously  3'4 
and  become  susceptible  to  re-infection  with  HCV.  Only  those  estimates  of  (i),  (ii)  and 
(iii)  which  provided  modelled  estimates  of  HCV  seroprevalence  consistent  with 
survey  data,  obtained  through  community-wide  studies  of  Glasgow  IDUs  between 
1990  and  199947,  were  used  in  the  projection  model  (Chapter  3,  Figure  3.6;  85%  of 
1000  simulation  runs  were  consistent  with  survey  data).  Model  parameter  values  for 
the  year  2000  were  applied  in  subsequent  years  up  to  2030.  Given  the  slow  course  of 
HCV  disease  progression,  cases  newly  infected  in  2001-2030  would  not  impact 
greatly  on  the  estimated  burden  of  severe  disease  during  this  period. 
6.3.3.4  The  rate  of  HCV  disease  progression 
In  the  progression  model,  individuals  infected  with  chronic  HCV  were  followed 
through  a  series  of  disease  states,  as  shown  in  Figure  6.1.  The  transition  rates,  by 
which  individuals  progress  from  one  disease  state  to  another,  were  obtained  through  a 
review  of  the  literature  (described  below). 
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Progression  from  chronic  HCV  to  compensated  cirrhosis  was  modelled  based  on  a 
Weibull  distribution  with  cirrhosis  prevalence  estimated  at  6.5%  (95%  CI  3.5-9.5%) 
and  20%  (10-40%)  after  20  and  40  years,  respectively,  according  to  a  recent 
systematic  review  of  nine  community-based  studies94'9s  Progression  from  chronic 
HCV  to  moderate  disease  (defined  as  3-5/6  on  fibrosis  stage  and/or  >3/18  on 
necroinflammation  grade240),  similarly,  was  estimated  from  these  community-based 
studies  (except  that  only  three  of  the  nine  studies  reported  relevant  data,  Table  6.1). 
An  estimated  56%  (43-70%)  of  chronically  infected  cases  had  moderate  disease  after 
20  years. 
An  increased  rate  of  progression  to  cirrhosis  among  chronically  HCV  infected 
individuals  who  were  (i)  male  (relative  risk  1.56,95%  CI  1.21-2.03;  Chapter  5),  (ii) 
older  at  HCV  acquisition  (1.08  per  year,  1.04-1.12)299,  (iii)  co-infected  with  HIV 
(2.92,1.70-5.01)221,  and  (iv)  heavy  alcohol  users  (2.33,1.67-3.26;  Chapter  5)  was  also 
explored  in  the  model.  The  assumed  risks  of  cirrhosis  at  20  and  30  years  following 
chronic  infection  according  to  these  characteristics  are  detailed  in  Table  6.2. 
6.3.3.4.2  Compensated  cirrhosis  to  decompensated  cirrhosis,  HCC  and  death 
The  transition  rates  of  HCV  chronically  infected  persons  following  the  development 
of  compensated  cirrhosis  are  detailed  in  Table  6.3  and  referred  to  as  transitions  (i)- 
(vii).  The  annual  probability  of  liver  transplantation  (iii)  among  decompensated 
cirrhosis  cases  was  based  on  the  Scottish  data  presented  in  Chapter  4.4.6.  For  the 
remaining  transition  rates,  pertinent  English-language  papers  were  identified  through 
the  PubMed  database  which  was  searched  to  the  end  of  January  2004  using  the  terms 
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transplantation",  and  augmented  by  additional  citations  from  these  papers. 
Quantitative  data  were  extracted  from  each  paper  on  (A)  the  cumulative 
probability  (s(t))  of  not  progressing  to  the  outcome  (or  who  had  survived)  at  t  years 
(t=5  for  transitions  (i),  (ii),  (iv),  (vii);  t=2  for  (v);  t=1  for  (vi));  (B)  the  total  number  of 
subjects  (n);  and  (C)  the  number  (or  estimate  of  the  number)  of  subjects  censored 
(c(t))  prior  to  t  years;  probabilities  s(t)  were  converted  into  average  annual 
progression  rates  (i.  e.  1-s(t)11)  and  are  presented  in  Table  6.3.  Pooled  estimates  (with 
95%  CIs)  of  s(t)  were  derived  using  random  effects  273'275,  where  the  variance  of  s(t) 
was  estimated  using  Peto's  method300  (i.  e.  s(t)(1-s(t))/(n-c(t))  ),  and  then  converted 
into  annual  progression  rates  as  above;  the  95%  Cl  ranges  of  the  pooled  annual 
progression  rates  were  used  in  the  model  (Table  6.3). 
6.3.3.4.3  Current  uptake  of  antiviral  therapy 
The  model  was  also  designed  to  take  account  of  chronically  HCV  infected  former 
IDUs'  (with  moderate  disease)  initiation  on,  and  response  to,  antiviral  therapy.  Other 
factors  influencing  eligibility  for  treatment  in  clinical  practice  (e.  g.  heavy  alcohol  use, 
HIV  co-infection  and  psychiatric  status)  were  not  considered.  Clearance  of  the  virus 
was  estimated  at  20%,  40%  and  50%  with  interferon  alone,  interferon  plus  ribavirin 
and  pegylated  interferon  plus  ribavirin,  respectively3oi,  3oz,  s  Compliance  to  HCV 
treatment  once  initiated  was  assumed  to  be  90%303,304  Re-treatment  of  non-responders 
to  initial  course  of  antiviral  therapy  was  not  considered  in  the  model.  The  number  of 
IDUs  who  had  been  initiated  on  antiviral  therapy  in  Scotland  by  the  end  of  2003  was 
estimated,  optimistically,  at  1,500  based  on  limited  data52;  a  third  were  assumed  to 
reside  in  Greater  Glasgow  and  25%,  30%  and  45%  were  assumed  to  have  received 
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ribavirin)  and  2001-03  (with  interferon  plus  pegylated  interferon),  respectively. 
Uptake  of  treatment  in  subsequent  years  was  set  the  same  as  in  2003;  different  uptake 
rates  were  also  applied  to  assess  the  potential  of  antiviral  therapy  to  reduce  the 
incidence  of  severe  HCV  disease  in  the  future  (described  below). 
6.3.4  Model  fitting 
The  aim  of  the  model  fitting  process  was  to  assess  the  validity  of  model  assumptions  - 
in  particular,  progression  to  compensated  cirrhosis  and  the  influence  of  host  factors 
(Table  6.2)  -  to  generate  outcomes  consistent  with  available  epidemiological  data. 
Each  simulation  generated  estimates  of  the  number  of  new  decompensated  cirrhosis 
cases  per  year  (Si)  which  were  compared  with  the  expected  number  determined 
through  record-linkage  (R),  for  years  1996-2001  (Table  4.6),  using  a  standard  x2 
goodness-of-fit  measure.  If  the  goodness-of-fit  test  statistic 
cool  (S 
-  R'  )2 
was 
i=1996 
Rr 
less  than  20.52,  the  99.9%  critical  value  for  the  x2  distribution  on  5  degrees  of 
freedom,  the  simulated  data  were  regarded  as  consistent  with  the  record-linkage  data; 
the  99.9%,  instead  of  95%  (i.  e.  11.07),  critical  value  was  chosen  to  allow  for 
uncertainty  in  the  number  of  cases  derived  through  record-linkage.  Simulations  were 
performed  until  1,000  accumulated  which  produced  simulated  results  consistent  with 
record-linkage  data  by  this  criterion. 
6.3.5  Different  antiviral  treatment  scenarios 
The  number  of  HCV  chronically  infected  former  IDUs  initiated  on  antiviral  therapy  in 
Glasgow  in  2005,  and  in  each  year  thereafter,  was  increased  from  the  estimated 
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of  chronic  HCV  disease  at  which  former  IDUs  were  initiated  on  treatment  was  varied 
between  (i)  moderate  disease  only,  (ii)  a  combination  of  moderate  disease  and 
compensated  cirrhosis,  and  (iii)  a  combination  of  mild  disease  and  moderate  disease; 
the  response  to  antiviral  therapy  was  assumed  the  same  irrespective  of  the  stage  of 
chronic  HCV  disease.  The  number  of  severe  HCV-related  events  (i.  e.  decompensated 
cirrhosis  and  HCC)  potentially  prevented  among  IDUs  in  Glasgow  as  a  result  of  the 
above  different  treatment  scenarios  during  2005-30  was  estimated. 
6.3.6  Extension  of  model  to  the  entire  Scottish  IDU  population 
The  model  developed  for  Glasgow  was  adapted  to  the  whole  of  Scotland,  based  on 
available  epidemiological  data,  by  adjusting  four  key  parameters.  First,  the  number  of 
individuals  who  commenced  injecting  each  calendar  year  was  increased  (2-fold  that 
used  for  Glasgow  by  1980,  increasing  to  3-fold  by  1990  and  4-fold  by  the  mid-1990s) 
in  accordance  with  data  on  the  prevalence  of  current  IDUs  in  Scotland'°°"°g 
Secondly,  the  percentage  of  current  IDUs  who  acquired  HCV  infection  each  calendar 
year  was  halved  for  Scotland  compared  to  that  for  Glasgow  in  1987  onwards,  in 
accordance  with  HCV  seroprevalence  data  among  current  IDUs  in  Scotlandso,  ioo 
Thirdly,  1,400  current  IDUs  were  infected  with  HIV  in  Scotland  during  1983-2000 
(the  majority  during  1983-85  as  described  in  6.3.3.2.2).  Fourthly,  1,500  former  IDUs 
with  chronic  HCV  infection  and  moderate  disease  in  Scotland  were  assumed  to  have 
been  initiated  on  antiviral  therapy  by  the  end of  2003  (as  described  in  6.3.3.4.3).  All 
other  parameters  on  cessation  of  injecting,  characteristics  of  IDUs,  HCV  disease 
progression  and  mortality  rates  were  retained  the  same  as  in  Glasgow.  The  model  for 
Scotland  was  fitted  to  record-linkage  data  on  the  estimated  incident  number  of 
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period  here  was  restricted  to  1997-2001  because  of  the  steeper  rise  in  cases  between 
1996  and  1997  in  Scotland  (42%)  than  in  Glasgow  (30%),  which  may  have  resulted 
from  later  implementation  of  widespread  HCV  antibody  testing  across  all  regions). 
6.4  Results 
6.4.1  Assessment  of  HCV  disease  progression  model 
Models  which  excluded  and  included  the  relative  risk  effect  of  covariates  (i.  e.  gender, 
age,  co-infection  with  HIV  and  heavy  alcohol  use)  on  progression  to  cirrhosis  and  a 
range  of  uptake  rates  for  heavy  alcohol  use  (i.  e.  0%,  20%  and  40%)  were  assessed. 
Excluding  the  effect  of  covariates  on  progression  to  cirrhosis  under-estimated  the 
incident  number  of  decompensated  cirrhosis  cases  among  ever  IDUs  in  Glasgow 
between  1996-2001  (a  mean  total  of  72  was  modelled  compared  to  158  estimated 
through  record-linkage,  Table  4.6);  and  in  only  9%  of  simulations  was  consistency 
achieved  with  record-linkage  results.  Model  consistency  improved  to  15%,  27%  and 
40%  following  the  inclusion  of  the  covariate  effects  with  rates  of  heavy  alcohol  use  at 
0%,  20%  and  40%,  respectively.  Covariate-specific  relative  risk  estimates  for 
progression  to  cirrhosis  among  HCV  chronically  infected  individuals  produced  by 
consistent  simulations  were  similar  to  those  employed  a  priori:  1.57  (95%  Cl  1.20- 
2.06)  for  males,  1.08  per  year  (1.04-1.12)  for  age  at  HCV  acquisition,  2.82  (1.74-4.97) 
for  HIV  co-infection,  and  2.38  (1.72-3.43)  for  heavy  alcohol  use. 
Simulations  which  achieved  consistent  results  had  employed  a  higher 
progression  to  cirrhosis  at  20  years  than  had  been  assumed  initially  based  on 
published  studies  (i.  e.  6.5%,  95%  CI  3.5-9.5%).  Therefore,  increasing  the  overall 
progression  to  cirrhosis  at  20  years  to  7.5%  (95%  Cl  5-10%)  generated  higher 
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heavy  alcohol  use,  and  27%  with  the  equivalent  model  for  Scotland.  The  consistent 
simulations  from  these  models  were  used  to  generate  outcomes  hereafter.  Applying  a 
different  model  fitting  approach,  which  compared  simulated  results  with  50 
realisations  from  the  Poisson  distribution  using  a  x2  goodness-of-fit  measure  with  a 
95%  critical  value,  produced  a  slightly  higher  consistency  for  the  Glasgow  model  of 
59%. 
6.4.2  Comparison  of  modelled  and  available  epidemiological  data 
6.4.2.1  The  prevalent  number  of  current  IDUs 
The  modelled  prevalent  numbers  of  current  IDUs  in  Glasgow  (mean  and  95%  CI  for 
years  1990  and  2000:  8,400,7,500-9,700;  and  7,000,6,200-8,400,  respectively)  and 
Scotland  (mean  and  95%  Cl  for  years  1990  and  2000:  22,200,18,700-26,700;  and 
26,000,19,000-37,200,  respectively)  were  consistent  with  published  estimates 
generated  mainly  through  capture-recapture  studies  (Glasgow  1990  and  2000:  8494, 
95%  Cl  7,490-9,72018;  7187,95%  CI  6,085-8,615100,  respectively;  and  Scotland  1990 
and  2000:  21,700108  and  25,140  respectively). 
Of  the  modelled  mean  of  7,000  current  IDUs  in  Glasgow  during  2000,28%, 
59%  and  13%  were  estimated  to  be  aged  <25,25-34  and  >35  years,  respectively;  a 
distribution  which  was  slightly  younger  than  that  derived  through  capture-recapture 
techniques  (23%,  63%  and  14%,  respectively;  personal  communication:  Dr.  Gordon 
Hay,  University  of  Glasgow).  For  all  Scotland,  31%,  58%  and  11%  were  estimated  to 
be  aged  <25,25-34  and  >35  years,  respectively;  a  distribution  which  was  comparable 
with  that  derived  through  capture-recapture  techniques  (30%,  56%  and  14%, 
respectively;  personal  communication:  Dr.  Gordon  Hay,  University  of  Glasgow). 
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The  modelled  mean  annual  number  of  deaths  among  current  IDUs,  unrelated  to  HCV 
and  HIV,  was  in  the  range  100-110  (limits  of  95%  CIs:  70-160)  and  350-390  (220- 
640)  between  1999-2002  for  Glasgow  and  Scotland,  respectively.  Given  that  90%  of 
these  deaths  were  drug-related305,  these  ranges  compare  reasonably  with  the  reported 
number  of  drug-related  deaths  during  this  period  by  the  Scottish  General  Register 
Office  of  96-126  for  Glasgow  and  291-382  for  Scotland3o6 
6.4.2.3  The  prevalence  of  HCV  infection  among  current  IDUs 
The  modelled  seroprevalences  of  HCV  among  current  IDUs  in  Glasgow  (mean  and 
95%  CI  for  years  1990  and  2000:  71%,  62-81%;  and  62%,  53-73%,  respectively)  and 
Scotland  (mean  and  95%  CI  for  years  1990  and  2000:  58%,  46-67%;  and  45%,  38- 
52%,  respectively)  were  generated  in  accordance  with  published  epidemiological  data 
(Glasgow  1990-91  and  2000:  74%,  95%  CI  67-82%47;  62%,  95%  CI  58-66%s°1 
respectively;  and  Scotland  2000:  44%,  95%  CI  30-54%100 
6.4.2.4  The  incident  number  of  HCV-related  decompensated  cirrhosis  cases 
Figure  6.2  presents  the  modelled  and  expected  annual  incident  number  of 
decompensated  cirrhosis  cases  among  HCV  chronically  infected  IDUs  in  (a)  Glasgow 
and  (b)  Scotland  during  1980-2030.  The  number  of  IDUs  with  newly  developed 
decompensated  cirrhosis  each  year  was  estimated  to  double  approximately  between 
2000  and  2020  in  Glasgow  (26  to  61;  95%  CIs  16-38  and  33-99,  respectively)  and 
Scotland  (81  to  154;  95%  CIs  61-101  and  90-236,  respectively).  During  periods  1990- 
1995  and  1996-2001,15-23%  and  7-12%  of  HCV-related  decompensated  cases  in 
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10%  and  2-4%  in  Glasgow,  respectively),  which  contributed  to  the  sharp  rise  in  cases 
during  the  earlier  period. 
6.4.3  Modelled  HCV  disease  burden  among  IDUs  in  Glasgow  and  Scotland 
Figure  6.3  illustrates  the  rise  in  the  prevalent  number  of  HCV  infected  (both  current 
and  former)  IDUs  in  (a)  Glasgow  and  (b)  Scotland  from  only  1,700  (95%  CI  800- 
2,800)  and  3,800  (1,900-6,100)  in  1980  to  15,700  (12,700-20,600)  and  37,800 
(28,000-53,200)  in  2000,  respectively.  The  prevalent  number  continued  to  increase 
during  2001-30  as  a  result  of  applying  the  estimated  incidence  of  HCV  infection  from 
2000  in  subsequent  years.  In  2000,12,100  (9,700-15,800)  and  28,700  (21,200-40,700) 
in  Glasgow  and  Scotland,  respectively,  were  estimated  to  have  chronic  HCV 
infection;  8,700  (6,300-12,600)  and  19,900  (13,700-29,200)  of  these,  respectively, 
were  among  former  IDUs  (Table  6.4).  Among  HCV  chronically  infected  former  IDUs 
in  Glasgow,  the  number  with  moderate  disease  was  estimated  to  increase  2.5,3.7  and 
4.1  -fold  between  2000  (a  mean  of  2,100;  95%  CI  1,200-3,700)  and  2010  (5,200; 
3,600-7,400),  2020  (7,800;  5,800-10,300)  and  2030  (8,600;  5,600-12,300), 
respectively.  The  prevalent  number  of  cirrhotic  HCV  infected  (both  current  and 
former)  IDUs  in  Glasgow  were  estimated  to  rise  1.6,2.4  and  2.6  -fold  between  2000 
(mean  of  500;  95%  Cl  400-700)  and  2010  (800;  600-1,200),  2020  (1,200;  700-1,800) 
and  2030  (1,300;  700-2,400),  respectively. 
6.4.4  Modelled  stage  of  HCV  disease  by  age  among  Glasgow  IDUs  in  2005 
Figure  6.4  illustrates  the  estimated  increasing  severity  of  HCV  disease  with  age 
among  current  and  former  Glasgow  IDUs  in  2005.  The  mean  prevalence  of  moderate 
145 disease  and  cirrhosis  increased  from  2%  and  0%  among  (both  current  and  former) 
IDUs  aged  under  30  years  to  32%  and  17%  among  those  aged  50  years  or  more, 
respectively.  Of  relevance  in  terms  of  targeting  HCV  treatment,  the  mean  estimated 
prevalence  of  moderate  disease  in  2005  was  16%  and  27%  among  all  former  IDUs 
aged  30-39  and  40-49  years,  respectively. 
6.4.5  Modelled  HCV  disease  progression  over  45  years  among  Glasgow  IDUs 
who  commenced  injecting  in  1985 
Figure  6.5  illustrates  the  mean  progression  of  a  cohort  of  Glasgow  IDUs  through  45 
years  following  their  commencement  of  injecting  in  1985  (at  mean  age  of  17.5  years). 
The  mean  percentage  of  IDUs  who  had  died  from  HCV-related  causes  (i.  e.  liver 
failure  and  HCC)  was  11  %  within  45  years  of  their  injecting  debut,  and  a  further  11  % 
and  40%  had  died  from  causes  unrelated  to  HCV  (or  HIV)  as  current  and  former 
IDUs,  respectively. 
6.4.6  Modelled  impact  of  different  treatment  scenarios  on  severe  HCV  disease 
A  total  of  2,180  IDUs  in  Glasgow  were  estimated  to  develop  severe  HCV  disease 
(consisting  of  1,460  and  720  cases  of  decompensated  cirrhosis  and  HCC,  respectively) 
during  2005-2030,  with  no  uptake  of  antiviral  therapy.  Table  6.4  (a)  shows  the 
number  of  cases  of  severe  HCV-related  disease  that  could  be  prevented  during  2005- 
30  among  IDUs  in  Glasgow  through  a  range  of  antiviral  treatment  strategies.  An 
estimated  60  cases,  and  only  3%  of  the  total  number,  of  severe  disease  could  be 
prevented  over  2005-30  with  the  current  level  of  treatment  to  former  IDUs  (with 
moderate  HCV  disease)  in  Glasgow  of  75  treated  cases  per  year.  Increasing  the 
number  initiated  on  antiviral  therapy  from  75  to  250,500  and  1,000  former  IDUs 
146 (with  moderate  disease)  per  year  was  estimated  to  prevent  a  further  100,230  and  350 
severe  HCV  disease  cases,  respectively.  Almost  twice  as  many  severe  HCV  events 
could  be  prevented  if  former  IDUs  with  compensated  cirrhosis  had  the  same 
opportunity  to  be  initiated  on,  and  if  they  could  respond  as  well  to,  antiviral  therapy  as 
those  with  moderate  disease. 
Of  the  2,180  IDUs  in  Glasgow  who  were  estimated  to  develop  severe  HCV 
disease  during  2005-2030,1,690  (78%)  had  become  cirrhotic  post  2005.  Tables  6.4 
(b)  and  (c)  show  the  number  of  severe  HCV-related  disease  events  during  2005-30, 
among  the  1,690  who  had  become  cirrhotic  post  2005,  which  could  potentially  be 
prevented  and  not  prevented  (i.  e.  unsuccessfully  treated),  respectively,  by  a  range  of 
antiviral  treatment  strategies.  Only  3%  to  27%  of  severe  HCV-related  events  during 
2005-30,  among  those  who  became  cirrhotic  post  2005,  could  be  prevented  by 
treatment  of  75  to  1,000  former  IDUs,  respectively,  with  either  mild  or  moderate 
HCV  disease;  however,  a  further  6%  to  43%  had  been  treated  unsuccessfully, 
respectively.  Thus,  treatment  with  more  effective  antiviral  therapies,  than  currently 
available,  of  75  to  1,000  former  IDUs  (with  either  mild  or  moderate  HCV  disease) 
could  potentially  prevent  in  the  ranges  3-9%  and  27-70%  of  severe  HCV-related 
events  during  2005-30,  respectively.  Similarly,  treatment  of  75  to  1,000  former  IDUs 
-  with  either  moderate  disease  or  compensated  cirrhosis  -  could  potentially  prevent  in 
the  ranges  4-15%  and  28-96%  of  severe  HCV-related  events  during  2005-30, 
respectively  (Table  6.4). 
6.5  Discussion 
This  is  the  first  attempt  to  estimate  the  current  and  future  burden  of  HCV  disease  in 
Scotland  related  to  injecting  drug  use,  which  will  aid  the  planning  of  a  public  health 
147 response  to  this  epidemic.  A  total  of  17,400  (95%  CI  14,300-22,200)  and  42,900 
(32,400-60,600)  persons,  who  had  ever  injected  drugs,  were  estimated  to  be  living 
with  HCV  antibodies  by  the  end  of  2003  in  Glasgow  and  Scotland,  respectively.  This 
compares  with  approximately  5,000  (29%)  and  13,900  (32%)  diagnosed,  respectively 
(assuming  77%  of  all  diagnosed  cases  were  IDUs  and  alive  at  the  end  of  2003, 
Chapter  4).  Of  these  HCV-infected  IDUs  in  Glasgow  and  Scotland,  13,200  (95%  CI 
10,800-16,900)  and  32,200  (24,300-45,500)  were  estimated  to  be  living  with  chronic 
HCV  and  therefore  at  risk  of  developing  cirrhosis.  In  Glasgow  and  Scotland 
respectively,  it  was  further  estimated  that  210  (95%  CI  140-330)  and  750  (490-1,060) 
HCV-infected  IDUs  had  died  prematurely  from  liver  failure  by  the  end  of  2003, 
mainly  over  the  last  decade;  this  compares  with  38  and  352  IDUs  known  to  have  died 
from  AIDS  in  Glasgow  and  Scotland,  respectively  (Personal  Communication:  Glenn 
Codere,  SCIEH). 
The  number  of  IDUs  developing  HCV-related  decompensated  cirrhosis  in 
Scotland  is  estimated  approximately  to  double  between  2000  and  2020.  Modelling 
efforts  in  other  countries  have  predicted  similar  rises  in  HCV-related  complications: 
mortality  from  HCV-related  liver  disease  is  estimated  to  increase  2-fold  between  2000 
and  2020  in  the  United  States82'84,2.5-fold  between  1990  and  2020  in  France  79,  and 
1.9-fold  between  1998  and  2020  in  Switzerland86;  in  Australia,  the  number  of  people 
living  with  HCV-related  cirrhosis  is  estimated  to  more  than  triple  between  2000  and 
202081. 
Several  countries  have  developed  models  to  forecast  the  future  course  of  their 
HCV  epidemic,  but  few  have  validated  their  predictions,  as  in  this  study,  by  fitting 
model  outcomes  to  past  epidemiological  trends  relating  to  HCV  and  its 
consequences79'83.  The  aim  here  was  to  capture  the  essential  features  of  the  HCV 
148 epidemic  among  IDUs,  initially  in  Glasgow  because  more  epidemiological  data  exist 
for  this  region  than  elsewhere  in  Scotland,  and  calibrate  model  parameters  with  data, 
principally,  on  the  prevalent  number  of  current  IDUs,  the  prevalence  of  HCV 
infection  among  current  IDUs  and  the  incident  number  of  HCV-related 
decompensated  cirrhosis  cases  among  IDUs.  Insights  gained  from  the  model  fitting 
process  in  Glasgow,  such  as  on  the  rate  of  progression  to  cirrhosis,  were  used  to  apply 
the  model  to  the  whole  of  Scotland. 
The  importance  of  including  the  effect  of  age  and  gender  on  the  progression  of 
chronic  HCV  in  models  has  reviousl  been  illustrated  79'83  py  but  the  potential 
limitation,  in  terms  of  under-estimating  HCV  disease  burden,  of  excluding  the 
influence  of  alcohol  abuse  and  HIV  co-infection  has  mostly  only  been 
acknowledged  79'82'86.  Discounting  the  influence  of  these  four  factors  on  disease 
progression  and  assuming  a  prevalence  of  cirrhosis  at  20  years  of  6.5%  (95%  CI  3.5- 
9.5%),  consistent  with  a  recent  systematic  review94,  under-estimated  the  number  of 
IDUs  developing  liver  failure  in  Glasgow  during  1996-2001  by  more  than  half  that 
expected  from  the  record-linkage  data  (Chapter  4).  For  Glasgow,  consistency  between 
model  and  record-linkage  data  improved  by  allowing  disease  progression  rates  to 
depend  on  age  at  HCV  acquisition,  gender,  HIV  co-infection  and  heavy  alcohol  use. 
However,  the  results  still  indicated  that  either  (i)  the  prevalence  of  cirrhosis  at  20 
years  was  higher  than  the  mean  of  6.5%  assumed,  (ii)  the  increased  rate  of  disease 
progression  by  co-factors  -  age,  gender,  HIV  co-infection  and  alcohol  -  had  been 
under-estimated,  or  (iii)  the  heterogeneity  in  progression  had  not  been  fully  explained. 
Projections  clearly  rely  on  the  accuracy  of  the  model  assumptions  used  to 
derive  them.  The  expected  numbers  of  IDUs  developing  decompensated  cirrhosis, 
data  which  are  integral  to  the  model  fitting  process,  were  based  on  the  number  of 
149 HCV  diagnosed  individuals  admitted  to  hospital  with  this  complication,  which  were 
then  adjusted  to  account  for  the  proportion  associated  with  injecting  drug  use  (88%) 
and  the  non-hospitalisation  (14%)  and  non-HCV-diagnosis  (18%)  of  decompensated 
cases  (Chapter  4).  To  allow  for  the  uncertainty  in  the  estimated  number  of  IDUs 
developing  decompensated  cases,  the  99.9%  critical  value  with  the  x2  test  statistic  was 
used  to  assess  the  goodness-of-fit.  The  specification  of  ranges  around  model 
parameters  were  derived,  through  the  synthesis  of  numerous  sources  of  data  from 
various  studies,  to  encompass  the  full  span  of  plausible  values,  but  more  formal 
methods  for  developing  prior  distributions  for  each  parameter  might  allow  a  full 
Bayesian  approach  to  model  fitting. 
As  new  data  become  available,  improvements  in  the  modelling  of  the  HCV 
epidemic  in  Scotland,  as  elsewhere,  will  be  possible,  leading  to  further  refinement  in 
these  estimates.  In  particular,  further  research  is  needed  to  validate  estimates  of  the 
incidence  and  cessation  of  injecting  drug  use,  to  examine  the  prevalence  of  heavy 
alcohol  use  by  gender  among  current  and  former  IDUs,  and  to  assess  the  influence  of 
age  and  gender  on  injector  mortality152.  Although  mortality  related  to  heavy  alcohol 
use307  was  not  dealt  with  separately,  the  model  assumed  a  raised  risk  of  death  from 
causes  unrelated  to  HCV  or  HIV  (i.  e.  two  to  five  times  higher  the  average  age  and 
gender  general  population  specific  rates)73'292.  The  annual  incidence  of  HCV  infection 
estimated  in  2000  was  carried  forward  to  years  2001-30,  but  clearly  could  be 
influenced  by  the  impact  of  future  prevention  initiatives  and  therefore  the  numbers 
progressing  to  moderate,  but  unlikely  severe,  disease  could  be  over-estimated. 
It  was  important  to  model  the  progression  to  moderate  disease  (defined  as  3- 
5/6  on  fibrosis  and/or  >3/18  on  necroinflammation  grades),  even  with  the  limited  data 
available,  because  patients  reaching  this  stage  are  recommended  for  treatment  with 
150 antiviral  therapy289.  Progression  to  moderate  disease  was  based  on  the  prevalence  of 
necroinflammation  activity,  which  can  fluctuate  over  time308,  either  because  it  is  not 
continuously  present  or  identifiable  309,  but  was  regarded  as  cumulative  for  the 
purposes  of  modelling.  A  comprehensive  review  of  the  literature  on  progression 
following  development  of  compensated  cirrhosis  revealed  higher  annual  rates  to 
decompensated  cirrhosis  (6.5%)  and  HCC  (3.5%)  than  had  been  used  in  previous 
model  applications  (4%  and  0.5-2%,  respective  ly)68,73,77,78'80'8z 
Compared  to  the  number  of  people  living  with  chronic  HCV  infection  in 
Scotland,  relatively  few  have  received  antiviral  therapy.  Progress  needs  to  be  made  in 
(i)  identifying  individuals  who  would  most  benefit  from  antiviral  therapy  and  (ii) 
retention  of  those  diagnosed  with  chronic  HCV  in  clinical  follow-up.  A  total  of  3,000 
(95%  Cl  1,800-4,800)  and  6,600  (3,900-10,300)  former  IDUs  were  estimated  to  be 
living  with  moderate  HCV  disease  in  2003  in  Glasgow  and  Scotland,  respectively;  if 
the  uptake  of  antiviral  therapy  continues  at  the  current  level,  these  numbers  were 
estimated  to  double  by  2010.  As  high  as  16%  and  27%  of  Glasgow  former  IDUs  in 
2005  aged  30-39  and  40-49  years,  respectively,  were  estimated  to  have  moderate 
disease  (32%  and  47%  of  those  chronically  infected,  respectively),  which  highlights 
the  potential  benefit  of  targeting  HCV  testing  at  these  age  groups  of  former  IDUs. 
Treatment  of  chronic  HCV  with  combination  therapy  of  pegylated  interferon 
plus  ribavirin  has  been  shown  to  be  cost-effective  73'310  and  is  expected  to  reduce 
future  disease  complications.  In  France,  however,  it  has  been  demonstrated  that  at 
least  half  of  their  HCV-infected  population  would  require  antiviral  therapy  to  curb  the 
future  rise  in  the  number  of  HCV-related  deaths  and  at  most  reduce  the  incidence  of 
decompensated  cirrhosis  by  almost  a  quarter  over  the  next  twenty  years79.  Increasing 
uptake  of  antiviral  therapy  among  former  IDUs  in  Glasgow  by  more  than  thirteen- 
151 fold,  to  1,000  cases  per  year  during  2005-2030,  similarly  did  not  have  a  dramatic 
impact  on  the  future  incidence  of  severe  HCV  disease,  with  reductions  of  only  19  to 
28%  depending  on  whether  patients  with  compensated  cirrhosis  could  be  treated  and 
respond  to  therapy  as  well  as  those  with  moderate  disease.  However,  the  treatment, 
with  more  effective  antiviral  therapies  than  currently  available,  of  up  to  1,000  former 
IDUs  per  year  in  Glasgow  with  moderate  HCV  disease  over  the  next  26  years  (15,000 
cases  in  total  and  62%  of  those  HCV  infected  by  the  year  2030)  could  potentially 
prevent  between  24%  and  86%  of  severe  HCV-related  events  during  2005-2030. 
The  simulations  did  not  consider  the  different  response  to  antiviral  therapy 
according  to  genotype,  the  re-treatment  of  non-responders  or  that  patients  who  had  not 
responded  to  antiviral  therapy  may  have  benefited  from  a  reduced  rate  of  liver  disease 
progression  311  °312  Thus,  the  model  may  have  under-estimated  the  potential  long-term 
benefit  of  antiviral  therapy,  but  illustrates  that  current  practice,  with  treatment  of  a 
relative  minority  of  HCV  infected  patients,  will  scarcely  impact  on  the  future  burden 
of  this  disease. 
There  is  some  urgency  for  action  because  HCV  is  frequently  asymptomatic 
until  cirrhosis  develops.  Once  hepatic  decompensation  occurs,  treatment  is  limited  by 
the  shortage  of  donor  transplant  organs.  Additional  research  regarding  the  cost- 
effectiveness  of  HCV  testing  strategies  targeted  at  former  IDUs  should  be  pursued  to 
help  formulate  public  health  policy  in  this  area.  The  identification  and  treatment  of  a 
larger  proportion  of  former  IDUs  with  advanced  HCV  disease,  education  about  the 
importance  of  minimal  alcohol  consumption,  and  the  development  of  better  tolerated 
therapies  may  help  to  achieve  a  greater  impact  on  the  morbidity  and  mortality  of  this 
disease.  Meanwhile,  the  development  of  initiatives  to  prevent  (i)  the  further  spread  of 
152 HCV  infection  among  current  IDUs  and  (ii)  the  initiation  of  non-IDUs  into  injecting 
should  not  be  neglected. 
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Table  6.2:  Assumed  risk  of  cirrhosis  at  twenty  and  thirty  years*  following  infection  with 
HCV  according  to  risk  profile  of  HCV  chronically  infected  individuals. 
Characteristics  influencing  HCV  disease  progression  Prevalence  of  cirrhosis  at: 
(mean  and  95%  CI) 
Gender  Age  at  HCV 
acquisition  (years) 
Co-infected 
with  HIV 
Heavy 
alcohol  user 
20  years  30  years 
Female  20  No  No  3.0%  (2.4-  3.0%)  5.8%  (4.4-  7.7%) 
Female  20  No  Yes  6.6%  (3.8-  9.1%)  12.8%  (6.9-20.6%) 
Female  20  Yes  No  8.4%  (3.9-13.1%)  14.8%  (7.1-27.9%) 
Female  20  Yes  Yes  16.9%  (6.2-33.5%)  28.7%  (10.9-53.5%) 
Female  30  No  No  6.2%  (3.3-  8.6%)  12.2%  (6.0-19.6%) 
Female  30  No  Yes  13.9%  (5.6-23.8%)  24.0%  (9.9-43.6%) 
Female  30  Yes  No  16.1%  (5.6-31.5%)  29.0%  (10.0-51.3%) 
Female  30  Yes  Yes  31.6%  (9.2-56.6%)  45.3%  (15.9-63.8%) 
Male  20  No  No  4.5%  (2.9-  6.0%)  8.8%  (5.2-14.2%) 
Male  20  No  Yes  9.6%  (4.6-17.1%)  17.5%  (8.5-33.6%) 
Male  20  Yes  No  11.8%  (4.6-24.1%)  21.3%  (8.6-43.4%) 
Male  20  Yes  Yes  24.1%  (7.7-47.4%)  38.9%  (13.4-61.0%) 
Male  30  No  No  9.0%  (4.2-16.6%)  16.9%  (7.6-33.6%) 
Male  30  No  Yes  18.7%  (6.7-38.1%)  31.8%  (12.0-56.5%) 
Male  30  Yes  No  22.8%  (6.9-47.2%)  36.5%  (12.2-60.5%) 
Male  30  Yes  Yes  39.2%  (11.3-62.2%)  52.7%  (18.6-63.9%) 
*  Progression  to  compensated  cirrhosis  was  calculated  based  on  a  Weibull  distribution  with  prevalence  estimated 
at  6.5%  (95%  Cl  3.5-9.5%)  and  20%  (10-40%)  after  20  and  40  years,  respectively,  and  adjusted  for  increased 
progression  with  older  age  at  HCV  acquisition  (relative  risk  1.08  per  year,  1.04-1.12),  males  (1.56,95%  CI  1.21- 
2.03),  co-infection  with  HIV  (2.92,1.70-5.01),  and  heavy  alcohol  use  (2.33,1.67-3.26). 
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0.0011 Table  6.3:  Estimated  annual  transition  probabilities  for  progression  of  HCV  infected  cirrhotic  persons. 
Progression  between  disease  states  Average  annual  transition  rates  estimated  from  literature  Pooled 
Initial  state  Outcome  Point  Total  number  of  First  author  estimate 
estimate  subjects  (reference  no)  (95%  CI*) 
(mean  years  of 
follow-up) 
(i)  Compensated  Decompensated  3.9%1  355  (5.1  years)  Fattovich  et  al.  (31R)  6.5% 
cirrhosis  cirrhosis  4.9%11  112  (4.5  years)  Hu  et  al.  (319)  (4,0-9.2%) 
(1  unrelated  to  6.4%1  136  (6.6  years)  Fattovich  et  at.  (320) 
HCC)  9.1%9  44  (3.3  years)  Serfaty  et  al.  (321) 
9.7%t  257  (5.3  years)  Gines  et  al.  (322) 
(ii)  Compensated  HCC  0.7%  124  (6.1  years)  Takano  et  al.  (323)  3.5% 
cirrhosis  1.0%t  405  (8.0  years)  Gentilini  et  al.  (324)  (2.4-4.6%) 
1.4%1  384  (5.1  years)  Fattovich  et  al.  (318) 
2.1%t  112  (4.5  years)  Hu  et  al.  (319) 
2.1%  136  (6.6  years)  Fattovich  et  al.  (320) 
2.5%#  163  (5.3  years)  Bruno  et  al.  (325) 
2.8%x  416  (5.7  years)  Degos  et  al.  (326) 
3.4%1  396  (4.2  years)  Mandelli  et  al.  (327) 
4.6%  166  (5.5  years)  Chiaramonte  et  al.  (328) 
4.7%  349  (5.8  years)  Ikeda  et  al.  (329) 
5.1%t  228  (3.7  years)  Imberti  et  al.  (330) 
5.1%  44  (3.3  years)  Serfaty  et  al.  (321) 
6.9%  45  (5.5  years)  Nishiguchi  S  at  at.  (331) 
12.3%t  400  (3.0  years)  Tsai  et  at.  (332) 
(iii)  Decompensated  Liver  transplant  2.1%  507  (1.9  years)  Hutchinson  et  al.  (Ch.  4)  2.0%* 
cirrhosis 
(iv)  Decompensated  Death  12.6%  24  (-)  Fattovich  et  at.  (320)  18.6% 
cirrhosis  12.9%t  65  (2.0  years)  Fattovich  et  al.  (318)  (13.7-25.0%) 
14.0%  49  (-)  Hu  et  al.  (319) 
22.3%  507  (1.9  years)  Hutchinson  et  al.  (Ch.  4) 
30.7%t  121  (-)  Gines  et  al.  (322) 
(v)  HCC  Death  54.0%  70  (0.7  years)  Hutchinson  et  al.  (Ch.  4)  60.5% 
57.6%t  60  (-)  Degos  et  al.  (326)  (54.5-67.6%) 
63.9%t  2573  (-)  EI-Serag  et  al.  (333) 
(vi)  Liver  transplant  Death  in  first  year  5.2%  58  (3.1  years)  Paik  et  al.  (334)  14.6% 
(for  decompensated  6.0%  97  (-)  Ascher  et  at.  (335)  (11.1-18.2%) 
cirrhosis)  7.0%  54  (3.4  years)  Shuhart  et  al.  (336) 
10.0%  128  (2.7  years)  Wali  et  at.  (337) 
13.0%  209  (4.1  years)  Neumann  et  al.  (338) 
16.0%  510  (2.5  years)  Ghobrial  et  al.  (339) 
20.0%  3084  (-)  Detre  et  at.  (340) 
21.0%  149  (3.0  years)  Gane  et  al.  (34! 
) 
21.8%  715  (9.4  years)  Jain  et  al.  (342) 
22.1%  1080  (-)  Fagiuoli  et  al.  (343) 
(vii)  Liver  Death  in  2"  +  3.0%  149  (3.0  years)  Gane  et  al.  (°)  4.4% 
transplant  (for  years  3.1%  1080  (-)  Fagiuoli  et  al.  (343)  (3.5-5.3%) 
decompensated  3.5%  715  (9.4  years)  Jain  et  al.  (342) 
cirrhosis)  3.6%  209  (4.1  years)  Neumann  et  al.  (338) 
5.1%  128  (2.7  years)  Wali  et  al.  (337) 
5.1%  3084(  -)  Detre  et  al.  (340) 
5.1%  510  (2.5  years)  Ghobrial  et  al.  (339) 
6.5%  54  (3.4  years)  Shuhart  et  al.  (336) 
10.0%  58  (3.1  years)  Paik  et  al.  (334) 
Includes  HCV  antibody  negative  persons;  $  Includes  persons  who  had  received  anti-viral  therapy;  (-)  Data  missing; 
*  Range/estimate  used  in  model. 
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M Chapter  7:  Summary  and  future  work 
7.1  Overview  of  the  approach  used  to  derive  HCV  projections 
A  forward  projection  approach  was  used  to  model  the  number  of,  both  current  and 
former,  IDUs  who  have  acquired  HCV  infection  and  will  either  have  progressed  or 
will  progress  to  mild,  moderate  and  severe  HCV  disease.  The  HCV  epidemic  among 
IDUs  in  Glasgow  was  modelled  initially  because  more  epidemiological  data  exist  for 
this  region  than  elsewhere  in  Scotland,  and  model  outcomes  calibrated  with  local  data 
relating  to  HCV  and  its  consequences.  Insights  gained  from  the  model  fitting  process 
in  Glasgow  were  then  used  to  extend  the  model  to  the  rest  of  Scotland. 
The  HCV  projection  model  incorporated  both  knowledge  and  uncertainty 
about  major  parameters  relating  to  (i)  the  incidence  and  cessation  of  injecting  drug  use 
and  mortality  from  causes  unrelated  to  HCV,  (ii)  the  incidence  of  HCV  infection 
among  current  IDUs,  and  (iii)  the  rate  of  HCV  disease  progression.  First,  incidence 
and  cessation  of  injecting  drug  use  in  Glasgow  were  derived  through  the  use  of  a 
modified  Delphi  approach  which  combined  expert  opinion  with  capture-recapture 
IDU  prevalence  estimates.  Mortality  from  causes  unrelated  to  HCV  among  current 
and  former  IDUs  was  based  on  estimates  from  the  literature.  Secondly,  stochastic 
simulation  was  developed  to  model  the  transmission  of  HCV  among  current  IDUs  in 
Glasgow,  according  to  their  injecting  risk  behaviours  and  the  characteristics  of  the 
virus,  and  to  estimate  the  past  incidence  of  HCV  infection.  For  the  third  component  of 
the  projection  model,  the  worldwide  literature  was  reviewed  to  inform  the  rate  of 
HCV  disease  progression  and  a  meta-analysis  was  performed  to  quantify  the  effect  of 
heavy  alcohol  use  on  progression  to  cirrhosis  in  persons  with  chronic  HCV.  Finally, 
modelled  outcomes  were  fitted  to  epidemiological  data,  in  particular  the  number  of 
164 IDUs  developing  HCV-related  decompensated  cirrhosis  each  year  which  had  been 
estimated  through  the  record-linkage  of  Scotland's  database  of  HCV  diagnosed 
persons  with  hospital  discharge  and  death  records. 
7.2  Main  findings  from  stages  undertaken  to  derive  HCV  projections 
The  following  five  sections  provide  a  synopsis  of  the  stages,  and  the  main  findings 
presented  in  Chapters  2-6,  undertaken  to  derive  projections:  (i)  estimating  the 
incidence  and  cessation  of  injecting  drug  use  in  Glasgow,  (ii)  estimating  the  past 
incidence  of  HCV  infection  among  injecting  drug  users  in  Glasgow,  (iii)  estimating 
the  severe  disease  burden  associated  with  HCV  infection  in  Scotland,  (iv)  estimating 
the  influence  of  alcohol  on  the  progression  of  HCV  infection,  and  (v)  estimating  the 
current  and  future  disease  burden  of  HCV  among  injecting  drug  users  in  Glasgow  and 
Scotland. 
7.2.1  Estimating  the  incidence  and  cessation  of  injecting  drug  use  in  Glasgow 
Glasgow  has  been  at  the  forefront  of  injecting  drug  use  prevalence  estimation:  log- 
linear  modelling  of  capture-recapture  data  estimated  8,490  (95%  CI  7,490-9,720)  and 
7,190  (6,090-8,620)  current  IDUs  in  1990  and  2000,  respectively.  Hitherto,  however, 
no  consensus  had  been  sought  on  the  size  and  shape  of  its  IDU  epidemic  curve.  A 
modified  Delphi  approach  was  used  to  elicit  one  for  Glasgow.  Twelve  experts  were 
asked  to  provide  their  opinion  on  the  prevalent  number,  incident  number,  and 
percentage  ceasing  injecting  each  year  for  quinquennia  during  1960-2000.  Instead  of 
the  usual  iterative  process  to  refine  experts'  consensus,  the  elicitation  of  IDU 
incidence  and  cessation  provided  an  opportunity,  not  previously  explored,  to  combine 
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1 these  data  and  examine  coherence  with  capture-recapture  estimates  on  the  prevalent 
number  of  injectors  during  1990  and  2000. 
Scrutiny  of  consensus  data  indicated  that  experts  had  under-estimated 
incidence  during  1985-1990,  and  over-estimated  prevalence  during  1995-2000  and 
cessation  during  1985-2000.  Coherent  estimates  indicated  that  prevalence  (median 
estimates:  149  to  557),  incidence  (28  to  49)  and  cessation  (1  to  2%)  remained  low  and 
stable  during  1960-1975,  rose  steeply  between  1975-1985  (median  prevalence  from 
557  to  4,438;  incidence  from  49  to  1,335;  cessation  from  2%  to  6%),  and  by  2000 
there  had  been  a  decline  in  incidence  (1,195)  but  further  rises  in  prevalence  (6,809) 
and  cessation  (15%).  Point  prevalence  estimates  from  capture-recapture  studies  were 
essential  to  anchor  experts'  consensus  and  derive  coherent  data.  The  rise  in  the 
cessation  of  IDU  throughout  the  1990s  is  a  promising  finding  in  the  context  of  the 
expansion  of  methadone  prescribing  and  other  harm  reduction  services  in  Glasgow. 
7.2.2  Estimating  the  past  incidence  of  HCV  infection  among  injecting  drug  users 
in  Glasgow 
Stochastic  simulation  was  used  to  model  quantitatively  the  transmission  of  HCV 
through  the  sharing  of  used  needles/syringes  among  current  IDUs  in  Glasgow  during 
1960-2000.  The  modelling  combined  information  on  (a)  the  incidence  and  cessation 
of  injecting  drug  use  in  Glasgow,  (b)  the  frequencies  with  which  Glasgow  IDUs 
injected  and  shared  needles/syringes,  and  the  numbers  of  different  persons  they  shared 
with,  and  (c)  the  susceptibility,  transmissibility  and  carriage  of  HCV  infection. 
The  model  that  considered  higher  infectivity  during  acute  viraemia  following 
infection  produced  seroprevalences  (median:  62-72%)  and  incidences  (18-30  per  100 
susceptible  injector-years)  consistent  with  observed  data  during  the  1990s,  and 
166 suggests  that  this  phenomenon  may  be  an  important  factor  in  the  spread  of  HCV,  as 
recognised  with  HIV.  Discounting  this  effect  would  have  under-estimated  HCV 
prevalence  which,  alternatively,  could  have  been  explained  by  the  model's  omission 
of  transmissions  occurring  through  other  routes  such  as  indirect  sharing  of  injecting 
equipment.  The  annual  number  of  new  HCV  infections  among  current  IDUs  (who  had 
no  previous  infection)  in  Glasgow  was  estimated  to  be  low  during  1960-1976  (median 
of  10-60),  rise  steeply  during  the  early  1980s  to  peak  in  1985  (1,120),  stabilise  during 
1991-1997  (510-610)  and  rise  again  during  1998-2000  (710-780).  Scenario  analyses 
indicated  that  potentially  as  many  as  4,500  HCV  infections  (10th  and  90th  percentiles: 
2,400-7,700)  had  been  prevented  in  Glasgow  during  1988-2000,  as  a  result  of  harm- 
reduction  measures  introduced  during  this  period. 
Scenario  analyses  also  permitted  the  gauging  of  changes  in  risk  behaviours 
required  to  effect  appreciable  reductions  in  the  incidence  of  HCV  infection.  Incidence 
can  be  successfully  reduced  if  IDUs  who,  unavoidably,  share  needles/syringes  confine 
their  borrowing  to  one  person;  with  this  strategy  alone  (i.  e.  reducing  the  mean  number 
of  partners  to  one  from  an  estimated  3-6,2,  and  3  during  years  1988-1990,1991-1997 
and  1998-2000,  respectively),  an  estimated  5,300  HCV  infections  (10th  and  90th 
percentiles:  4,100-6,700)  could  have  been  averted  during  1988-2000.  Alternatively, 
permitting  only  11-20%  of  IDUs  in  Glasgow  to  share  a  needle/syringe  at  least  once 
annually  during  1988-2000  would  have  similarly  averted  an  estimated  5,200  HCV 
infections  (10th  and  90t"  percentiles:  4,200-6,600).  Such  insights  will  inform  those 
responsible  for  developing  new  ways  to  prevent  HCV  transmission  among  IDU 
populations.  A  serious  commitment  to  implement,  and  evaluate  the  cost-effectiveness 
of,  strategies,  which  could  achieve  appreciable  reductions  in  risk  behaviours  among 
IDUs,  is  urgently  needed  to  influence  the  future  course  of  the  HCV  epidemic. 
167 7.2.3  Estimating  the  severe  disease  burden  associated  with  HCV  infection  in 
Scotland 
To  monitor  the  emergence  of  sequelae  related  to  HCV  infection  requires  national 
surveillance  systems,  currently  lacking  in  the  UK  and  elsewhere,  which  detect  not 
only  advanced  liver  disease  but  also  the  aetiological  factors.  The  laboratory  reporting 
of  diagnostic  positive  tests  for  HCV  antibodies  in  Scotland  linked  electronically  to 
clinical  data  gathered  from  hospital  and  death  records  provided  a  unique  national 
epidemiological  dataset  on  diagnosed  HCV  infection  to  estimate  the  numbers 
developing  HCV-related  decompensated  cirrhosis  and  HCC. 
A  substantial  proportion  of  persons  who  test  positive  for  HCV  antibodies 
report  no  risk  factors  for  infection:  32%  (3,874/12,096)  in  Scotland.  Of  12,096 
diagnosed  HCV  antibody  positive  persons  studied  in  Scotland,  61  %  reported  injecting 
drug  use  with  their  HCV  diagnosis  and a  further  27%,  yielding  a  total  of  88%,  were 
established  as  IDUs  through  log-linear  modelling  of  record-linkage  data  from  four 
sources  (i.  e.  HCV  diagnoses,  HIV  test,  hospital  and  death  records). 
Approximately  500  and  200  diagnosed  HCV  antibody  positive  persons  in 
Scotland  had  developed  and  died  of  liver  failure,  respectively,  by  the  end  of  2001. 
Relatively  low  prevalences  of  HCV  infection  were  estimated  among  individuals  with 
HCC  and  decompensated  cirrhosis  presenting  to  hospital  (13%  and  6%,  respectively) 
or  having  died  (11%  and  5%,  respectively)  in  Scotland  during  1996-2001;  these 
estimated  rates  incorporated  adjustments  to  account  for  (i)  the  inability  to  link  a 
proportion  of  HCV  diagnosed  persons  due  to  insufficient  identifiers  and  (ii)  the  non- 
diagnosis  of  HCV  infection  among  HCV  infected  HCC  and  decompensated  cirrhosis 
cases.  The  hospital  morbidity  data  alone,  however,  under-estimated  the  incidence  of 
168 severe  HCV-disease  since  25%  and  14%  of  HCV  diagnosed  individuals  who  had  died 
-  according  to  death  records  held  by  General  Registrar  Office  for  Scotland  -  from 
HCC  and  decompensated  cirrhosis,  respectively,  were  not  identified  with  these 
conditions  in  the  hospital  register.  The  number  of  persons  with  newly  developed 
HCV-related  decompensated  cirrhosis  in  Scotland  was  estimated  to  have  increased  by 
30%  from  230  (95%  Cl  220-250)  in  1996-1998  to  300  (280-320)  cases  in  1999-2001, 
highlighting  HCV  as  a  growing  significant  burden  on  healthcare  resources  in 
Scotland. 
Alcohol  was  a  prominent  factor  among  HCV  diagnosed  persons  who  had  died 
(78%  of  134)  or  were  hospitalised  (72%  of  442)  with  decompensated  cirrhosis  during 
1996-2001  in  Scotland.  The  younger  age  of  decompensated  patients  presenting  to 
hospital  in  Scotland  during  1996-2001  with  both  HCV  and  alcohol  (78%  of  320  were 
aged  <50  years)  suggests  that  the  combined  effect  of  these  two  factors  accelerates 
liver  disease  progression  more  than  if  only  one  (decompensated  cirrhosis  patients  with 
only  HCV:  48%  of  122;  and  with  only  alcohol:  33%  of  8,465)  or  neither  of  these 
factors  (17%  of  1,681)  were  present.  In  light  of  the  potential  synergistic  effect 
between  alcohol  and  HCV,  limiting  the  alcohol  consumption  of  chronically  infected 
individuals  is  important  to  help  prevent  future  HCV-related  morbidity  and  mortality. 
7.2.4  Estimating  the  influence  of  alcohol  on  the  progression  of  HCV  infection 
The  elucidation  of  the  factors  that  influence  progression  to  severe  HCV  disease  is 
important  at  an  individual  level  -  so  that  appropriate  counselling  of  those  affected  and 
help  in  making  decisions  regarding  antiviral  therapy  can  be  given  -  and  at  a 
population  level  -  so  that  covariate  influences  in  projection  models  aimed  at 
estimating  the  future  burden  of  disease  can  be  accommodated.  A  convincing,  yet 
169 inconsistent,  pattern  which  demonstrates  increased  progression  of  HCV-related  liver 
disease  with  heavy  alcohol  use  has  emerged.  A  meta-analysis  which  examined  twenty 
articles,  involving  over  15,000  HCV  chronically  infected  persons,  published  between 
1995  and  2004  was  therefore  undertaken  to  explore  the  relationship  between  advanced 
liver  disease  -  either  advanced  fibrosis,  cirrhosis  or  decompensated  cirrhosis  -  and  the 
consumption  of  alcohol. 
The  pooled  RR  of  cirrhosis,  including  decompensated  cirrhosis,  associated 
with  heavy  alcohol  intake  (defined  in  the  range  of  at  least  210  to  560g  per  week)  was 
2.33  (95%  CI  1.67-3.26)  by  the  random  effects  model.  The  risk  of  HCV-related 
disease  associated  with  heavy  alcohol  intake  increased  with  severity  of  the  outcome: 
the  lowest  (1.63;  95%  CI  1.22-2.17)  and  highest  (3.54;  2.14-5.85)  pooled  RR 
estimates  were  obtained  for  advanced  fibrosis  and  decompensated  cirrhosis, 
respectively.  Studies  varied  widely  in  their  definition  of  significant  alcohol  intake, 
ranging  between  210  and  560g  per  week,  and  so  the  true  threshold  above  which 
alcohol  accelerates  HCV  disease  progression  remains  uncertain. 
Studying  the  relationship  between  HCV  and  alcohol  is  problematic  because  of 
difficulties  in  obtaining  an  accurate  history  of  alcohol  intake.  Moreover,  studies 
investigating  the  risk  of  HCV-related  cirrhosis  necessarily  include  patients  undergoing 
liver  biopsy  and  therefore  could  under-represent  heavy  alcohol  users,  as  patients 
consuming  alcohol  at  toxic  levels  may  have  been  precluded  from  biopsy.  Such 
selectivity  may  have  under-estimated  the  regression  effect  of  alcohol  in  the  meta- 
analysis.  Nevertheless,  the  evidence  overwhelmingly  shows  a  worsened  outcome  for 
those  with  chronic  HCV  and  concurrent  alcohol  use.  Alcohol  consumption  should  be 
minimised  as  much  as  possible  in  those  who  have  chronic  HCV  until  a  safe  threshold 
is  more  definitively  determined. 
170 7.2.5  Estimating  the  current  and  future  disease  burden  of  HCV  among  injecting 
drug  users  in  Glasgow  and  Scotland 
To  plan  a  public  health  response  to  the  HCV  epidemic  in  Scotland,  in  terms  of  both 
treatment  needs  and  preventive  measures,  quantitative  estimates  of  the  current  and 
future  burden  of  HCV  disease  are  required.  The  aims  were  to  develop  a  model  to 
estimate  (i)  the  numbers  of,  both  current  and  former,  IDUs  who  acquired  HCV 
infection  and  progressed  to  mild,  moderate  and  severe  HCV  disease  in  Glasgow  and 
Scotland  between  1960  and  2030,  and  (ii)  the  number  of  cases  of  severe  HCV-related 
disease  (i.  e.  decompensated  cirrhosis  and  HCC)  among  IDUs  that  could  be  prevented 
in  the  future  through  a  range  of  antiviral  treatment  strategies.  Several  countries  have 
developed  models  to  forecast  the  future  course  of  their  HCV  epidemic,  but  few  have 
validated  their  predictions,  as  in  this  study,  by  fitting  model  outcomes  to  past 
epidemiological  trends  relating  to  HCV  and  its  consequences. 
A  total  of  17,400  (95%  CI  14,300-22,200)  and  42,900  (32,400-60,600) 
persons,  who  had  ever  injected  drugs,  were  estimated  to  be  living  with  HCV 
antibodies  by  the  end  of  2003  in  Glasgow  and  Scotland,  respectively.  This  compares 
with  approximately  5,000  (29%)  and  13,900  (32%)  diagnosed,  respectively.  Of  these 
HCV-infected  IDUs  in  Glasgow  and  Scotland,  13,200  (95%  CI  10,800-16,900)  and 
32,200  (24,300-45,500)  were  estimated  to  be  living  with  chronic  HCV  and  therefore 
at  risk  of  developing  cirrhosis.  The  number  of  IDUs  developing  HCV-related 
decompensated  cirrhosis  in  Scotland  is  estimated  approximately  to  double  between 
2000  and  2020. 
Consistency  between  model  and  record-linkage  data  improved  by  allowing 
disease  progression  rates  to  depend  on  age  at  HCV  acquisition,  gender,  HIV  co- 
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prevalence  of  cirrhosis  at  20  years  was  higher  than  the  mean  of  6.5%  assumed  or  the 
strength  of  factors  influencing  progression  had  not  been  fully  explained.  A  review  of 
the  literature  on  progression  following  development  of  compensated  cirrhosis 
revealed  higher  annual  rates  to  decompensated  cirrhosis  (6.5%)  and  HCC  (3.5%)  than 
had  been  used  in  previous  model  applications  (4%  and  0.5-2%,  respectively). 
A  total  of  3,000  (95%  CI  1,800-4,800)  and  6,600  (3,900-10,300)  former  IDUs 
were  estimated  to  be  living  with  moderate  HCV  disease  in  2003  in  Glasgow  and 
Scotland,  respectively;  if  the  uptake  of  antiviral  therapy  continues  at  the  current  level, 
these  numbers  were  estimated  to  double  by  2010.  As  high  as  16%  and  27%  of 
Glasgow  former  IDUs  in  2005  aged  30-39  and  40-49  years,  respectively,  were 
estimated  to  have  moderate  disease  (32%  and  47%  of  those  chronically  infected, 
respectively),  which  highlights  the  potential  benefit  of  targeting  HCV  testing  at 
former  IDUs  who  belong  to  these  age  groups. 
The  treatment  with  antiviral  therapy  of  15,000  former  IDUs  in  Glasgow  with 
moderate  HCV  disease  over  the  next  26  years  (62%  of  those  HCV  infected  by  the 
year  2030)  could  potentially  prevent  between  24%  (based  on  45%  response  and 
compliance  to  therapy)  and  86%  (based,  unrealistically,  on  100%  response  and 
compliance  to  therapy)  of  severe  HCV-related  events  during  2005-2030.  The 
identification  and  treatment  of  a  larger  proportion  of  former  IDUs  with  HCV  disease, 
education  about  the  importance  of  minimal  alcohol  consumption,  and  the 
development  of  more  effective  and  better  tolerated  therapies  are  needed  now  to  help 
achieve  a  greater  impact  on  the  future  morbidity  and  mortality  of  this  disease. 
Meanwhile,  the  development  of  initiatives  to  prevent  (i)  the  further  spread  of  HCV 
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not  be  neglected. 
7.3  Key  data  required  to  refine  future  HCV  projection  modelling  work 
Projections  clearly  rely  on  the  accuracy  of  the  model  assumptions  used  to  derive 
them.  As  new  data  become  available,  improvements  in  the  modelling  of  the  HCV 
epidemic  in  Scotland,  as  elsewhere,  will  be  possible,  leading  to  further  refinement  in 
these  estimates.  The  following  six  sections outline  areas  for  future  work  related  to 
HCV  projections  in  Scotland. 
7.3.1  Scotland-wide  data  on  the  incidence  and  cessation  of  injecting  drug  use 
The  importance  of  estimates  on  the  incidence  and  cessation  of  IDU  has  long  been 
recognised,  yet  few  attempts  have  been  made  to  estimate  these  in  the  UK.  A  modified 
Delphi  approach  was  used  to  derive  these  for  Glasgow  by  combining  expert  opinion 
with  capture-recapture  IDU  prevalence  estimates.  Given  the  wide  certainty  ranges 
surrounding  experts'  consensus  on  incidence  and  cessation,  likely  brought  about  by 
the  difficulty  in  quantifying  these  parameters,  other  approaches  need  to  be  considered 
to  validate  these  estimates  in  Glasgow  and  provide  data  throughout  Scotland. 
A  lag-correction  method  has  been  adapted  from  AIDS  epidemiology  to 
estimate  recent  trends  in  the  incidence  of  heroin  use  in  south-eastern  England  by 
adjusting  reported  numbers  of  heroin  users  visiting  drug  treatment  agencies  for  the 
time  lag  between  onset  of  heroin  use  and  first  treatment  requests".  This  approach 
could  similarly  be  applied  in  Scotland  to  estimate  the  relative  incidence  of  injecting 
drug  use  from  reports  to  the  Scottish  Drugs  Misuse  Database121.  This  database 
however  only  dates  back  to  1992  and  therefore  limits  estimation  with  the  lag- 
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the  IDU  epidemic  are  required  to  estimate  completely  the  past  incidence  of  HCV  in 
this  population. 
In  Australia,  the  back-calculation  approach,  using  national  data  on  opioid 
overdose  deaths,  has  generated  estimates  of  the  numbers  of  people  starting  to  inject 
heroin  between  1960  and  1997112.  The  validity  of  the  back-projection  estimates 
depends  on  the  consistency  and  completeness  of  the  surveillance  data  over  time. 
Reports  of  drugs-related  deaths  in  Scotland  increased  4-fold  between  1993  (33)  and 
1994  (139)  as  a  result  of  an  improved  system  of  collecting  information  on  all  deaths 
involving  drugs  or  persons  known  or  suspected  to  be  drug-dependent  344  Thus, 
adjusting  historical  data  on  the  number  of  drug-related  deaths  in  Scotland  for 
inconsistencies  caused  by  the  reporting  systems  is  essential  in  order  to  use  these  data 
to  generate  estimates  of  the  incidence  of  injecting  drug  use  through  back-calculation. 
A  study,  implemented  by  SJH,  SMB  and  DJG  in  2004,  linking  SCIEH's  national  HIV 
test  database  with  Scotland's  deaths  register  will  allow  the  examination  of  the  vital 
status  of  approximately  12,500  Scottish  IDUs,  who  had  tested  negative  for  HIV 
antibodies  during  1988-2003,  and  inform  the  adjustment  of  historical  reports  for 
misclassification  of  overdose  deaths. 
Injecting  drug  users  are  a  difficult  group  to  follow  prospectively,  and  therefore 
many  studies  -  usually  cross-sectional  -  of  this  population  are  restricted  to  elucidating 
short-term  changes  in  injecting  behaviour.  However,  long-term  cohort  studies 
measuring  the  injecting  patterns  of  individuals  following  commencement  of  injecting 
drug  use  are  required  to  allow  accurate  estimation  of  the  cessation  of  IDU,  both 
regionally  and  temporally,  in  Scotland.  Meanwhile,  the  estimation  of  cessation  rates 
may  be  achieved  by  combining  available  data  on  IDU  prevalence  and  mortality  with  a 
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methods  outlined  in  Chapter  2. 
7.3.2  Mortality  among  current  IDUs 
The  simplest  assumption  of  a  common  and  constant  risk  of  death  was  applied  among 
current  IDUs  (1-2%  per  annum)  in  the  HCV  projection  model  in  Chapter  6  and  among 
heroin  users  (0.6-1%  per  annum  for  overdose  death)  in  back-calculation  models 
estimating  the  past  incidence  of  injecting  heroin  use112.  However,  de  Angelis  et  al. 
have  demonstrated  the  sensitivity  of  back-calculation  estimates  to  the  assumption  of  a 
common  and  constant  risk  of  overdose  death345,  and  underlined  the  need  for  reliably 
estimated  gender  and  age  specific  rates. 
Relating  reported  drug-related  deaths  in  Scotland  to  the  prevalent  number  of 
current  IDUs  generated  through  capture-recapture  studies,  with  assumptions  about  the 
age  and  gender  distributions,  indicated  that  these  deaths  were  more  common  among 
men  (1.7  times  more  frequent  than  among  females)  and  those  older  than  34  years  of 
age  (2.1  to  6.6  times  more  frequent  than  those  younger  than  25  years)152. 
Corroboration  of  these  findings  is  needed  from  cohort  studies  of  IDUs,  which  can 
directly  calculate  mortality  by  gender  and  age.  The  study  proposed  above  linking  the 
records  of  approximately  12,500  Scottish  IDUs,  who  had  tested  negative  for  HIV 
antibodies  during  1988-2003,  to  the  deaths  register  provides  a  relatively  cheap 
opportunity  to  assess  the  influence  of  gender  and  age  at  HIV  test  uptake  on  drugs 
related  mortality.  Scrutiny  of  the  record-linkage  data  will  inform  on  mortality  not  only 
related  to  drugs  but  also  alcohol  and  other  causes  of  death. 
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The  meta-analysis  in  Chapter  5  illustrated  a  significantly  increased  risk  of  cirrhosis 
(RR  2.3;  95%  Cl  1.7-3.3)  associated  with  alcohol  intake  defined  in  the  range  of  at 
least  210  to  560g  per  week.  The  record-linkage  of  12,096  HCV  diagnosed  positive 
persons  to  hospital  admission  data,  presented  in  Chapter  4,  identified  alcohol  as  a 
factor  in  71%  of  514  cases  developing  HCV-related  liver  failure  during  1991-2001  in 
Scotland.  Despite  the  recognition  that  alcohol  is  one  of  the  main  predictors  of  a 
worsened  outcome  with  chronic  HCV,  the  drinking  patterns  of  IDUs  (the  group  most 
affected  by  HCV  infection  in  resource-rich  countries)  have  thus  far  received  little 
attention.  A  particular  concern  is  that  drug  injectors  who  have been  treated  for  their 
drug  problems  may  subsequently  substitute  their  illicit  drug  use  with  alcohol346'347 
Studies  of  drug  users  receiving  drug  treatment  in  England  have  reported 
prevalences  of  either  problem  drinking  or  drinking  above  the  recommended  safe 
limits  in  the  range  of  15-45%219'296,297,298  To  accommodate  this  range  of  uncertainty 
in  the  HCV  projection  model,  outlined  in  Chapter  6,  three  rates  (0%,  20%  and  40%) 
of  heavy  alcohol  use  were  explored.  Varying  disease  progression  rates  according  to 
40%  uptake  (versus  0%  and  20%)  of  heavy  alcohol  use  -  along  with  age at  HCV 
acquisition,  gender  and  HIV  co-infection  -  improved  the  consistency  of  simulated 
outcomes  with  record-linkage  results. 
Further  research  is  required  to  determine  accurately  the  prevalence  and 
determinants  (e.  g.  gender,  current/former  injector  status  and  HCV  antibody  status)  of 
heavy  drinking  among  IDUs  in  Scotland.  Building  upon  the  record-linkage  work 
developed  in  Chapter  4,  which  established  that  17%  of  12,096  HCV  diagnosed 
persons  in  Scotland  had  a  history  of  alcohol  abuse  resulting  in  either  hospitalisation  or 
death,  the  same  approach  could  be  used  to  determine  the  prevalence  of  alcohol-related 
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Drugs  Misuse  Database  (SDMD)  holds  data  on  all  individuals  who  have  sought 
treatment  for  their  drug  use  for  the  first  time  ever  or  in  the  last  six  months:  including  a 
minimum  set  of  identifiers  (i.  e.  forename  and  surname  initials,  fourth  letter  of 
surname,  date  of  birth  and gender)  to  enable  internal  and  external  linkage  of  records 
and  information  on  ever  and  recent  (i.  e.  last  month)  injector  status  to  distinguish 
between  non-IDUs,  former  IDUs  and  current  IDUs.  Linkage  of  the  SDMD  to  hospital 
discharge  diagnoses  records  will  therefore  help  gauge  the  alcohol  abuse  patterns  of 
current  and  former  IDUs  by  region  in  Scotland.  A  limitation,  however,  of  the  hospital 
data  is  the  absence  of  information  on  the  quantity  of  alcohol  consumed  by  patients. 
Surveys  of  current  and  former  IDUs  would  aid  interpretation  of  the  hospital  data  by 
quantifying  the  alcohol  consumption  of  those  who  have  and  have  not  been 
hospitalised  with  an  alcohol-related  problem. 
7.3.4  Progression  of  liver  disease  among  HCV  chronically  infected  persons  in 
Scotland 
The  projection  model,  outlined  in  Chapter  6,  estimated  the  increasing  severity  of  HCV 
disease  with  age  among  current  and  former  Glasgow  IDUs  in  2005.  The  mean 
prevalence  of  moderate  disease  increased  from  6%  among  chronic  HCV  infected 
(both  current  and  former)  IDUs  aged  under  30  years  to  29%,  47%,  and  53%  among 
those  aged  30-39,40-49  and  50  years  or  more,  respectively.  Meanwhile,  the  mean 
prevalence  of  cirrhosis  increased  from  4%  among  those  aged  30-39  years  to  9%  and 
28%  among  those  aged  40-49  and  50  years  or  more,  respectively. 
To  assess  the  accuracy  of  these  projection  estimates,  there  is  need  to  collate 
information  on  the  histological  status  -  together  with  the  patient's  age,  gender,  risk 
177 group  of  HCV  acquisition,  health-board  of  residence,  HIV  status,  and  alcohol  history 
-  of  HCV  chronically  infected  patients  in  Scotland  undergoing  liver  biopsy.  A  project 
initiated  by  the  Scottish  Viral  Hepatitis  Group,  funded  by  the  Scottish  Executive  and 
currently  in  the  early  stages  of  implementation,  aims  to  collect  the  above  and  other 
key  epidemiological  and  clinical  data  on  HCV  infected  persons  in  Scotland  who  are, 
or  have  been,  in  clinical  care  to  form  the  Scottish  Clinical  HCV  database.  The  factors 
causing  patients  to  present  for  clinical  assessment  and  undergo  a  liver  biopsy,  as 
discussed  in  the  meta-analysis  of  Chapter  5,  will  likely  influence  the  histological 
results  by  over-estimating  the  prevalence  of  moderate  and severe  liver  disease;  these 
biases  would  therefore  need  to  be  considered  when  comparing  liver  biopsy  results 
with  projection  estimates. 
Liver  biopsy  is  internationally  recognised  as  the  gold  standard  for  assessment 
of  hepatic  fibrosis,  as  non-invasive  markers  developed  to  date  are  unable  to  predict 
reliably  the  stage  of  liver  disease348.  The  importance  of  liver  biopsy  for  chronic  HCV 
was  highlighted  in  a  recent  study  that  showed  a  substantial  proportion  (68%:  25/37)  of 
biopsy  proven  cirrhosis  patients  were  not  identified  as  cirrhotic  through  clinical 
diagnosis349,  which  is  important  since  these  patients  are  generally  not  offered  therapy 
because  of  concerns  over  safety  and  efficacy.  Despite  this,  a  recent  statement,  made  at 
the  Consensus  Conference  on  HCV  in  Edinburgh  during  April  2004350,  dismissed  the 
role  of  liver  biopsy  in  the  clinical  follow-up  of  certain  HCV-infected  patients  -  on  the 
basis  of  the  morbidity  and  mortality  risks  associated  with  biopsy  and  the  impressive 
response  rates  (up  to  80%)  from  clinical  trials  of  pegylated  combination  therapy  for 
some  genotypes351.  The  absence  of  information  on  stage  of  HCV  disease  from  liver 
biopsy,  or  equivalent  markers,  may  however  prove  to  be  a  major  impediment  in 
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HCV  infected  persons  in  Scotland. 
7.3.5  Validating  record-linkage  estimates  of  the  incidence  of  HCV-related  severe 
disease  in  Scotland 
Knowledge  of  the  number  of  HCV-infected  IDUs  developing  decompensated 
cirrhosis  each  year  in  Scotland  was  integral  to  the  fitting  of  the  projection  model  in 
Chapter  6.  Estimates  were  based  on  findings  from  the  record-linkage  work,  as 
described  in  Chapter  4,  of  the  numbers  of  HCV  diagnosed  individuals  admitted  to 
hospital  with  decompensated  cirrhosis,  which  were  adjusted  to  account  for  the 
proportion  associated  with  injecting  drug  use  (88%)  and  the  non-hospitalisation  (14%) 
and  non-HCV-diagnosis  (18%)  of  decompensated  cases.  The  hospital  morbidity  data 
alone  under-estimated  the  incidence  of  severe  HCV-disease  as  14%  of  deaths  from 
decompensated  cirrhosis  among  HCV  diagnosed  persons  were  not  identified  with  this 
complication  in  the  hospital  register.  In  addition,  the  non-HCV-diagnosis  rate  was 
taken  as  the  proportion  (18%)  of  hospitalised  HCV-related  decompensated  cirrhosis 
cases  who  were  not  diagnosed  with  HCV  infection  until  >14  days  after  their 
hospitalisation. 
Further  study  of  the  HCV  antibody  status  of  patients  presenting  with  severe 
liver  disease,  particularly  those  with  other  aetiological  factors  such  as  alcohol  abuse, 
is  needed  to  validate  the  record-linkage  results  and  assess  whether  or  not  all  HCV- 
infected  cases  had  been  estimated  using  this  approach.  Matching  the  identifiers  of 
patients  either  presenting  to  hospital  or  dying  with  decompensated  cirrhosis  and  HCC 
in  Glasgow  and  Edinburgh  against  local  Regional  Virus  Laboratory  HCV  test  records 
will  establish  the  HCV  test  uptake  of  cases  in  these  regions  and  inform  whether  or  not 
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severe  liver  disease  in  Scotland. 
7.3.6  Determining  the  most  cost-effective  approaches  to  testing  and  treating  IDUs 
for  chronic  HCV  in  Scotland 
A  total  of  43,000  persons,  who  had  ever  injected  drugs,  were  estimated  to  be  living 
with  HCV  antibodies  by  the  end  of  2003  in  Scotland  (from  modelling  work  presented 
in  Chapter  6),  of  whom  approximately  14,000  (32%)  had  been  diagnosed.  Of  these 
HCV-infected  IDUs  in  Scotland,  32,000  were  estimated  to  be  living  with  chronic 
HCV  and  therefore  at  risk  of  developing  cirrhosis.  In  comparison,  relatively  few 
Scottish  IDUs  have  received  antiviral  therapy  (estimated  optimistically  at  1,500  in  the 
projection  model).  Progress  needs  to  be  made  in  identifying  individuals  eligible  for 
antiviral  therapy  and  in  retaining  those  diagnosed  with  chronic  HCV  in  clinical 
follow-up. 
The  concern  is  that  those  who  would  benefit  most  from  an  HCV  diagnosis  - 
infected  persons  with  moderate  hepatitis  who  do  not  (or  no  longer)  inject  drugs  -  are 
not  being  offered  and  recommended  a  test  or  are  lost  to  clinical  follow-up.  An 
evidence-based  approach  to  chronic  HCV  case-finding  is  essential  if  limited  resources 
are  to  be  used  effectively  in  identifying  those  most  in  need  of  antiviral  therapy.  The 
modelling  presented  in  this  thesis  highlighted  the  potential  benefit  of  targeting  HCV 
testing  at  former  IDUs  aged  30-39  and  40-49  years  as  16%  and  27%  of  those  in 
Glasgow,  respectively,  were  estimated  to  have  moderate  disease  in  2005  (32%  and 
47%  of  those  chronically  infected,  respectively).  Further  research  is  needed  to 
examine  the  clinical  benefits  and  cost-effectiveness  of  different  HCV  testing 
strategies  targeted  at  former  IDUs. 
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The  projection  model,  designed  and  calibrated  for  IDUs  in  Glasgow,  provides 
the  foundation  to  examine  the  cost-effectiveness  of  the  latest  available  treatments  for 
chronic  HCV  among  patient  subgroups  with  different  stages  of  disease  and  host 
factors.  A  key  finding  from  the  HCV  projection  work  undertaken  for  Glasgow  was 
that  consistency  between  model  and  epidemiological  data  improved  by  allowing  HCV 
disease  progression  rates  to  depend  on  age  at  HCV  acquisition,  gender,  HIV  co- 
infection  and  heavy  alcohol  use.  Incorporating  this  heterogeneity  in  the  natural  history 
of  chronic  HCV  into  cost-effectiveness  models  may  have  important  implications  for 
treatment  decisions  in  an  evolving  patient  population. 
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